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Abstract
The results detailed in this thesis were aimed at elucidating further the role of the
isoforms of the proto-oncogene K-Ras in development and the implications of
deregulated K-ras isoform function in tumorigenesis.
In order to investigate the role of K-ras isoforms in vitro ES cells with the genotype K-
ras+/'",A4A were generated by gene targeting of ES cells by homologous recombination
using a targeting vector that deleted the K-ras exon 4A, and hence homozygous ES cells
of genotype YL-ras"nA4A/"nA4A were derived. These cells enabled the dissection of the role
of K-ras 4A in cellular functions including proliferation, differentiation and apoptosis,
highlighting functional differences between the K-Ras isoforms. Analysis of cell cycle
parameters in ES cell cultures showed that both K-Ras protein isoforms were
dispensable for proliferation and regulation of cell cycle checkpoints. However, K-Ras
4B was critical for the differentiation of ES cells following LIF withdrawal.
Inactivation of both K-ras isoforms together in ES cells resulted in a reduced
requirement for LIF and maintenance of the ability to undergo stem cell renewal, while
deletion of K-ras 4A alone did not do so. The K-Ras 4A protein was found to be
critical for initiation of apoptosis. Whilst K-rastmA ,mA4A ES cells do undergo apoptosis
following treatment with etoposide they suffer a delay. Investigation in to the pathways
involved suggested that this might be due to the failure of the K-Ras 4A protein to
generate appropriate pro-apoptotic signals via pathways such as the MAPK pathway to
counteract the anti-apoptotic signals generated via the PI-3Kinase pathway in these
cells.
The K-ras gene products are critical for mouse development, since K-ras" mice are
unable to complete embryogenesis. To examine the role of K-ras 4A in mouse
development K-ras +/""A4A mice were produced by blastocyst injection of the targeted ES
cells. These mice are viable and fertile with no overt abnormalities. Breeding for
animals homozygous for the tmA4A mutation is on going at the time of writing. This
will provide a powerful tool to investigate the requirement of the K-Ras 4A protein
during embryonic development.
viii
Investigation of the expression of the K-Ras proteins in human tumours showed that the
K-Ras 4A and K-Ras 4B proteins are expressed in colon adenocarcinomas with known
K-ras mutations. In particular K-Ras 4A protein expression was up-regulated in these
tumours compared to normal colon. In cervical intraepithelial neoplasia the expression
of the K-Ras isoforms is lost.
The expression of the K-Ras 4B protein was investigated during mouse development.
This investigation highlighted tissue specific regulation during embryonic development
and regulation was found to continue in neonatal and adult tissues.
These studies provide insight into the possible differential regulation of cellular
functions by the K-Ras proteins, since activating mutations occur within codons shared
by the K-Ras isoforms these findings highlight the possibility of the synergistic
interaction of protein function in the development of cancer.
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Chapter 1
Introduction
The research detailed here was aimed at elucidating the role of the K-ras gene products
in development and neoplasia. This took the form of investigations into the differences
between the isoforms of K-ras to highlight the functional differences of these two
proteins.
The Ras superfamily is a diverse group of guanine nucleotide binding proteins, which
function as important switches in cellular signalling events, by binding guanine
nucleotides, which determine the activity of the protein. Although they are known to
function in the growth and differentiation of cells their exact physiological functions are
still poorly understood. However, it is known that ras gene mutations are present in
approximately 30% of all cancers, supporting the view that inappropriate activation of
these genes is an important step in the path of cancer development.
1.1 The ras gene family
The ras genes encode 21KDa proteins, which are present in all eukaryotes including
yeast, and have a high degree of conservation between species. Humans and rodents
encode three functional ras genes K-, H-, and N-ras. These three genes share a large
degree of structural homology. Functional homology between species has also been
demonstrated, since human ras genes are able to rescue ras deficient yeast cells
(reviewed Lowy and Willumsen, 1993). Other members of the Ras protein family
include R-Ras, TC21 (R-Ras2) and M-Ras (R-Ras3), which are believed to constitute a
subfamily (Kimmelman et ai, 1997) and also genes that encode the Ral, Rap, and Rho
families of proteins (reviewed Denhardt, 1996).
The mutated ras genes were identified by their ability to transform NIH/3T3 cells after
DNA transfection (reviewed Bos et al., 1989). Viral oncogenes of certain acute
transforming retroviruses were the first to be identified (v-ras). The H- and K-ras
genes were identified as human homologs of the v-H-ras of Harvey (Ha) and the v-K-
ras of Kirsten (Ki) murine sarcoma viruses (MuSV) respectively. N-ras was found in a
1
neuroblastoma cell line as a transforming gene with homology to the other ras genes.
The genes are unlinked and map to different chromosomes: H-ras maps to chromosome
11, K-ras to chromosome 12 and N-ras to chromosome 1 in humans and these genes
map to chromosomes 7, 6 and 3 respectively in the mouse (reviewed Barbacid, 1987).
Although the ras genes differ in their overall gene size due to variations in intron
length, the arrangement of the exons is very similar. The mammalian ras genes have a
5' non-coding exon and four coding exons. The fourth exon encodes the heterogeneous
region, and the exons encode the same part of the protein for each gene (reviewed Lowy
and Willumsen, 1993). Initiation of transcription occurs at multiple start sites within a
GC-rich promoter region that lacks a TATA or CCAAT box in common with other
housekeeping genes (Hoffman et al., 1987). W-ras has an alternative splice site, which
results in the translation of a protein called p 19 and it has been hypothesised that this
may have an inhibitory function (Codony et al., 2001). K-ras is unique, as it contains
two alternative fourth coding exons 4A and 4B respectively. This leads to the
production of two proteins K-Ras 4A and K-Ras 4B by alternative splicing (Capon et
al., 1983; McGrath et al., 1983). The diagrammatic representation of the gene structure
and resulting mRNA following alternative splicing are depicted in figure 1.1.
Two separate K-ras homologues exist in the human genome c-K-ras 1 and c-K-ras 2.
c-K-ras 1 is a pseudogene and appears to be a processed version of c-K-ras 2 probably
generated via a mature c-K-ras 2 mRNA intermediate (McGrath et al., 1983). The c-K-
ras 1 pseudogene has a high degree of homology to the K-ras 4B sequence, whereas the
sequence of the K-ras 4A product is highly homologous to v-K-ras, there is in fact only
a single conservative amino acid difference distinguishing the two within the sequence
derived from exon 4A (McGrath et al., 1983). The complete murine K-ras gene
sequence, which is approximately ~38Kb is available as part of the mouse genome
project (http://www.ncbi.nlm.nih.gov accession number AC019026).
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Figure 1.1. Diagrammatic representation of the exonic structure of the K-ras gene. The K-ras gene
encodes five coding exons. The diagram shows the alternative splicing to the two fourth coding exons.
The K-ras 4A mRNA is larger than that of the K-ras 4B mRNA, as it contains the transcribed exon 4B
sequence. However, a translation stop site at the end of the exon 4A means that this sequence is not
translated. Both transcripts also contain a 3' untranslated region (UTR) downstream of exon 4B.
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1.2 Ras Proteins
The K-Ras 4A, N-Ras and H-Ras proteins are all 189 amino acids long, the K-Ras 4B
protein is one amino acid shorter at 188 amino acids long. (Lowy and Willumsen,
1993). Analysis of the amino acid sequence encoded by these genes suggests that they
show a high degree of homology in their first 164 amino acids (figure 1.2). This region
contains the effector, exchange factor and guanine nucleotide binding domains. Based
on primary sequence comparisons, Ras proteins can be viewed as consisting of three
contiguous regions. The first region encompasses the N-terminal 86 amino acids, which
are 100% identical among different Ras proteins. Within this region lies the Ras
effector domain (amino acids 32 to 40), which is the critical interaction site with all
known downstream targets of Ras. The next 80 amino acids define a second region
where mammalian Ras proteins diverge only slightly from each other, exhibiting an
85% homology between any protein pair. The third region shows significant divergence
and is the last 24/25 amino acids of the protein. This region is termed the hypervariable
region (HVR). There appears to be strong selective influences operating in this
heterogeneous C-terminal region, as this shows strong conservation between species
(Lowy and Willumsen, 1993). The heterogeneity in the C-terminal may be important in
explaining observed functional differences between Ras proteins. This region
undergoes posttranslational modifications and is important for membrane localisation; it
is therefore possible that this could result in unique membrane localisation sites for the
individual isoforms.
1.3 Posttranslational modifications
The Ras protein is synthesised in the cytoplasm as pro-p21, which then undergoes post¬
translational modifications. The modification of the Ras proteins increases the
hydrophobicity of the molecule and therefore membrane binding affinity, which is
essential for their activity (Jackson et al., 1994). Until recently it was thought that to be
biologically active, Ras proteins must be located at the inner surface of the plasma
membrane, where they effectively interact with their upstream activators and
downstream targets. However, recent research has challenged this hypothesis showing
Ras signalling can occur on other membranes as well, which is associated with
signalling pathway specificity (Chiu et al., 2002).
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The HVR contains two signal sequences that cooperate to target the proteins to the
plasma membrane. The first of these is the CAAX (C cysteine; A aliphatic acid; X
serine or methionine) motif at the carboxyl terminal. The CAAX motif is modified
sequentially: the cysteine residue is farnesylated, the AAX sequence removed by
proteolysis and the now C-terminal cysteine is carboxymethylated. The carboxyl
methylation of the isoprenylcysteine is important for the correct localisation of the Ras
proteins to the plasma membrane (Bergo et al., 2000). In cells deficient for the
isoprenylcysteine carboxyl methyltransferase the Ras proteins remain trapped in the
cytoplasm. In addition, K-Ras 4A, H-Ras and N-Ras are then palmitoylated at upstream
cysteine residues (cysteine 181 of N-Ras, cysteines 181 and 184 of H-Ras and cysteine
180 of K-Ras 4A) (Hancock et al., 1989). Whilst polyisoprenylated but non-
palmitoylated H-Ras proteins are biologically active and associate weakly with cell
membranes, palmitoylation increases the avidity of this binding (Hancock et al., 1989).
These cysteine residues in the K-Ras 4B sequence are substituted by a polybasic domain
consisting of six lysine residues (175-180) (Hancock et al., 1990, 1991). This polylysine
domain acts as the second signal sequence of K-Ras 4B. These signals alone are
sufficient to target the Ras proteins to the plasma membrane (Hancock et al., 1991). An
important consequence of this is that the membrane anchors of these Ras protein
isoforms are all different, and correct membrane localisation is important for biological
activity of these proteins.
The K-Ras 4B isoform has been shown to be a substrate for geranylgeranylation as well
as farnesylation in vitro and possibly also in vivo (James et al., 1995, 1996; Lerner et
al., 1995). More recently it has been shown that K-Ras 4B can be geranylgeranylated
in vivo when cells are subjected to specific farnesyltransferase inhibitors (FTIs) (Rowell
et al., 1997), although under normal circumstances K-Ras 4B was shown to be
farnesylated. H-Ras however does not undergo geranylgeranylation when treated with
FTIs (Rowell et al., 1997).
5
1 85 165 188/189 amino acids
H-Ras HKLR K LN P P
N-Ras YRMK K LN s s
K-Ras 4A YR LK K I S KE
K-Ras 4B HKE K MS KD
DE SGPGCMSCK CV L S
DDGTQGCMGLPCVVM
E KT PGCVK I KKCI I M
G KKKKKKS KTKCVI M
100% 15%
Figure 1.2. Diagrammatic representation of the Ras protein showing regions of homology and the
sequence of the HVR for the Ras isoforms. The consensus CAAX sequence directs posttranslational
modifications. H-Ras, N-Ras and K-Ras 4A then undergo additional palmitoylation at the downstream
cysteine residues, which mediates membrane localisation and anchoring. K-Ras 4B interacts with the
plasma membrane via its polybasic region.
1.4 Membrane Trafficking
The current view of Ras membrane trafficking is that the Ras proteins are prenylated in
the cytosol and then translocated to the endoplasmic reticulum (ER) for further
processing, as the protein prenyltransferases are cytosolic, and both the endoprotease
and the Ras methyltransferase are located in the ER (Ashby et al., 1998; Dai et al.,
1998; Schmidt et al., 1998). Since methylesterification is the final CAAX modification,
this suggests that CAAX processing is completed on the cytoplasmic leaflet of the ER
membrane. Ras proteins are then targeted to the plasma membrane. However, K-Ras
4B is diverted from the classical exocytic pathway proximal to the Golgi apparatus,
unlike the other Ras proteins (Choy et al., 1999; Apolloni et al., 2000). The second
signal in the form of the polybasic region appears to be required for the clearing K-Ras
4B from the ER and excluding it from the Golgi apparatus, whereas the palmitoylation
signal of N-Ras and H-Ras appears to be responsible for their trafficking through the
Golgi apparatus to the plasma membrane (Choy et al., 1999; Apolloni et al., 2000).
Therefore, the second membrane signal is not important for endomembrane association,
but for the subsequent trafficking out of the endomembrane system. Importantly, when
taken together these two studies show that the C-terminal motifs of the HVR contain all
the appropriate signals for correct membrane localisation of these proteins. Moreover,
they demonstrate that the palmitoylated proteins H-Ras and N-Ras use the same
trafficking pathway, but that the polybasic region of K-Ras 4B appears to direct this
protein to an alternative trafficking pathway.
A search for factors involved in the intracellular trafficking of K-Ras identified a
specific and prenylation-dependent interaction between K-Ras 4B and
tubulin/microtubules. This association is specific to K-Ras 4B, since H-Ras and other
prenylated proteins do not bind. The location of newly synthesised K-Ras 4B was
disrupted by the treatment of the cells with either paclitaxel or taxol, leading to an
accumulation of the protein intracellularly, rather than at the plasma membrane as seen
in untreated cells (Thissen et al., 1997, Apolloni et al., 2000). The localization of H-
Ras was not disrupted by this treatment, nor was that of N-Ras, which still showed the
predominant plasma membrane localization (Chen et al., 2000). The polylysine domain
immediately upstream of the prenylation site is important for this interaction, since the
loss of this region meant that K-Ras 4B trafficking was no longer susceptible to
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disruption by treatment with paclitaxel (Chen et al., 2000). Therefore, the intact
microtubule network is necessary for K-Ras 4B to transit the cell, apparently uniquely
so for this protein. This could imply that K-Ras 4B has a direct interaction with the
microtubule network, although there is not a consensus for this (Chen et al., 2000;
Apolloni et al., 2000). Whilst the trafficking of the K-Ras 4A protein was not explored
in this series of experiments, it seems likely that this protein would traffic in a manner
similar to N-Ras and H-Ras via the ER due to its palmitoylation modifications.
1.5 Membrane Localisation (Plasma membrane microdomains)
The plasma membrane can be divided simplistically into lipid raft and non-raft
compartments. Evidence has shown that H-Ras is localised to caveolae and non-
caveolae lipid rafts and K-Ras 4B to an unidentified, non-caveolae region (Roy et al.,
1999; Prior et al., 2001). Motility studies using GFP-K-Ras with a codon 12 activating
mutation (G12V) (see section 1.6) also confirm that K-Ras is unlikely to be restricted to
such regions (Niv et al., 1999). The use of dominant-negative caveolin mutants
(CavDGV) showed that whilst the activation of membrane recruited Raf by H-RasG12V
was blocked by Cav DGV little effect was seen on K-RasG12V-catalysed Raf activity
(Roy et al., 1999). This appears to be the result of depletion of cholesterol from the
plasma membrane. The interaction of H-Ras with lipid rafts is GTP-dependent, since
GTP binding causes H-Ras to disassociate with the lipid raft (Prior et al., 2001). Raf
activation by H-Ras occurs more potently in non-raft fractions. Association of H-Ras
with cholesterol rich microdomains has been shown to be important for MAPK
activation following stimulation with insulin (Rizzo et al., 2001) and that endocytosis
and activation of the MAPK pathway are coupled. Following insulin stimulation
internalisation of cholesterol rich regions of the plasma membrane with which Ras, Raf
and MAPK are associated occurs (Rizzo et al., 2001). The association of Ras with
endocytosis following insulin stimulation is dependent upon C-terminal modifications,
as GFP- tagged C-terminal amino acids mimic the response of the full-length protein
(Rizzo et al., 2001). However, it must be noted that Raf can be activated when targeted
to either raft or non-raft regions of the plasma membrane (Chen et al., 2001), suggesting
that Raf activation is not dependent upon membrane microdomains. ERK activation
was not correlated to raft localisation. Therefore, while H-Ras has a relatively tightly
controlled although dynamic association with specific cholesterol-rich regions of the
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plasma membrane, K-Ras appears to have no such restrictions upon its lateral
movement within the plasma membrane. Therefore, differential membrane localisation
may be one of the physiological mechanisms underlying biological differences between
Ras proteins.
1.6 Biochemical Activity
The Ras proteins are members of the small guanine nucleotide binding protein family
and as such Ras proteins bind guanine nucleotide triphosphates (GTP) and guanine
nucleotide diphosphates (GDP) with high affinity. The activity of the Ras proteins is
determined by the guanine nucleotide with which they are associated and they can cycle
between active and inactive forms. Ras proteins are in an active conformation if they
are bound to GTP and become inactivated when bound to GDP (reviewed Bollag &
McCormick, 1991). The guanine nucleotide bound to the Ras protein is determined by
at least two groups of proteins, the guanine nucleotide exchange factors (GEF) and the
GTPase activating proteins (GAP). In cells most Ras proteins are in the Ras.GDP
conformation. The disassociation of Ras from the GDP nucleotide is facilitated by the
interaction of Ras with guanine nucleotide exchange factors (GEF). The mammalian
homologue of the Drosophila Son of sevenless (mSos) is the archetypal GEF. Since
GTP is present at greater concentrations in the cell compared to GDP, once Ras is
unbound GTP will bind preferentially (reviewed Bollag & McCormick, 1991).
Regulation of specific Ras protein signal transduction can occur at the level of the GEF.
The small G protein GDP dissociation stimulator (smg GDS) has been shown to
function as a guanine nucleotide exchange factor (GEF) on a subset of GTPases,
including K-Ras 4B (Mizuno et al., 1991; Orita et al., 1993). This GEF has been shown
to translocate K-Ras 4B from the membrane to the cytoplasm (Kawamura et al., 1993;
Nakanishi et al., 1994). However, recent analysis has shown that smg GDS can interact
with H- and N-Ras, although this interaction was exclusive to the nucleotide free form
of these proteins and smg GDS was unable to promote nucleotide exchange (Vikis et
al., 2002). This suggests that the interaction of smg GDS with K-Ras is qualitatively
different from that of H- and N-Ras and may reflect two distinct modes of binding.
Furthermore, H-Ras has been shown to interact with the GEF Ras-GRF2, but neither K-
, or N- or R-Ras are activated by this GEF (Jones and Jackson, 1998; Gotoh et al.,
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2001), whereas Ras-GRFl activates both H-Ras and R-Ras in cells (Gotoh et al., 2001).
The signalling specificity of Ras-GFRl and Ras-GRF2 is mediated by the sequences of
the HVR (Gotoh et al., 2001). Therefore, differences in affinity for GEFs may enable
H-Ras and K-Ras 4B to associate with a set of molecules distinct from those shared by
the other Ras proteins and hence have unique biological outcomes.
Ras proteins have an intrinsic GTPase activity, which limits the activity of the Ras
proteins by reducing the length of time the Ras.GTP association lasts. This hydrolysis
of GTP to GDP returns the protein to the inactive state. Levels of the Ras.GTP bound
form only rise above basal levels under certain circumstances, for example if a cell is
stimulated by a growth factor (reviewed Bollag & McCormick, 1991a). Association
with GAPs increases the hydrolysis of GTP to GDP dramatically and therefore the
transition from active to inactive form. Thus, GAPs are important regulators of the
duration of Ras signal transduction. Five mammalian GAPs have been described
(Boguski and McCormick, 1993) including pl20GAP, the archetype for this class of
protein and NF1 (the product of the type 1 neurofibromatosis gene). The crystal
structure of the Ras-GAP complex has been analysed (Scheffzej et al., 1997). GAPs
have been shown to be negative regulators of Ras activity in several cell types (Yao and
Cooper, 1995). Specificity between Ras proteins is not limited to positive regulators but
also occurs with negative regulators. NF1 exhibits a four-fold greater affinity for H-Ras
than N-Ras (Bollag and McCormick, 1991b). The pl90GAP, which mediates signalling
via Rho, Rac and CDC42 binds to the pl20GAP (Wang et al., 1997), thereby linking the
regulation of these two pathways.
Other proposed regulators of Ras biochemical activity include the Ca2+- binding protein
calmodulin (CaM). This protein has been shown to have a regulatory effect upon the
Ras/Raf/MEK/ERK signalling cascade. In cultured fibroblasts Ca2+ and CaM were
important for inactivating this pathway (Bosch et al., 1998). The activation of Ras
induced by CaM inhibition preferentially leads to the activation of the
Ras/Raf/MEK/ERK pathway. It has further been shown that the binding of CaM to Ras
is GTP dependent and K-Ras 4B specific (Villalonga et al., 2001). K-Ras 4A, H-Ras
and N-Ras were unable to bind to CaM in pull down experiments. This evidence
suggests a mechanism by which differential down-regulation of the K-Ras 4B signalling
pathways may occur.
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Mutational activation of the Ras proteins is associated with point mutations in a number
of codons most frequently 12, 13, 59, and 61(reviewed Bollag and McCormick, 1991).
Mutations at codon 12 frequently result in an amino acid substitution from glycine to
valine (G12V). The mutations in codons 12, 13, 59 and 61 are associated with impaired
GTPase activity. These point mutations result in the Ras protein becoming
constitutively active, leading to inappropriate signal transduction. Altered nucleotide
exchange rates are associated with mutations in codons 16, 17, 116, 119, 144, and 146
(reviewed Bollag and McCormick, 1991). The mutation occurring at codon 17
(RasN17) resulting from a single substitution leads to a dominant inhibitory effect, since
RasN17 binds GDP with preferential affinity over GTP, which results in inhibition of
endogenous Ras activation by sequestering guanine nucleotide exchange factors. This
mutant has been used extensively to study Ras protein function; some of these studies
are discussed as part of this literature review.
1.7 Signal transduction pathways
The Ras family members are key regulators of signal transduction pathways connecting
cell surface receptors to the nucleus. Ras activates multiple downstream pathways;
including Raf-1 and the MAPK cascade, RalGDS and Ral proteins and PI-3Kinase and
Racl. Alterations in the balance of the activity of the pathways may contribute to the
differential cellular responses elicited by Ras (figure 1.3).
The most extensively studied of the Ras signalling pathways is the Ras/Raf/MEK
(mitogen-activated protein kinase/ERK)/ERK (extracellular-signal-regulated kinase)
cascade (reviewed Kolch, 2000). Extracellular or intracellular signals generate the
Ras.GTP form. Activated Ras then functions as an adapter that binds to the Raf
serine/threonine kinase with high affinity and causes their translocation to the inner
surface of the plasma membrane where Raf activation takes place. Raf activation leads
to the initiation of a mitogen activated protein kinase (MAPK) cascade that carries
signals to the nucleus (McCormick, 1994) and plays a leading role in the mitogenic
signal transduction. Raf acts as the MAPKKK (MAPK kinase kinase) and transfers the
mitogenic signal by phosphorylation of MEK (MAPKK (MAPK kinase)), which in turn
phosphorylates ERK (MAPK). In mammals, there are three isoforms of Raf; c-Raf-1,
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A-Raf and B-Raf. Ras proteins have been shown to bind to different Raf isoforms with
different affinities, which leads to different levels of activation of the Raf kinase (Weber
et al., 2000). However, Raf activation of MEK is not necessary for activation of ERK
to occur (Huser et al., 2000), suggesting that the classical idea of the
Ras/Raf/MEK/ERK pathway being a linear progression may not be correct. K-Ras 4A
and K-Ras 4B have been shown to differ in their abilities to activate the Raf-1 effector
protein, with K-Ras 4B activating Raf-1 more efficiently than K-Ras 4A and the other
Ras family members (Yan et al., 1998; Voice et al., 1999). Additionally, H-Ras and N-
Ras were shown to regulate MAPK activity by different mechanisms in vivo (Hamilton
and Wolfman, 1998). One of the ultimate targets of the signalling pathway is the
nuclear transcriptional machinery, particularly transcription factors such as c-Jun, which
is part of the AP-1 transcription factor, c-Myc and Ets (Westwick et al., 1994; Yang et
al., 1996; Kerkhoff et al., 1998; Paumelle et al., 2002). Ras can also modulate
functional repression of transcription factors for example; the activity of the TTF-1
transcription factor in thyroid cells is repressed via direct phosphorylation of TTF-1 at
three serine residues by ERK (Missero et al., 2000).
Phosphatidylinositol-3-OH kinase (PI-3Kinase) is a heterodimeric lipid kinase
consisting of a p85 regulatory subunit and a pi 10 catalytic subunit. Multiple forms of
PI-3Kinase with distinct mechanisms of regulation and different substrate specificities
exist in mammalian cells (reviewed Carpenter and Cantley, 1996). This lipid kinase is
responsible for converting phosphatidylinositol (4,5)-bisphosphate to
phosphatidylinositol (3,4,5)-triphosphate. Ras directly targets PI-3Kinase in a GTP
dependent manner through its effector region, which interacts with the pi 10 catalytic
subunit (Rodrigez-Viciana et al., 1994). The crystal structure of the Ras/PI-3Kinase has
been analysed (Pacold et al., 2000). One well-characterised downstream effector of PI-
3Kinase is the serine/threonine kinase PKB (protein kinase B)/Akt (reviewed Franke et
al., 1997). In quiescent or serum-starved cells, catalytically inactive PKB/Akt resides
within the cytosol. Upon stimulation of cells with growth factors and cytokines,
PKB/Akt is recruited to the plasma membrane by second messengers in the form of
phosphorylated phosphoinositides, which are generated by the phosphorylation of
inositol lipids by PI-3Kinase (as described above).
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Figure 1.3. Diagrammatic representation of the downstream effectors of Ras signal transduction
pathways. RalGDS is activated by direct interaction with Ras and activates Ral A/B proteins by
stimulating guanine nucleotide exchange. Ral proteins act as GAPs for Rac and CDC42 and therefore
negatively regulate their activity. Ral can also interact with phospholipase D1 (PLD1). Following
activation by Ras, Raf phosphorylates and activates the dual specificity kinases MEK1/2, which in turn
phosphorylate and activate the ERK1/2 (MAPK), which translocate into the nucleus where they
phosphorylate and activate transcription factors such as Elk 1, c-Myc, and c-Jun. Ras interacts with the
pi 10 catalytic subunit of PI-3Kinase, to stimulate its activity. Akt/PKB serine/threonine kinase
phosphorylates multiple targets including FKHRL1 a member of the forkhead transcription factor family,
the pro-apoptotic protein Bad, and caspase 9 (casp 9) leading to their inactivation. It activates IKK that
inactivates IkB resulting in activation ofNFicB. PI-3Kinase can also cause activation of Rac and Rac can
activate NFkB. Furthermore cross talk can occur between Akt/PKB and the MAPK pathway at various
points including phosphorylation and downregulation of Raf activity by Akt/PKB.
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At the plasma membrane PKB/Akt is catalytically activated by phosphorylation at
threonine308 and serine473 (Alessi et al., 1996; Stokoe et al., 1997; Stephens et al., 1998;
Alessi et al., 1997; Kohn et al., 1996). PI-3Kinase can also activate the Rho GTPases
family member Rac (reviewed Scita et al., 2000), which together with Akt facilitates
Ras activation of the NF-kB transcription factor (reviewed Shields et al., 2000).
Stimulation of cells with tumour necrosis factor (TNF) activates the TNF receptor
(TNFR1) and induces tyrosine phosphorylation of the p85 subunit of PI-3Kinase and
activation of Akt/PKB, which activates NF-kB by phosphorylation of IkB kinase
complex (IKKa), leading to the phosphorylation of IkB and its dissociation from NF-
kB, which allows NF-kB to translocate to the nucleus (Ozes et al., 1999). Platelet
derived growth factor (PDGF) has also been shown to activate NF-kB via Akt/PKB
phosphorylation of IKK (Romashkova and Makarov, 1999). Insulin induced the
phosphorylation of the forkhead transcription factor AFX by way of both PI-3Kinase
Atk/PKB and Ras/Ral signalling pathway in vitro and in vivo inhibiting its
transcriptional activity following growth factor stimulation (Kops et al., 1999). Other
targets of Atk/PKB include glycogen synthease kinase-3 (GSK-3) and p70S6kinase
(reviewed Franke et al., 1997). Signalling via the PI-3Kinase pathway is important for
transformation of mammalian cells by activated Ras and essential for Ras-induced
cytoskeletal re-organisation (Rodriguez-Viciana et al., 1997). H-Ras is a more potent
activator of PI-3Kinase than K-Ras (Yan et al., 1998), this differential activation of
pathways may lead to functional differences between these proteins.
The Ras/Raf/MEK/ERK and PI-3Kinase/Akt signalling pathways are further
complicated by the observations that cross-talk between these pathways exists. The PI-
3Kinase pathway can interact with the Ras/Raf/MEK/ERK at several different levels.
PKB/Akt can negatively regulate B-Raf activity through phosphorylation of several
residues in its amino terminal regulatory domain (Guan et al., 2000). Raf-Akt cross¬
talk is regulated in a concentration- and ligand-dependent manner (Moelling et al.,
2002). In the presence of high, but not low concentrations IGF-1, PKB/Akt can inhibit
Raf kinase activity in MCF-7 cells (Moelling et al., 2002). However, PI-3Kinase can
also have a dual inhibitory role up-stream of Ras and ERK activation by low levels of
EGF, but not high doses (Wennstrom and Downward, 1999). Furthermore, p21
activated kinase (PAK); a downstream target of PI-3Kinase via activation of Rac can
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promote stimulation of MEK by phosphorylation on serine (Frost et al., 1996; Frost
et al., 1997). K-RasG12V is a more potent activator of Rac-1 in vivo then H-RasG12V
(Walsh and Bar-Sagi, 2001). The differential activation was elegantly demonstrated to
be the result of the Ras F1VR. Chimaeric H-Ras proteins generated with the K-Ras C-
terminal region caused cells to undergo K-RasG12V responses in terms of membrane
ruffling.
Ras also activates a family of guanine nucleotide exchange factors (GEF) for the Ral
family of proteins (RalGDS, RGF and Rlf). RalGDS, RGF and Rlf all bind to and are
activated by Ras.GTP, which in turn cause the activation of Ral proteins by promoting
the release of GDP allowing GTP to bind in its place (reviewed Shields et al., 2000).
Activated Ral proteins can influence a variety of cellular processes by interacting with a
distinct set of down stream target proteins. These include RalBPI (RFIP) (Cantor et al.,
1995; Jullien-Flores et al., 1995; Park and Weinberg, 1995), which binds to a family of
related EH domain proteins, Rep 1 (Yamaguchi et al., 1997), POB1 (Ikeda et al., 1998)
and the AP2 complex (Jullien-Flores et al., 2000). These associations have implicated
Ras function through Ral activation in the regulation of endocytosis (Nakashima et al.,
1999). RalBPI also negatively regulates Rac and CDC42 activity, since it can act as a
GAP for these proteins and Ral.GTP binds to the actin cross-linking protein filamin
(Ohta et al., 1999). Therefore, Ral proteins are likely to be involved in the regulation of
the cytoskeleton. Ras proteins are important regulators of phospholipase D (PFD), via
the RalGDS/Ral A pathway (Voss et al., 1999; Fucas et al., 2000). PFD catalyses
formation of phosphatidic acid (PA) from the membrane phospholipid,
phosphatidylcholine (PC), linking the RalGDS pathway to the control of vesicular
trafficking and cell growth and differentiation. Furthermore, transformation of human
cell lines by expression of constitutively active Ras has been associated with signal
transduction via the RalGDS/Ral pathway, but not the Raf or PI-3Kinase pathways
(Hamad et al., 2002).
Furthermore, Chiu and co-workers have recently hypothesised that far from being
restricted to the plasma membrane Ras signalling can occur on other membranes
including the endoplasmic reticulum and Golgi apparatus and that this may confer
signalling specificity to Ras proteins (Chiu et al., 2002). Golgi tethered Ras was more
efficient at activating ERK and Akt than c-Jun NH^-terminal kinase (JNK). In contrast,
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Ras tethered to the endoplasmic reticulum activated JNK more efficiently than ERK and
Akt.
Mutations within the Ras proteins effector domain, which spans amino acids 32-40 have
been characterised, and used extensively for analysis of Ras signal transduction
pathways to elucidate the downstream effectors of the signal transduction pathways
described above, but also to define the cellular outcomes associated with these
pathways. (Joneson et al., 1996; Matsuguchi et al., 1998). These Ras effector mutants
are able to signal by only one specific pathway as follows: Ras T35S, couples almost
exclusively to the Raf/ERK pathway; Ras Y40C, couples exclusively to the PI-3Kinase
pathway and Ras E37G, results in signal transduction via RalGDS.
1.8 Regulation of the Cell Cycle by ras gene products
The progression of the mammalian cell cycle is controlled by complexes of cyclins and
cyclin dependent kinases (CDK). The progression through the Gl phase of the cell
cycle is mediated by the sequential activation of D-type cyclins (Dl, D2 or D3) in
complexes with, either CDK4, or CDK6 and the cyclin E-CDK2 complex. In GO and
early Gl the Rb protein (product of the retinoblastoma susceptibility gene) is
hypophosphorylated and functionally active, forming a complex with the E2F-DPI
transcription factor, thereby inhibiting the expression of E2F-DPI responsive genes
(reviewed by Takuwa and Takuwa, 2001). The Rb protein is phosphorylated by cyclin
D-CDK4/CDK6 during mid-Gl, finally becoming hyperphosphorylated by cyclin E-
CDK2 later in Gl, resulting in its inactivation and release of the E2F-DPI transcription
factor, leading to the expression of E2F-DPI responsive genes which are required for S
phase entry (reviewed in Takuwa and Takuwa, 2001).
Seminal experiments have demonstrated that Ras is essential for the progression of
quiescent cells through the Gl phase of the cell cycle into S phase (Mulcahy et al.,
1985; Feig and Cooper, 1988; Cai et al., 1990). Following the microinjection of
NIH3T3 cells with monoclonal antibodies against cellular Ras proteins, cells were
unable to enter S phase following mitogenic stimulation. Closer examination of the
requirement for Ras during the Gl phase of the cell cycle indicated that Ras activity was
necessary at multiple points during Gl progression, almost until entry into S phase
16
(Dobrowolski et al., 1994; Aktas et al., 1997). Expression of dominant negative Ras
N17 blocked the activation of cyclin D1 and cyclin E dependent kinases and prevented
the appearance of the hyperphosphorylated form of Rb in serum stimulated cells,
preventing their entry into S phase (Leone et al., 1997), which was associated with
inhibition of EF2 mediated gene transcription. The Ras proteins regulate cyclin D1 and
cyclin E activity through the downregulation of the CDK inhibitor p27kipl (Aktas et al.,
1997) and its dissociation from cyclin E-Cdk2 complexes, which results in
phosphorylation of Rb. However, Ras activity was not required for progression through
the Gl/S phase restriction point in the absence of Rb indicating that the regulation of Rb
activity by Ras was a critical target for cell cycle progression to occur (Leone et al.,
1997). Nevertheless, the regulation of Rb activity by Ras has an added level of
complexity, since the Rb protein has a regulatory role in the activation of Ras proteins
in vitro. In the absence of Rb, N-Ras and K-Ras had significantly increased activity
following serum stimulation of quiescent MEF (Lee et al., 1999). Therefore, Rb may
function to downregulate Ras activity in vitro in response to serum stimulation.
The requirement of ras gene products during the G1 phase of the cell cycle has been
intensively studied. Ras activation following growth factor stimulation of quiescent
cells is biphasic (Gille and Downward, 1999). The first peak occurring ~30mins after
simulation, this is associated with ERK activity. The second peak occurring 2-4hrs after
exit from quiescence and is associated with PI-3Kinase activity mediated via Akt/PKB,
Ral activity and to a lesser extent Rac, which are required for expression of endogenous
cyclin Dl, E2F activity and S phase entry of NIH 3T3 fibroblasts (Gille and Downward,
1999).
However, the expression of activated ras genes in primary cell lines; including primary
rat Schwann cells, pheochromocytoma cells, rodent fibroblasts and primary mouse
keratinocytes (Bar-Sagi and Feramisco, 1985; Benito et al., 1991; Franza et al., 1986;











Figure 1.4 Diagram showing the mechanism by which activated Ras induces senescence in non-
immortalised cell lines. The expression of activated ras genes in non-immortalised cell lines leads to
cellular senescence via the up-regulation of pl6INK4a, p53 and p21Clf>1, which inhibit cyclin
D/CDK4/CDK6, cyclin E/CDK2 and cyclin A/CDK2 complexes, preventing phosphorylation of Rb. The
hypophosphorylated Rb remains complexed with E2F, preventing E2F dependent transcription and Gl/S
transition.
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The expression of oncogenic ras in either primary human or rodent cells resulted in G1
arrest associated with an accumulation of p53, p21upl, pl6INK4j and pl9ARF and a
decline in the levels of hyperphosphorylated Rb, cyclin A and CDK2 kinase activity
(Serrano et al., 1997; Lin and Lowe, 2001). Whilst decreases in the abundance of
hyperphosphorylated Rb, cyclin A and CDK2 activity are characteristic of G0/G1 cell
cycle arrest associated with quiescence, p53, p21cipl and pl6INK4a accumulation are not.
The up-regulation of these proteins is associated with cellular senescence, suggesting
that activated ras may be inducing cell-cycle arrest through mechanisms associated with
replicative senescence. Cell cycle arrest induced by activated ras could be overcome in
the absence of either p53 or pl6INK4a. The introduction of activated H-ras into INK4a-
deficient fibroblasts resulted in neoplastic transformation (Serrano et al., 1996; Serrano
et al., 1997). This effect was also abrogated in the absence of pl9ARF presumably
because the activated Ras protein was unable to efficiently activate p53 (Lin and Lowe,
2001). Further analysis of the mechanisms underlying this growth arrest showed that
this it was mediated in part via an induction of the CDK inhibitor (CDI) p21cipl by Raf
and the subsequent inhibition of cyclin D and cyclin E-dependent kinases and an
accumulation of hypophosphorylated Rb protein (Lloyd et al., 1997; Sewing et al.,
1997; Woods et al., 1997). Increased p21cipl protein synthesis induced by ras
expression occurred via the MAPK pathway by transcriptional and posttranscriptional
mechanisms, in a p53-independent manner (Kivinen et al., 1999; Gartel et al., 2000).
Whilst activated Ras leads to increase in p21cipl and cell cycle arrest, Rho acts to down
regulate p21upl in a transcriptional dependent way (Olson et al., 1998). Importantly
cellular fate was determined by the intensity of the signal strength, as only higher Raf
activity elicited cell cycle arrest, whereas moderate levels of Raf activity led to
activation of cyclin D1/CDK4 and cyclin E/CDK2 complexes and cell cycle progression
(Sewing et al., 1997; Woods et al., 1997). Whilst the Rb and pl07 proteins are both
separately dispensable for Ras induced cellular senescence, the absence of both these
genes leads to unrestrained proliferation (Peeper et al., 2001) despite the activation of
the p!9ARF/p53 pathway, suggesting that redundancy may exist between members of the
Rb family. Another mechanism through which Ras mediates cellular senescence
appears to be ubquitin mediated degradation of cyclin D1 (Shoa et al., 2000). Escape
from ras induced premature senescence requires cooperating mutations in the genes
described, such mutations are often present in immortalised cell lines, which leads to the
transformation of these cell lines. Therefore, cell cycle arrest is a natural defence to
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counter uncontrolled mitogenic signalling, and elimination of this mechanism by the
occurrence of additional mutations is critical for transformation and presumably tumour
progression.
The expression of activated ras genes in immortalised cell lines is associated with a
shortening of the G1 phase and acceleration of cell cycle progression (Lui et al., 1995;
Winston et al., 1996; Fan and Bertino, 1997) and a reduced requirement for growth
factor stimulation. This acceleration in G1 progression is associated with an increased
expression of cyclin Dl, and accumulation of cyclin D1/CDK4 complexes (Liu et al.,
1995; Winston et al., 1996). Activated ras induced acceleration of G1 progression
could be mimicked by over-expression of cyclin Dl alone (Liu et al., 1994), as cyclin
Dl together with its respective CDK phosphorylate Rb and thus inactivate the G1
restriction point control. Examination of the effect of the specific activation of the K-
ras gene on cell cycle stimulators and inhibitors in a human breast carcinoma line
showed that the cell cycle stimulators cyclin A, D3 and E and the E2F family of
transcription factors were up-regulated (Fan & Bertino, 1997). Down-regulation of
p27kipl and up-regulated p53, which was accompanied by up-regulation p21wafI/cipl and
Gadd45 two negative regulators, were also seen. Additionally, up-regulation of Bcl2
was also seen, supporting a role for K-ras in apoptosis suppression (Fan & Bertino,
1997). The effect of K-ras on the cell cycle therefore appears to rely upon a balance
between opposing factors, which may be deregulated in cancer.
Ras may mediate these effects by signal transduction pathways that result in cell cycle
dependent alteration of either transcription factor or repressor activity. The Ets
repressor factor (ERF) is a ubiquitously expressed transcriptional repressor and member
of the Ets family. It is a direct target of ERK, which binds to and phosphorylates ERF
at multiple sites (Gallic et al., 1999). ERK-dependent phosphorylation of ERF
determines its cellular localisation: upon mitogenic stimuli ERF is immediately
phosphorylated and exported from the nucleus to the cytoplasm. Conversely upon
serum withdrawal ERF is rapidly dephosphorylated and imported into the nucleus.
Mutated ERF proteins that were phosphorylation deficient displayed a predominantly
nuclear localisation and resulted in G0/G1 cell cycle arrest (Gallic et al., 1999). This
suggests that ERF may be a Ras responsive transcriptional repressor that is important
for the control of cellular proliferation. AFX-like Forkhead transcription factors appear
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to mediate cell-cycle regulation by Ras through p27kipl (Medema et al., 2000). AFX-
mediated transcription is negatively regulated through PI-3Kinase-Akt/PKB and
Ras/Ral signalling (Kops et al., 1999).
1.8.1 Cell cycle control in stem cell populations
ES cells, unlike somatic cells, do not undergo exit from the cell cycle following serum
withdrawal, but continue to proliferate (Schratt et al., 2001). In the absence of a
quiescent state, activation of the immediate early gene (IEG) response by serum
response factor (SRF) following signal transduction through the MAPK pathway is
dispensable for ES cell growth. This may be explained by the observations that ES cells
are not regulated by the normal cell cycle controls. ES cells cycle quickly and have a
short G1 phase with an absence of hypophosphorylated Rb protein and an apparent
reduction in the overall level of this protein following the exit from mitosis (Savatier et
al., 1994). Indeed, the Rb protein is detected mainly in its hyperphosphorylated form in
ES cells. In addition, ES cells express very low levels of cyclin E/CDK2 complexes,
p21cipl and p27k,pl CDIs (Savatier et al., 1996). Cyclin D/CDK 4-associated kinase
activity was undetectable and only low levels of cyclin D1 and no cyclin D2 or cyclin
D3 were detectable. Furthermore, over-expression of pl6INK4a, which is associated with
activated ras induced cell cycle arrest (Serrano et al., 1997) did not cause growth arrest
in ES cells (Savatier et al., 1996). Therefore, ES cells are not regulated by the normal
cell cycle controls characteristic of somatic cells, but maintain a continuously
proliferating population, which is growth factor independent. This has been shown
recently to be associated with differential requirement for Ras/MEK/ERK and PI-
3Kinase signal transduction pathways (Jirmanova et al., 2002). ERK activity was
dispensable for ES cell proliferation and G1 to S phase transition. However, following
differentiation of ES cells by retinoic acid (RA) ERK activity was found to be necessary
for proliferation. Signal transduction via the PI-3Kinase pathway was critical for the




Ras proteins have been implicated as key regulators of proliferation and differentiation.
Ras may be important for the maintenance of a proliferative or stem cell compartment
as shown by the role of Ras in the maintenance of ES cell renewal. Activation of the
MAPK pathway following cytokine stimulation of the gpl30 receptor (Boulton et al.,
1994; Ernst et al., 1996; Sheng et al., 1997; Yin and Yang, 1994), suggested that ras
might be important for the maintenance of ES cell renewal. This was demonstrated
directly by the observation that expression of v-H-ras reduced ES cell requirement for
LIF by approximately 8 fold (Ernst et al., 1996).
A marked inhibition of morphological differentiation induced by nerve growth factor
(NGF) and fibroblast growth factor (FGF) is seen in PC 12 cells expressing a mutant H-
Ras protein (Szeberenyl et al., 1990). High levels of the mutant H-Ras, also inhibited
induction of early response genes (fos, jun, and zif268) by NGF and FGF, but not 12-0-
tetradecanoylphorbol-13-acetate (TPA).
Approximately day 4.5 post coitum one of the first differentiation processes during
mouse embryogenesis takes place in the blastocyst. Some of the cells of the inner cell
mass differentiate into primitive endoderm (PrE) and subsequently differentiate into
parietal endoderm (PE). Using the F9 embryonal carcinoma (EC) cell line as a model
system both of these differentiation processes were found to be mediated by Ras signal
transduction. Differentiation to PrE was associated with increased endogenous Ras and
ERK activity, whilst differentiation to PE was accompanied by a decrease in
endogenous Ras and ERK activity (Verheijen et al., 1999a). Expression of activated ras
was sufficient to cause differentiation to a PrE-like morphology, but prevented further
differentiation to a PE-like morphology following treatment with parathyroid hormone.
However, further analysis of the pathways associated with Ras induced differentiation
to PrE using Ras effector mutants, showed this this occurred via an interdependent
action of RalGEFs and ERK (Verheijen et al., 1999b).
Appropriate expression of ras genes in the epidermis is also important for correct
differentiation. Normal epidermis is a self-renewing tissue composed of stratified
epithelium, containing a basal layer of mitotically active cells. Expression of a
dominant-negative mutant Ras (N17) by the specific basal layer keratin 14 promoter in
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mice caused these animals to have extremely thin skin, which was characterised by
terminally differentiated cells (Dajee et al., 2002). However, the expression of activated
RasG12V by this same promoter resulted in hyperplasia, and an absence of
differentiation. This clearly indicated that spatial localisation of Ras signalling is
important for appropriate epidermal tissue proliferation and differentiation. Therefore,
it appears that expression of Ras proteins is important for proliferation and controls
differentiation at least in part by the appropriate cessation of signalling. Inappropriate
signalling as described above overrides the differentiation signals and maintains a
proliferative population.
1.10 Regulation of Apoptosis by Ras signalling cascades
Apoptosis is a normal physiological process of programmed cell death that is essential
for embryonic development and homeostasis of adult tissues. Disorders of the apoptotic
process cause various pathologies, including autoimmune and neurodegenerative
diseases (Rinkenberger and Korsmeyer, 1997). The abrogation of apoptotic pathways is
vital for cancer development and may influence the tumour's net growth and
accumulation of further mutation due to the retention of mutated cells, which would
normally undergo apoptosis. Apoptosis is characterised by its morphological features
of cell shrinkage and nuclear chromatin condensation and the formation of apoptotic
bodies (Kerr et al., 1972), which distinguishes it from other forms of cell death such as
necrosis.
One of the early events of apoptosis is the exposure of phosphatidyl serine (PS) upon
the surface of apoptotic cells, which triggers specific recognition and removal by
macrophages and is important for clearage of apoptotic cells before they rupture (Fadok
et al., 1992). PS externalisation is a widespread event during apoptosis regardless of the
initiating event (Martin et al., 1995). This underlies one of the most important
characteristics of apoptosis: the dying cells are removed quickly without the generation
of an inflammatory response. In necrosis however, the dying cell swells and ruptures
releasing its contents, which induce an inflammatory response.
Apoptosis is executed by a family of proteins called caspases, which are an
evolutionarily conserved class of cysteine proteases that cleave after asparate residues in
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target proteins, with homology to the C. elegans ced-3 gene (reviewed Meier and Evan,
1998). Caspases are produced as inactive zymogen precursors and are activated by
cleavage at sites that conform to caspase substrate consensus sequences. Activation of
apical caspases appears to occur by an autocatalytic process, these activated caspases
then cleave downstream effector caspases, which implement apoptosis by cleaving
cellular substrates (reviewed Meier and Evan, 1998).
Another family of proteins exist in vertebrates that are structurally and functionally
related to the C. elegans death suppressor ced-9, the archetypal member of this family
being the Bcl-2 protein (reviewed Meier and Evan, 1998). However, this family has
been shown to have members that interact with each other to either promote or inhibit
apoptosis. The pro-apoptotic Bad in its unphosphorylated state antagonises the anti-
apoptotic function of Bcl-2 and Bcl-xL by forming inactivating Bad-Bcl-2 and Bad-
Bc1-xl heterodimers (Zha et al., 1996), thereby neutralising their protective effect and
promoting cell death. Following stimulation with the survival signal IL-3 Bad is
phosphorylated, causing Bad to be sequestered to the cytoplasm bound to 14-3-3 (Zha et
al., 1996). When uncomplexed with Bad, Bcl-2 and Bc1-xl are capable of abrogating
Bax-mediated apoptosis through the formation of Bax-Bcl-2 and Bax-Bcl-xl
heterodimers (Zha et al., 1996; Reed et al., 1998). In addition, members of this family
have been shown to suppress caspase 9 activation through direct interaction with Apaf-1
(Pan et al., 1998). Apaf-1 is the mammalian homologue of the C-elegans ced-4 gene
and acts as an adapter protein for formation of the apoptosome with cytochrome c and
caspase 9.
Apoptosis can be initiated by many different stimuli, including death receptors, which
are members of the tumour necrosis factor receptor superfamily (Nagata, 1997). These
death receptors can induce apoptosis triggered by binding of their ligands and are
characterised by the presence of death domains within their cytoplasmic regions, which
can interact physically with caspases and receptor oligmerisation by ligand directly
initiates the caspase proteolytic cascade (Cohen, 1997). Alternatively apoptosis can be
initiated by stimuli that indirectly activate caspases, included in this lists are treatments
that induce DNA damage such as etoposide (reviewed McConkey et al., 1998).
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1.10.1 Identification of Ras pathways involved in apoptosis
Several lines of investigation suggest that Ras proteins may have an important function
in the control of apoptotic pathways. However, there is a great deal of conflicting
evidence to whether this is a pro- or anti-apoptotic role. Some of the Ras apoptotic
pathways are shown diagrammatically in figure 1.5.
The use of Ras effector-loop mutants has helped to identify those pathways that are
involved in pro- and anti-apoptotic Ras-mediated signalling. Expression of activated
RasG12V is an effective promoter of apoptosis induced by c-Myc, through the Raf
pathway in fibroblasts (Kauffman-Zeh et al., 1997). However, specific activation of the
PI-3Kinase pathway alone by a Ras effector loop mutant suppresses apoptosis induced
by c-Myc via the activation of Akt/PKB in the same cells. This apparently
contradictory finding has also been demonstrated in rat thyroid cells. Transformation
with RasG12V sensitises the cells to apoptosis induced by matrix detachment,
compared to parental cells (Cheng and Meinkoth, 2001). A Ras effector loop mutant
that could only signal via the Raf/MEK pathway was similarly sensitive, but cells
expressing activated Ras able to signal only via the PI-3Kinase pathway were no longer
sensitive to matrix detachment induced apoptosis (Cheng and Meinkoth, 2001). Thus,
demonstrating that RasG12V activates multiple intracellular pathways in response to
apoptotic stimuli. Therefore, it can be postulated that the determination of cellular fate
results from the synergistic outcome of signalling by these opposing pathways,
determined by other unknown modulators. However, it should be noted that in rat
fibroblasts Ras activation has been reported to cooperate with activation of c-Myc to
cause cellular transformation by inhibiting apoptosis in a Raf/MEK dependent manner
(Tsuneoka and Mekada, 2000).
Furthermore, in fibroblasts, treated with FasL expression of K-Ras G12V suppressed
apoptosis. The use of effector loop mutants showed that this suppression was mediated
by specific signalling via the Raf/MEK pathway, and neither the PI-3Kinase nor the
RalGDS pathway were capable of mimicking this response (Kazama and Yonehara,
2000).
Therefore, the cell fates determined by these pathways also appear to be dependent upon
the cell type, apoptotic stimulus and possibly experimental conditions. Activated Ras
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has been shown to promote cell survival in various cell types by signalling through both
the Raf/MEK and PI-3Kinase pathways; including sympathetic neurons (Mazzoni et al.,
1999, Xue et al., 2000) and murine haematopoietic cells (Kinoshita et al., 1995;
Kuribara et al., 1999; Terada et al., 2000). Rat sympathetic neurons are dependent upon
Ras signalling for NGF mediated survival. Expression of RasG12V in these cells
protects them from apoptosis induced by NGF withdrawal (Xue et al., 2000). However,
only signalling via the PI-3Kinase pathway protects from apoptosis induced by NGF
withdrawal. The Raf/ERK pathway protects from araC induced apoptosis in these cells.
Therefore, these two pathways both mediate survival in response to different stimuli
with no functional overlap. However, another group showed that Ras suppression of
sympathetic neuron survival in the absence of NGF was mediated mainly by PI-
3Kinase, but also by Raf-1 (Mazzoni et al., 1999). This survival was as a result of
activated Ras suppression of the increases in c-jun, p53 and Bax proteins normally
associated with NGF withdrawal.
1.10.2 Regulation of anti-apoptotic signals via the PI-3Kinase pathway
Whilst signal transduction through the Raf/MEK pathway can apparently mediate either
pro- or anti-apoptotic signals, to date signal transduction via the PI-3Kinase pathway
has only been implicated in anti-apoptotic responses. The PI-3Kinase effector PKB/Akt
has been shown to regulate apoptosis by direct phosphorylation of several components
of the apoptotic machinery. PKB-Akt can directly phosphorylate pro-caspase-9 at ser1%
thereby preventing its activation by the Apaf-l/cytochrome c oligmeric complex
(Cardone et al., 1998). PKB/Akt also regulates the activity of FKHRL1, a member of
the Forkhead family of transcription factors (Brunet et al., 1999). In the presence of
survival signals phosphorylation by PKB/Akt results in association of FKHRF1 with
14-3-3 proteins leading to its sequestering in the cytoplasm, thereby inhibiting
FKHRL1-dependent transcription. Withdrawal of survival factors results in
dephosphorylation of FKHRL1 and translocation to the nucleus leading to apoptosis
possibly by activating transcription from thefas ligand gene (Brunet et al., 1999).
Ras can also mediate cell survival signals through PI-3Kinase activation of Akt and/or
Rac/Cdc42, which stimulates Pak and leads to phosphorylation of the pro-apoptotic
factor BAD (Tang et al., 2000). Furthermore, the PI-3Kinase and Raf/MAPK pathways
have been postulated to phosphorylate distinct serine residues of the BAD protein. The
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PI-3Kinase pathway phosphorylates BAD at ser " and the Raf/MAPK pathway
phosphorylates BAD at ser112 (Bonni et al., 1999; Fang et al., 1999). This
phosphorylation allows the 14-3-3 protein to interact with and sequester BAD in the
cytoplasm resulting in its inactivation (Datta et al., 1997; Zha et al., 1996). Activation
by phosphorylation of the cAMP response element binding (CREB) protein by the
Raf/MAPK pathway also promoted cell survival; a known transcriptional target of
CREB is Bcl-2 (Bonni et al., 1999). Activated Ras has previously been shown to
regulate the expression of Bcl-2 and its related survival proteins (Kinoshita et al., 1995).
These findings suggest that Ras proteins may promote cell survival by transcription-
dependent and -independent mechanisms. The PI-3Kinase pathway can also delay the
onset of p53-mediated apoptosis in BRK epithelial cells but cannot prevent it (Sabbatin
and McCormick, 1999).
In rat fibroblasts, the pro-apoptotic effects of activated Ras are mediated by concerted
activation of the ERK and JNK MAP kinase cascades (Joneson and Bar-Sagi, 1999).
However, Rac-mediated signals are necessary and sufficient to protect against Ras-
induced apoptosis through a pathway that involves NF-kB activation (Joneson and Bar-
Sagi, 1999). PI-3Kinase via Akt stimulates NF-kB predominantly by up-regulating the
transactivation potential of the p65 subunit in response to H-RasG12V (Madrid et al.,
2000). H-RasG12V and constitutively active MEKK1 can stimulate nuclear
translocation of NF-kB by increased activity of IkB kinase (IKK) complex and
degradation of IkB, but PI-3Kinase does not in this cell type. However, other groups
reported that PI-3Kinase activation of NF-kB via Akt following stimulation with TNF
and PDGF was associated with mechanisms involving IKK-dependent phosphorylation
and subsequent degradation of IkB (Ozes et al., 1999; Romashkova and Makarov,
1999). Furthermore, activated K-ras has been reported to induce the nuclear
translocation and activation of NF-kB through the NIK-IKK(3-lKBa signalling pathway
(Kim et al., 2002).
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Figure 1.5. The downstream effectors of Ras that regulate both pro- and anti-apoptotic signals. The
activation of PI-3Kinase pathway generates anti-apoptotic signals via phosphorylation and inactivation of
pro-apoptotic targets such as pro-caspase 9, FKHRL1 and Bad by the serine/threonine kinase Akt/PKB.
PI-3Kinase also activates NF-kB regulated gene transcription through Rac and Akt/PKB. The
Raf/MEK/ERK pathway can promote either pro- or anti-apoptotic signals possibly though positive and/or
negative regulation of members of the Bcl-2 family. The RASSF1/MST1 and NORE/MST1 effectors
promote pro-apoptotic pathways although the downstream effects of this pathway have yet to be
established.
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1.10.3 Ras regulation of the Bcl-2 family of proteins
Ras has also been investigated as an important mediator of murine interleukin-3 (IL-3)
mediated cell survival of haematopoietic cells. Activation of Ras resulted in a rapid up-
regulation of Bcl-2 and Bc1-xl in haematopoietic cells (Kinoshita et al., 1995). The
survival effects of activated Ras were mediated via the MEK and PI-3Kinase pathways
(Kuribara et al., 1999). The survival signalling effects of these pathways seem to be
associated with suppression of activation of the pro-apoptotic protease caspase-3 upon
IL-3 removal (Terada et al., 2000). Other pathways are also postulated to be involved
because although the MEK and PI-3Kinase pathways are partly responsible activated
Ras still causes suppression of apoptosis even when these pathways are inhibited
(Terada et al., 2000).
The expression of a constitutively active ras gene in Jurkat T cells renders them
susceptible to apoptosis caused by withdrawal of protein kinase C (PKC) (Chen and
Faller, 1995), which may be regulated by direct interaction of Ras and Bcl-2 (Chen and
Faller, 1996). PKC/Ras mediated apoptosis was cell cycle dependent and required
expression of Gl/S cyclins (Chen et al., 1998). Further analysis showed that Fas-
independent, FADD/caspase-8 signalling is involved in PKC/Ras-mediated apoptosis,
and JNK may be an upstream effector of caspase activation (Chen et al., 2001).
K-Ras, H-Ras and N-Ras have all been found to associate with Bcl-2 in the
mitochondria (Rebollo et al., 1999). However, their mitochondrial localisation is
differentially regulated. In addition, Ras and Raf were also found to be associated with
phosphorylated Bcl-2 protein following induction of apoptosis by withdrawal of serum
from Ras transformed brown adipocytes (Navarro et al., 1999). Activated H-ras
sensitised these cells to apoptosis induced by serum withdrawal in a Raf-dependent, but
MEK-independent fashion (Navarro et al., 1999). This response was associated with
the up-regulation of the pro-apoptotic Bcl-xs and a down-regulation of the anti-
apoptotic Bcl-2.
1.10.4 Novel Ras apoptotic pathway
RASSF1, which is a putative tumour suppressor, binds to Ras in a GTP dependent
manner and appears to mediate pro-apoptotic signals generated by activated Ras (Vos et
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al., 2000). NORE is a non-catalytic protein that binds Ras and several other GTPases in
the Ras subfamily in a GTP-dependent manner in vitro and in vivo and is homologous to
RASSF1. Serum and EGF can stimulate the binding of NORE to both endogenous and
recombinant Ras in several cell types, clearly demonstrating that NORE is amongst
Ras' physiological effectors. MST-1 has the ability to engage in a ternary complex with
Ras-GTP and NORE. NORE-MST1 complex has been implicated as a pro-apoptotic
effector of constitutively active forms of Ras. In HEK 293 cells over-expression of K-
RasG12V efficiently induced cell death. In contrast, over-expression of H-RasG12V
did not result in significant cell death. This may be due to the greater activation of PI-
3Kinase by H-Ras, since an effector loop mutant of H-Ras, which was unable to bind to
either Raf-1 or PI-3Kinase elicited substantial cell death in 293 cells (Khokhlatchev et
al., 2002).
1.10.5 Specificity of response by Ras family members to apoptotic stimuli
The evidence cited above clearly indicates that there are important differences in the
cellular fate determined by a complex interaction of multiple Ras effector pathways,
which is further complicated by cell type and stimulus differences. However, the
evidence cited below indicates that an additional level of complexity exists, since the
different Ras proteins appear to differentially mediate these responses. K-ras can
function to promote apoptosis in response to DNA damaging agents. This is best seen
in K-ras knockout cells, where K-ras'1' ES cells and K-ras'1' mouse embryonic
fibroblasts (MEFs) are more resistant to apoptosis induced by treatment with, either
etoposide, or cisplatin, or TNFa in the presence of cycloheximide, compared to their
wild-type counterparts (Brooks et al., 2001; Wolfman and Wolfman, 2000). This is
further evidenced by rescue strategies introducing, either wild-type K-ras, or K-ras
G12V minigenes into K-ras'1' ES cells, which results in sensitivity to apoptotic stimuli
comparable to wild-type levels and above respectively (Brooks et al., 2001). Thereby
showing that oncogenic K-ras G12V in this system is responsible for an increased
sensitivity to apoptosis. This maybe as a result of a p53 dependent mechanism, since
increased pl9ai1 mRNA levels accompanied the apoptotic response of K-ras'' ES cells
expressing the K-ras G12V mingene to etoposide treatment (Brooks et al., 2001). In
contrast, N-rax homozygous null MEFs are more sensitive to apoptotic stimuli than
wild-type MEFs (Wolfman and Wolfman, 2000). Therefore, N-ra.v may have an
opposing anti-apoptotic function. Analysis of the role of N-ras in apoptosis has
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revealed that there are several anti-apoptotic mechanisms involved, which provide more
than one survival signal (Wolfman et al., 2002). N-ras'1' cell lines had elevated JNK
and p38 activity. Therefore, it appears that N-Ras provides a second survival signal in
addition to up-regulating Akt and Bad levels, by specifically attenuating the magnitude
and duration of JNK and p38 activation in response to the induction of apoptosis by
down-regulating the upstream kinase activator of JNK and p38 (Wolfman and
Wolfman, 2000; Wolfman et al., 2002). H-ras appears to be similar to K-ras, as
transformation of brown adipocytes, leads to increased apoptosis, compared to wild-
type cells following serum starvation (Navarro et al., 1999).
This subject is further complicated as it appears that the method of apoptotic induction
and the cell system used lead to different results. Oncogenic K-ras G12V and v-H-ras
have been shown to negatively regulate Fas-mediated killing. K-ras G12V strongly
inhibits Fas mediated apoptosis in Balb3T3 cells via the MAPK pathway (Kazama &
Yonehara, 2000) and v-H-ras inhibits Fas action in NIH3T3 cells and an established
mouse mammary epithelial cell line by down-regulating the expression of Fas (Peli et
al., 1999). However, Chen and co-workers show that by increasing ras activity by
either expressing v-ras or by inhibiting GAPs with antisense oligonucleotides leads to
an acceleration of Fas mediated apoptosis (Chen et al., 1998) in Jurkats and mouse LF
cells. Although these results were found in v-H-ras transfected cells the authors report
that identical results were seen with v-K-rax transfected cells, suggesting that functional
overlap may occur between these proteins.
1.10.6 Caspase cleavage of downstream components of the Ras signal
transduction pathways
One of the clearest indications of the importance of Ras mediated signalling pathways
for the suppression of apoptosis is the observation that several of the downstream Ras
effectors are substrates for caspase cleavage. Following FasL induced apoptosis Cdc42
and Rac were cleaved by caspase-3 and caspase-7 (Tu and Cerione, 2001). However,
Ras itself and Rho were not cleaved. Other Ras effectors cleaved by caspases following
apoptotic stimulation by FasL, etoposide and UV c were RasGAP, Raf-1 and Akt
(Widmann et al., 1998). The cleavage of RasGAP was also observed in Fas induced
apoptosis of Jurkat T cells (Wen et al., 1998). This result clearly demonstrates the
importance of turning off Ras-mediated survival signals for appropriate apoptosis.
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1,10.7 Ras and apoptosis: implications for tumoriqenesis
As detailed above expression of activated ras genes in many different cell type results
in reduced sensitivity to different types of apoptotic stimuli. This is further supported by
observations made by Arends and co-workers showing that the transfection of mutant
H-ras genes into immortalised rat fibroblasts resulted in reduced levels of apoptosis
(Arends et al 1993). In addition, following doxorubicin incubation a rat cell line stably
transfected with v-H-ras also showed reduced apoptosis (Nooter et al., 1995), implying
that expression of mutant ras genes may promote survival during treatment and
therefore lead to a selection of cells harbouring ras mutants which have gained a growth
advantage. These observations appear to have clinical relevance following the
observation that tumours with K-ras mutations have a significantly lower apoptotic
index than those tumours, which have the wild type allele (Ward et al., 1997),
suggesting that K-ras has a role in inhibiting apoptosis in vitro and in vivo. Therefore,
K-ras mutations potentially drive cancer development by promoting survival of mutant
cells.
However, clearly this is not the complete picture, since in an in vivo system co-
expression of K-Ras G12V and SV-40 T antigen (TAg) in postmitotic villus enterocytes
of the small intestine caused cells to undergo apoptosis in a p53-independent manner
(Coopersmith et al., 1997). Expression of SV-40 TAg caused the cells to re-enter the
cell cycle, since expression of K-RasG12V alone did not cause apoptosis, this indicated
that the apoptosis was cell cycle dependent. Furthermore, there is data to indicate that
oncogenic Ras elicits an anti-tumorigenic response mediated by the up-regulation of
both p 1 9arf and pl6INK4a, which in turn activate the tumour suppressors p53 and
retinoblastoma respectively (Palmero et al., 1998).
1.11 Gene Targeting and transgenic animal models
The ability to manipulation the genome of an animal for the creation of targeted gene
mutations, allows the investigation of proteins in vivo. The use of such technology has
led to massive steps forward in our understanding of the roles of certain proteins during
development and in the maintenance of adult tissues.
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Embryonic stem (ES) cells are an integral part of the ability to manipulate the mouse
genome. ES cells were first isolated in 1981 (Evans and Kauffman, 1981; Martin,
1981). They were derived from the inner cell mass of preimplantation blastocysts by
direct culture in vitro and had a pluripotent capacity, which could be maintained despite
long term culturing when grown on a layer of STO fibroblasts. Pluripotency was
confirmed by their ability to differentiate into a wide variety of cell types either in vitro
or in vivo after inoculation into a mouse as a teratoma. Recent progress has shown that
ES cells originate from the epiblast (primitive ectoderm) and isolation of early epiblasts
yielded ES cells at a higher frequency than culture of intact blastocysts (Brook and
Gardiner, 1997). Further advances were made following the realisation that conditioned
medium from Buffalo rat liver cells (BRL) containing an agent differentiation-inhibiting
activity (DIA) could substitute for feeders (Smith and Hooper, 1987). The purified
cytokine leukaemia inhibiting factor (LIF) maintains the ES cell's ability to contribute
to the germline of chimaeric mice (Smith et al., 1988; Williams et al., 1988).
The successful isolation of ES cell paved the way for attempts to alter the mouse
genome by homologous recombination. Homologous recombination allows the
insertion of foreign DNA into the genome between two arms of homologous DNA.
Using a replacement vector chromosomal sequences can be replaced by the vector
sequences by a double crossover event involving the flanking homologous regions. The
first successful example of this was achieved for the selectable hypoxanthine
phosphoribosyl transferase (HPRT) gene locus (Doetschman et al., 1987; Thomas and
Cappecchi, 1987). The development of strategies to enrich for homologous
recombination such as the integration of the neomycin resistance gene (neor) under the
control of a strong promoter, subsequently allowed the targeting of non-selectable genes
such as int-2 and c-abl (Mansour et al., 1988; Schwartzberg et al., 1989). This type of
selection is known as positive selection. The selection can then be enriched for clones
that have undergone homologous recombination as opposed to those that have
undergone random integration by a strategy known as "positive/negative selection"
(Mansour et al 1988). In addition to the neor (positive selection) a thymidine kinase (tk)
gene from the Herpes simplex virus (HSV) is inserted at the end of the linearised
targeting construct. The cells that have undergone homologous recombination will have
lost the HSV-t/: cassette and therefore will be unaffected by treatment with the
nucleoside analogue ganciclovir, whereas cells that have the targeting vector integrated
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randomly will retain the HSW-tk cassette and therefore will be sensitive to the toxic
affects of ganciclovir (negative selection) (figure 1.6). The DNA used to construct the
homology arms of non-isogenic targeting vectors is derived from a different mouse
strain than the ES cells to be targeted. This leads to a reduced frequency of homologous
recombination, which results from strain specific differences in the DNA sequence of
the homology arms, compared to the genome. In this scenario, the enrichment resulting
from positive/negative selection is particularly important for targeting strategies, to
enrich for the low frequency of homologous recombination occurring. However,
isogenic targeting vectors do not require this additional selection method, since the
efficiency of homologous recombination is much greater.
A potential drawback of this technology could be that the phenotype of the knockout is
so severe that it results in an embryonic lethality, making assessment of the function in
adult tissues impossible. This has led to the generation of technology to enable tissue
specific deletion of a gene of interest at a specific time point, this technology is known
as Cre-Lox technology. Cre is the product of the cre gene of the bacteriophage PI
(Sternberg, 1978) and is a site-specific DNA recombinase. Cre recognises a 34 base
pair site on the PI genome called locus of X-over of PI (loxP) and catalyses reciprocal
conservative DNA recombination between pairs of loxP sites (Austin et al., 1981). Cre
mediated recombination between two directly repeated loxP sites results in the excision
of the DNA between them as a covalently closed circle, since it requires no accessory
factors or DNA topological requirements Cre-mediated DNA recombination is a useful
tool for genomic manipulation of eukaryotic cells (Sauer, 1988). The implementation
of this strategy is similar in many ways to that described above, since the target gene is
modified by homologous recombination in ES cells so that two loxP sites flank it.
Importantly, the offspring resulting from the injection of these ES cells into blastocyst
are phenotypically normal. They are then crossed to mice that expression Cre in the
tissue of interest and Cre-mediated excision results in the tissue specific ablation of the
target gene. This strategy was first reported by Gu and co-workers using a mouse in
which the promoter and first exon of the DNA Polymerase (3 gene ipol/3) were flanked
by loxP sites. When crossed with a transgenic mouse, which specifically expressed Cre
in T cells the polfi gene was inactivated in the T cell population, but not in any other
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Figure 1.6. Homologous recombination using positive/negative selection. Homologous recombination
occurs between the homology arms and the genomic DNA, which results in the integration of the neor
cassette into the genome deleting the sequence of interest and allowing selection for clones with the
targeting vector integrated by G418 (positive selection). The HSV-r& cassette is not integrated into the
genome following homologous recombination. However, if random integration of the targeting vector
has occurred then these clones can be selected against using the nucleoside analogue ganciclovir, since
only those clones with the HSV-rA: cassette will be killed by this treatment (negative selection).
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This is a powerful strategy and there are currently many Cre transgenic mice available;
including liver (Kellendonk et al., 2000) and pancreas specific strains (Ray et al., 1999).
However, this system requires identification of tissue-specific promoters which restrict
its usefulness. The generation of synthetic inducible systems provides an attractive
alternative. The tetracycline-regulated transcription systems (Gossen et al., 1992 and
1995) allow the induction of cre expression at a desired time, either by simply dosing an
animal with tetracycline, or by withdrawing animals from tetracycline administration.
Alternatively, viral-mediated gene transfer of Cre recombinase can be utilised (Anton
and Graham, 1995). Parts of the viral genome are replaced with a Cre expression
construct, leading to replication deficient viruses, which are still capable of host cell
infection. This is a highly efficient method of gene targeting and has been utilised in
vivo for amongst other purposes the analysis of inducible K-ras mutations in the mouse
lung (Jackson et al., 2001).
The generation of homozygous null ES cell for a particular mutation can be achieved by
several methods. Firstly, the sequential gene targeting of both alleles using a targeting
vector that contains a neox cassette, followed by a second round of targeting with a
targeting vector containing a different selectable marker such as hygromycin B-
resistance gene (Mortensen et al., 1991). Alternatively, it is possible to generate
homozygous null ES cell line using a single targeting construct, by high G418 selection
(Mortensen et al., 1992). Here heterozygous null ES cells that have been generated by a
targeting vector containing a neo' cassette are grown in high concentrations of the
selectable agent G418. Following this selection many of the surviving cells have
undergone loss of heterozygosity (LOH) at the targeted locus and contain two copies of
the neo cassette. This process selects for those cells that have undergone spontaneous
LOH, which occurs at a frequency of approximately 10"5, as only those cells with a
duplicated neo can survive higher doses of G418 (Lefebvre et al., 2001). This
spontaneous LOH is believed to result either by chromosome loss and duplication, or
mitotic recombination.
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1.12 Role in development
1.12.1 Ras RNA expression in embryonic and adult tissues
Analysis of the expression of cellular oncogenes during the development of the mouse,
showed that these oncogenes participated in normal development (Muller et al., 1982).
Furthermore, the H-ras and K-ra.v transcripts were found to be ubquitiously expressed
in all embryonic stages and adult tissues examined (Muller et al., 1983), although
differences in the level of expression were noted. Closer examination of RNA levels
showed that there was a differential expression pattern of the ras gene family in mice
(Leon et al., 1987). H-ras was more prevalent in the brain, muscle and skin and the
highest levels of expression for K-ras were seen in gut, lung and thymus. N-ras was
expressed most strongly in the thymus and testis (Leon et al., 1987). Analysis of
expression of ras genes during development by Northern blot experiments showed that
the ras family members were temporally regulated during embryonic development.
Levels of K-ras and N-ras RNA were high at E10, but decreased towards late gestation,
H-ras RNA levels were found to remain relatively constant (Muller et al., 1983; Leon et
al., 1987).
Differential expression of the K-ras isoforms was detected by analysis of the RNA
expression (Pells et al., 1997). The pattern of the K-ras 4A isoform mRNA was greatly
restricted, compared to that of the K-ras 4B, which was found ubquitiously. The K-ras
4A isoform mRNA was not detected in embryonic stem (ES) cells, but during the
differentiation stage there was a marked induction (Pells et al., 1997). A rapid
induction of K-ras 4A was seen in the yolk sac at El2 and is detectable in the gut at
E15, however K-ras 4B was ubquitiously expressed from the earliest embryonic stage
examined (E9) (Pells et al., 1997). The level of the K-ras 4A isoform mRNA did not
exceed that of the K-ras 4B isoforms even in those tissues where it was most strongly
expressed. The highest levels of expression of the K-ras 4A isoform were detected in
the kidney, stomach and large intestine. The large intestine was found to have levels of
K-ras 4A expression comparable to those of the K-ras 4B isoform, but the K-ras 4A
isoform was a minor species in the liver (Pells et al., 1997). Analysis of the isoforms'
expression by Northern blot hybridisation (Wang et al., 2001) confirmed the previous
findings showing the same restricted pattern of K-ras 4A RNA expression.
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Therefore, ras genes are regulated in a complex manner with differences in expression
occurring through pre- and postnatal development and with certain adult tissues
showing preferential expression of one of the family members.
1.12.2 Ras protein expression in embryonic and adult tissues
Immunohistochemistry on histological samples from normal foetal and adult human
tissues using a pan-Ras monoclonal antibody showed that significant quantities of Ras
are expressed not only by cells in the proliferative compartments, but also by certain
mature cells carrying out specialised functions, such as neurons and the epithelial cells
of endocrine glands (Furth et al., 1987). This suggests a role for Ras in both cellular
proliferation and specialised cellular functions. A wide range of normal human tissues
express Ras, but within these tissues expression is often sharply restricted to cells at
specific stages of differentiation. Garin Chesa and colleagues showed that terminally
differentiated cells generally showed a stronger reactivity to pan-Ras antibodies than did
rapidly proliferating cells in human tissues (Garin Chesa et al., 1987). Fetal and adult
tissues were also found to have corresponding patterns of Ras expression, and that the
distribution of Ras in neoplasms paralleled the pattern in the normal tissue from which
they were derived (Garin Chesa et al., 1987). Detection of Ras in early rat embryos
shows that there is evidence of expression from day E6.5. The expression appeared to
be temporally and spatially regulated, with expression in the visceral and parietal
endoderm not becoming obvious until development was proceeding through the
primitive streak stages (Brewer et al., 1992). By day E10 of development all the tissues
were positive for Ras staining, strong staining was seen in the heart and neural
elements. Therefore, Ras does not appear to be ubquitiously expressed in the rat
conceptus prior to gastrulation, but shows differential distribution, appearing later in
endodermal derivatives. Possibly Ras is involved in determination of the ectodermal
and endodermal lineages (Brewer et al., 1992).
1.12.3 Transgenic models of Ras
The differential expression of members of the Ras family during embryonic
development suggested that these proteins might be important regulators of embryonic
development.
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Ras activity is essential for mouse embryos to develop through the two-cell stage
(Yamauchi et al., 1994). As demonstrated by microinjection of neutralising antibodies,
antisense oligonucleotides and constructs expressing the dominant negative RasN17
mutant into fertilised eggs, which inhibited development through the two-cell stage.
Inhibition of development through the two-cell stage could be overcome by
simultaneous injection of an activated raf oncogene, suggesting that the Ras/Raf
pathway was important for this progression to occur. This effect was specific to
progression through the two-cell stage, as microinjection of late two-cell stage eggs
with RasN17 did not affect subsequent cleavages and development to morulae and
blastocysts (Yamauchi et al., 1994).
More recent gene targeting experiments have demonstrated that, neither N-ras, nor H-
ras are essential for, either mouse development, or fertility. Tissues from N-raY mice
were analysed for either pathological or abnormal histological features, but these where
found to be indistinguishable from their heterozygous and wild-type siblings (Umanoff
et al., 1995). Even in haematopoietic cells where N-ras is expressed at high levels there
were no obvious abnormalities. Furthermore, recent studies have shown that mice
lacking both the W-ras and N-rav loci are still capable of developing normally (Esteban
et al., 2001). Characterisation of lymphocyte subsets in the spleen and thymus and
neuronal markers in the brain, showed no significant differences between wild-type and
H-ras'1' mice. Crossing of H-ras'1' and N-ras'1' mice gave rise to viable double knockout
offspring. Therefore, with regards to the Ras family, mice containing only a functional
K-ras gene are capable of normal growth, development and fertility.
This confirms the observations based on transgenic studies of the K-ra.v gene (Johnson
et al., 1997; Koera et al., 1997). K-ras'1' embryos die progressively between embryonic
day 12.5 (El2.5) and term. Both studies noted that K-ras'1' embryos exhibited smaller
size and delayed growth, compared to wild-type littermates, although Johnson and co¬
workers additionally noted features consistent with anaemia, without gross external
abnormalities. Johnson and colleagues found the liver to be the only consistently
defective tissue in the K-ras'1' embryos. K-ras'1' livers were reported to contain
typically 2- to 8-fold fewer cells than control livers, with apparent cell death detected
(Johnson et al., 1997). K-Ras has recently been reported to be important for E-
cadherin-based adherens junction (AJ) formation in fetal hepatocyte culture (Matsui et
39
al., 2002). AJ formation was defective in fetal hepatocytes from K-ras'1' mice, but not
from either H- or N-ras'1' mice and was rescued by expression of K-ras, but not H- or
N-ras, which may explain the abnormalities observed in the fetal liver of K-ras'' mice
(Johnson et al., 1997). However, it should be noted that Koera and co-workers reported
that the liver of K-ras'1' embryos appeared almost histologically normal.
Reduced thickness of the ventricular myocardium was also reported in K-ras'' embryos
at E15.5, possibly due to reduced proliferation (Koera et al., 1997). By El 1.5 K-ras'1'
mice showed increased cell death of motorneurons in the medulla and cervical spinal
cord. Thus, neuronal apoptosis appears to be influenced by K-ras, suggesting a possible
role for K-ras in the development of the nervous system (Koera et al., 1997). However,
Johnson and co-workers reported neither of these findings. Therefore, these studies
attribute the lethality of the K-ras'1' embryos to different mechanisms.
Analysis of chimaeras generated by the microinjection of blastocysts with K-ras'' ES
cells revealed that there was also a low contribution of K-ras'1' cells to the liver and also
the spleen, lung and multiple haematopoietic lineages (Johnson et al., 1997), indicating
that K-ras has a role in the development of these tissues. In their series of experiments
Johnson and co-workers also showed that the survival of N-ras knockout mice was due
to rescue by wild-type K-ras by crossing to K-ras+'~ animals. Interestingly, deletion of
both of these ras gene resulted in a much more severe phenotype, with K-ras'1'/N-ras'1'
offspring undetectable at E9, suggesting that there may be cooperative effects.
Although the growth and differentiation of many tissues can proceed normally in the
absence of K-ras, in a subset of tissues K-ras is essential for the completion of
embryogenesis. However, the tissues dependent upon K-Ras protein function during
embryonic development cannot be clearly defined due to conflicting data. Furthermore,
since residual Ras proteins in the form of H- or N-Ras are unable to rescue the effects of
the K-ras knockout, these studies suggest that K-Ras may have unique functions during
mouse development. Therefore, with regard to the ras genes, K-ras is essential and
sufficient for mouse embryonic development. The role of K-ras in development is still
to be fully elucidated. However, the use of transgenic models to study this has
increased the level of understanding of the role of K-ras in mouse development.
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1.13 Role in Neoplasia
Mutations in the ras genes can be found in a variety of human tumours. The highest
incidence of ras gene mutations have been reported in adenocarcinoma of the pancreas
(90%), high incidences have also been reported in cancers of the colon (40-50%), lung
(30%), thyroid (30%) and myeloid leukaemia (30%) (Bos et al., 1989). Overall, ras
mutations are associated with approximately 30% of all cancers.
However, mutations in the different ras gene family members seem to be specifically
associated with certain types of cancers. For example over 90% of pancreatic
adenocarcinomas contain mutations in the K-ras gene, but mutations in N- or H-ras are
rarely seen. In colon cancers, roughly 40-50% of cases exhibit K-ras activating
mutations, yet only a few percent contain N-ras mutations and W-ras mutations are very
uncommon (Bos et al., 1989). The reason for this selectivity is still unknown, but it
may be due to the level of contribution that each particular gene makes to the cell types
involved.
Support for this hypothesis also comes from in vitro analysis of the transforming
potentials of the different ras family members. It was demonstrated that the different
members of the ras family had different transforming potentials in vitro (Maher et al.,
1995). Furthermore, these differences appear to be cell-type specific. In Rat-2 and
NIH3T3 fibroblasts, transformation assays showed that H-Ras was more transforming
than either N-Ras or K-Ras. However, in the human haematopoietic cell line, TF-1, N-
Ras had the greater transforming potential. In rat intestinal epithelial cells H-Ras and
K-Ras 4A induced transformed foci with greater efficiency than K-Ras 4B and N-Ras
(Voice et al., 1999). When anchorage independent growth was analysed K-Ras 4A
expression enabled a greater number of foci to form than the other Ras proteins.
An alternative mechanism of ras activation may occur through the increased production
of the normal gene product. Quantitative alterations of the ras gene product are known
to induce neoplastic transformation of cells of various species including humans (Chang
et al., 1982; Schwab et al., 1983; DeBortoli et al., 1985). Amplification of the K-ras
gene has also been detected in some human tumours including renal clear cell
adenocarcinoma (Kozma et al., 1997) and Kaposi's sarcoma (Nicolaides et al., 1994).
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In addition, high levels of ras mRNA and p21 are found in a wide variety of human
tumours; including colonic tumours (Slamon et al., 1984; Gallick et al., 1985).
Previous studies have found that high expression of Ras, independent of mutational
activation, is a common feature of carcinomas with poor prognosis (Horan Hand et al.,
1987).
1.13.1 Colorectal Cancer
Clinical and histopathological observation that many if not all carcinomas arise in pre¬
existing adenomas has led to the concept that colorectal cancer progresses in a stepwise
manner, known as the adenoma-carcinoma sequence (reviewed Leslie et al., 2002).
This sequence encompasses the progression from normal to dysplastic epithelium to
carcinoma, through sequentially worsening degrees of adenomatous dysplasia. It is
widely accepted that this is associated with a progressive accumulation of mutations in
both sporadic and familial colonic cancers, leading to the clonal evolution of the
descendents of a single cell initiated by a somatic mutation. Additional mutations may
lead to a subset of daughter cells forming, which acquire a growth advantage. Further
proliferation of this clone may ultimately lead to the appearance of a microscopic
adenoma or polyp. This concept led to attempts to determine the mutational events
associated with this progression. Four somatic events in particular have been
highlighted in this sequence, mutation of K-ras, inactivation of Adenomatous Polyposis
Coli (APC), inactivation of p53 and allelic losses of occurring on chromosome 18q. A
series of non-invasive and invasive adenomas and carcinomas were analysed for the
presence of these somatic events (Vogelstein et al., 1988), which led to the generation
of a model for the genetic basis of colorectal neoplasia (Fearon and Vogelstein, 1990).
The model proposed that either mutation or loss of APC was probably the earliest event,
leading to hyperproliferative epithelium. Hypomethylation is also present in very small
adenomas. Mutations in the K-ras gene were proposed to be associated with the
progression of pre-existing small adenomas to larger more dysplastic tumours. Allelic
deletions of chromosome 17p (associated within activation of p53) and 18q were
proposed to occur at later stages of tumorigenesis. However, Vogelstein and co¬
workers observed that it was the accumulation of these mutational events, rather than
the order of their accumulation that was of importance in this model (Vogelstein et al.,
1988). The allelic loss at 18q was originally thought to be important for the inactivation
of the gene DCC (Deleted in Colorectal Cancer), but recent evidence suggests that it is
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SMAD4, which also resides in this region that is involved in the allelic losses of
chromosome 18q (reviewed Arends, 2000). Intense investigation in the ten years since
this model was proposed has led to a considerable elaboration of the molecular events
involved in colorectal tumorigenesis, including the identification of other mutations that
occur at a high frequency, which has resulted the emergence of a much more complex
picture of interactions (reviewed Houlston, 2001, Leslie et al., 2002). Furthermore, a
recent analysis of 106 colorectal tumours found that the progressive accumulation of
mutations in APC, K-ras and p53 was not a prerequisite for colorectal tumour
development (Smith et al., 2002). Indeed, the occurrence of mutations in all three genes
was extremely rare in the cases examined, clearly indicating that alternative
mechanisms of tumour progression exist.
As described above, one of the earliest events in this progression is believed to be the
mutation of the K-ras gene. These mutations have been identified in high frequencies
in aberrant crypt foci (ACF), which have been identified as putative pre-neoplastic
lesions in the colon, and not in morphologically normal crypt areas from the same
patients (Pretlow et al., 1993). Increased levels of Ras protein and mRNA have been
seen in aberrant crypts in rats (Stopera et al., 1992). K-ras mutations have been found
with equal frequency in dysplastic and non-dysplastic polyps unlike mutations in the
APC gene, which is also closely linked to the development of colorectal cancer (Jen et
al., 1994; Smith et al., 1994). Furthermore, a high frequency of K-ras codon 12
mutations has been identified in histologically normal mucosa found adjacent to areas
of tumour in patients who have K-ras mutation positive colorectal cancers (Zhu et al.,
1997). This and other evidence (reviewed Arends, 2000), suggests that K-ras gene
mutations may be involved in the actual initiation of colorectal tumorigenesis, rather
than progression as previously proposed (Vogelstein et al., 1988).
Nevertheless, K-ras gene mutations were analysed in 738 adenomas and found to be
associated with 17.2% of these (Maltzman et al., 2001). The K-ras mutations were
found to be more commonly associated with adenomas with villous histology and in
adenomas with high-grade dysplasia, which corresponds well with the Fearon and
Vogelstein model of colorectal tumorigenesis, since these observations suggest that K-
ras mutations were associated with the histologic features of adenoma progression
(Maltzman et al., 2001). However the examination of benign adenomas and adenomas
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with focal carcinoma, suggest that the K-ras gene mutations occur during the late stage
of adenoma progression (Ohnishi et al., 1997). However, there is some evidence to
suggest that heterogeneity with regard to K-ras mutations may exist within carcinomas.
Some primary carcinomas with K-ras mutations have been shown to also contain areas
in which only the wild-type gene is present. This implies that the K-ras gene mutation
even when present may not have been necessary for the establishment of the malignant
phenotype within these primary carcinomas (Al-Mulla et al., 1998).
Finally, evidence suggests that K-ras mutations may be associated with certain types of
colorectal cancer, since a preferential association of the K-ras oncogene with the
polypoid type of colorectal cancer, compared to the ulcerative type of colorectal cancer
has been demonstrated (Chiang et al., 1998). This observation may be indicative of the
existence of different pathways of tumour progression.
1.13.2 Mouse models of cancer
Using a hit and run gene targeting strategy a mouse model has been generated that
expresses activated K-ras (Johnson et al., 2001). The expression of the oncogenic K-
ras gene occurs randomly following spontaneous somatic recombination within the
targeted K-ras allele. These mice were highly predisposed to developing a range of
tumours, predominantly early onset lung cancers, but tumours were also seen in the
thymus and the skin (Johnson et al., 2001). This model interestingly did not show the
development of pancreatic or colon carcinomas despite the high rate of tumours seen in
these sites in humans with associated K-ras mutations. Significantly however all of the
mutant mice examined did have ACF of the colon, whereas wild-type littermates did
not. When these mice were crossed on to the p53+/ background the lung tumours
showed more malignant features, suggesting that the p53 mutation contributes to the
development of these lung tumours. Crossing to the Ape111"1 strain did not alter the
intestinal polyp phenotype (Johnson et al., 2001). This was an exciting development as
this model more closely represents the spontaneous oncogenic activation seen in human
tumours. Additional work from two groups has further pointed to an intimate
relationship between K-ras gene mutations and lung cancer initiation. Jackson and co¬
workers showed that by using an adeno-Cre inducible K-ras mutant that numerous
surface lung lesions were apparent after only 4 weeks post treatment. The number of
lung adenomas was directly proportional to the amount of virus used for infection
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(Jackson et al., 2001). Fisher and co-workers also using an inducible system showed
the development of lung tumours following expression of mutant K-Ras, but most
interestingly that these tumours regressed following the withdrawal of the inducing
agent. The tumours were found to arise faster in the absence of tumour suppressors p53
or Ink4a/Arf, but tumours in these bitransgenic mice did not persist following removal
of the inducer either (Fisher et al., 2001).
Recently a mouse model of K-ras intestinal tumorigenesis has been developed, by the
expression of K-ras G12V under the control of the mouse villin promoter in epithelial
cells of the large and small intestine (Janssen et al., 2002). This model was found to
closely recapitulate the progression of tumour formation associated with human disease,
including the detection of spontaneous mutations in the tumour suppressor gene p53 in a
proportion of lesions examined. However, associated mutations in the APC gene were
not detected.
1.13.3 Mechanisms underlying tumoriqenesis
The literature discussed in previous sections indicates that activated ras genes can
inhibit apoptosis under certain circumstances and in the presence of co-operating
mutations can cause uncontrolled cellular proliferation and transformation of cell lines
in vitro and the prevention of appropriate differentiation. All these features of activated
ras genes are hypothesised to be the mechanisms by which activated ras genes drive
tumorigenesis. Other mechanisms by which activated ras may contribute to
tumorigenesis include: inappropriate angiogenesis and alterations in cell adhesion.
Angiogenesis is the normal physiological process that produces new blood vessels.
However it can also become part of the pathological processed involved in diseases
such as cancer. Mutant ras oncogene dependent vascular endothelial growth factor
(VEGF) expression has been shown to be necessary, but not sufficient for tumour
growth in vivo (Okada et al., 1998). This has been shown for H-ras and for two
colorectal carcinoma cell lines known to carry a single mutant K-ras allele. Signalling
through K-Ras up-regulated VEGF in a PI-3K dependent manner and also appeared to
enhance Wnt signalling, which has been shown to strongly up-regulate VEGF (Zhang et
al., 2001).
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The development of metastases is perhaps one of the most significant steps in the
progression of cancers into more aggressive lesions with a markedly worse prognosis.
The intercellular adhesion molecule carcinoembryonic antigen (CEA), which is
important for the establishment of basolateral polarity in colon epithelial cells is up-
regulated by the mutant K-ras gene but not H-ras (Yan et al., 1997b). Oncogenic K-ras
but not W-ras also prevented normal glycosylation of the integrin (31 -chain of the
collagen receptor, blocking its maturation and preventing the apicobasal polarization of
colon epithelial cells (Yan et al., 1997a). Clinical evidence has linked alterations in the
ratio of the (31 integrin precursor to the mature form of (31 integrin in invasive and
metastatic colorectal cancers (Yan et al., 1997a). By the up-regulation of CEA, K-ras
may prevent lateral adhesion of adjacent colon epithelial cells and the selective effects
of mutant K-ras on integrin (31-chains also affecting adhesion may have important
implications, partly accounting for the selection of K-ras mutants in human tumours.
Activated K-ras reduced the cell surface expression of the al(3l collagen/laminin
receptor and the oc5(31 fibronectin receptor, both of which are implicated in maintenance
of a non-transformed phenotype (Schramm et al., 2000). It also increased cell surface
expression of the cx3(31 laminin/collagen/fibronectin receptor and the av(35 vitronectin
receptor, which may also have a role to play in metastatic behaviour (Schramm et al.,
2000).
Epithelial cell scattering is likely to play an important role in the process of carcinoma
cell invasion and metastasis. It has been shown that Ras has a positive role in epidermal
growth factor (EGF) induced cell scattering. It was also able to induce cell dispersion
in the absence of the growth factor (Boyer et al., 1997), implicating Ras as a potential
regulator of epithelial cell scattering.
The production of proteases is associated with invasion and metastasis. Colorectal
carcinomas with mutant forms of ras have significantly higher expression levels of
cathespin B or L cysteine protease than carcinomas in which these alterations were not
detected (Kim et al., 1998). Additionally, an association between activated ras
oncogenes and an increase in matrix metalloproteinase (MMP) activity has been
reported (Meade-Tollin et al., 1998).
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1.13.4 Prognostic factors
Since the importance of K-ras mutations in colorectal cancer became apparent research
has strived to find ways of using this knowledge for the benefit of the patient. It is
possible that the detection of K-ras mutations using molecular methods such as PCR of
tissues or fluids may be helpful in the early detection of primary cancers and
micrometastases, also in the assessment of tumour burden and efficacy of treatment
regimens (Nomoto et al., 1998; Urban et al., 1993; Yamada et al., 1998), although large
clinical trials are needed to ascertain the true benefit of these measures.
K-ras activating mutations have also been investigated as a potential prognostic marker
for colorectal cancer. However, there are conflicting reports regarding the relevance of
this approach. The presence of K-ras mutation has been demonstrated to have no affect
on patients' prognosis (Kressner et al., 1998). However, others report that mutations in
the K-ras gene correlate with prognosis, with ras over expression predicting a poor
prognosis independent of Duke's stage, DNA ploidy and S-phase fractions (Sun et al.,
1998).
In addition, the type of mutation present appears to determine the phenotype of the
tumour, with some mutations being associated with decreased overall survival and
increased risk of disease recurrence, suggesting these mutations may confer a more
aggressive phenotype to cancers (Al-Mulla et al., 1998; Cerottini et al., 1998).
However, these studies all suffer from a lack of numbers and this may explain the
conflicting observations. A large multicentre study (RASCAL) with nearly 3000
patients showed that K-ras mutations were associated with increased risk of relapse and
death, and that some mutations conferred a more aggressive phenotype that others. In
particular, any mutation of guanine to thymine, but not to adenine or to cytosine
increased the risk of recurrence and death. However, only the specific valine codon 12
mutation was independently associated with increased risk of recurrence and death
(Andreyev et al., 1998).
Therefore, K-ras mutations may prove to be useful biomolecular markers, and in
combination with histopathological parameters may help to identify colorectal cancer
patients with an increased risk of disease recurrence and/or death and therefore help
with the choice of appropriate treatment regimens.
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1.13.5 Therapeutic approaches
The activity of Ras proteins is dependent upon specific post-translational modifications
that occur at the C-terminus. These modifications namely farnesylation and
geranylgeranylation increase the hydrophobicity of the proteins and cause them to be
located at the inner surface of the plasma membrane. Drug therapies have been
developed to specifically target the enzymes responsible for these modifications. The
anti-tumour effects of a farnesyltransferase inhibitor (FTIs) have been tested on
mammary and lymphoid tumour models over-expressing N-Ras and were found to be
an effective treatment (Mangues et al., 1998). However, due to the nature of K-Ras
post-translational modifications it is necessary to use both FTIs and
geranylgeranyltransferase I inhibitors (GGTIs) to prevent K-Ras 4B processing, MAP
kinase activation and growth in nude mice of K-Ras 4B transformed NIH3T3 cells (Sun
et al., 1998). Although. FTIs effectively inhibit the farnesylation of H-Ras, they do not
completely inhibit the prenylation of K-Ras, as it remains prenylated in FTI treated cells
due to modification by the related prenyltransferase, geranylgeranyltransferase I.
Hence, cells transformed with K-ras tend to be more resistant to FTIs than H-ras.
Therefore, to investigate methods to overcome this, cells were treated with FTIs, GGTIs
and dual prenylation inhibitors that have both FTI and GGTI activity, but problems of
toxicity were associated with this treatment. (Lobell et al., 2001)
In murine cells, the MAPK pathway is clearly critical for tumorigenesis and is also
commonly activated in human tumours (Hoshino et al., 1999). As a consequence this
pathway has been extensively investigated as a potential target for therapeutic
approaches. A variety of pharmacological and antisense approaches have been
developed to block the activities of Raf and MEK and are now under clinical
investigation, (reviewed Sebolt-Leopold et al., 2000). Inhibition of MEK with the
orally active small molecule PD184352, suggested that tumours containing high-level
expression of phosphorylated ERK are the most sensitive to treatment with this agent
(Sebolt-Leopold et al., 1999). PD 184352 was found to significantly inhibit the growth
of colon carcinomas of both mouse and human origin at doses that were well tolerated.
In addition to impairing tumour proliferation PD 184352 was found to block the
disruption of cell adhesion contact and motility required for invasion (Sebolt-Leopold et
al., 1999).
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Another therapeutic strategy currently being researched is the use of peptide aptamers.
Peptide aptamers have been identified that preferentially bind to the activated allelic
form of H-Ras. Transfection of mammalian cells with these peptide aptamers resulted
in abolition of Raf kinase activity stimulated by EGF (Xu and Lou, 2002).
1.14 Aims and objectives
As outlined above there are many conflicting sets of data concerning the role of Ras
proteins in certain cellular processes, such as differentiation, proliferation and apoptosis.
Depending upon the experimental settings in vitro, Ras can induce opposite effects,
making assessment and extrapolation of the physiological role of Ras in any given
tissue or cell type extremely difficult, underscoring the need for in vivo studies.
The aim of this project is three fold. The first of these is to elucidate the contribution of
the individual K-ras isoforms during mouse development. This is to be addressed by
the development of mice homozygous for the deletion of exon 4A, which can be used to
investigate whether expression of both isoforms is essential for normal embryonic
development. In addition, immunohistochemical analysis of embryonic stages will be
performed to detail the tissues and cell lineages that express the K-Ras isoforms, to
investigate whether differential protein expression occurs during embryonic
development.
The second aim is to assess the expression of the individual isoforms in
adenocarcinomas of the colon with known K-ras mutations. To investigate whether the
K-ras activating mutations are associated with increased expression of both isoforms
and to contrast this analysis with the expression pattern detected in cervical
intraepithelial neoplasia, the progression of which is not normally associated with K-ras
mutations.
The third aim of this study is to develop ES cells homozygous null for the deletion of
the K-ras 4A exon by gene targeting and to characterise these by examining in vitro the
effect of this mutation upon growth, differentiation and apoptosis, in order to identify





2.1 Maintenance of Embryonic Stem Cell lines
2.1.1 Routine Embryonic Stem Cell Culture
Embryonic stem (ES) cells were routinely cultured on gelatinised tissue culture plastic
(Costar, Corning), in a humidified 37°C incubator with 5% CCE injection (Sanyo). All
ES cell work was carried out in a class 2 biological safety cabinet (Microflow), using
aseptic techniques.
Gelatinised plastics for ES cell culture were prepared at least one hour before use, by
covering the growth surface with 0.1% gelatin (w/v) (Sigma) made up in sterile water.
The residual gelatin was removed just prior to the use of the plastics. ES cells were
routinely cultured in BHK-21 Glasgow modified eagles medium (Life Technologies),
which was supplemented with 5% (v/v) new born calf serum (NCS) (Life Technologies,
selected batches), 5% (v/v) foetal calf serum (FCS) (Life Technologies, selected
batches), 1% non-essential amino acids (Life Technologies) and lOmM sodium
pyruvate (Life Technologies). (3-mercaptoethanol (Sigma) was added at 0.01% (v/v)
and leukaemia inhibiting factor (LIF) conditioned medium was added at 0.005% (v/v).
The LIF-conditioned medium was produced by culturing Cos 7 cells containing the
pCIO plasmid expressing the recombinant LIF protein. This medium was used in all
cases unless otherwise stated.
2.1.2 Thawing cells after cryopreservation
When cells were raised from liquid nitrogen storage the thawing process was carried out
quickly to maintain cell viability. Vials were defrosted at 37°C, the cell suspension
removed into 10ml of pre-warmed medium in a 50ml falcon tube, which was then
centrifuged at l,000rpm 5 min (MSE Mistral 1000). The supernatant was removed and
cells were resuspended in 6ml of fresh medium and transferred to a 25cm" tissue culture
flask and cultured at 37°C with 5% CCL. The medium was aspirated the following day
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to remove any cellular debris and remaining traces of dimethyl sulfoxide (DMSO), and
replaced with 7ml of fresh pre-warmed medium. Medium was replenished at least every
second day, to avoid serum starvation. When the cells were approximately 80%
confluent they were sub-cultured to avoid over acidification of the medium as described
below.
2.1.3 Sub-culturinq of ES cells
When the cells reached a state of approximately 80% confluence observed
microscopically (Leica) they were, either sub-cultured into fresh gelatinised flasks, or
prepared for cryopreservation. The medium was removed and the monolayer was
washed with IX phosphate buffered saline Ca2+/Mg2+ free (PBS) (Life Technologies) to
remove any excess medium, which if not removed inhibited the trypsin. Trypsin-EDTA
(appendix I) was added and incubated at 37°C until the cells started to detach from the
surface. The flask was given a sharp tap to detach the cells and medium added to
approximately 10X the volume to neutralise the trypsin, then transferred to a falcon tube
and centrifuged at l,000rpm for 5 min (MSE Mistral 1000). The supernatant was
discarded and the cells resuspended in an appropriate volume of fresh medium to give
the required dilution. The cell suspension was then added to a fresh gelatinised tissue
culture flask or plate.
2.1.4 Cryopreservation of ES cell stocks
Cryopreservation medium was complete medium supplemented, with additional FCS to
give a total of 15% (v/v) and 10% (v/v) DMSO (Sigma). Cells were harvested in the
manner used for routine sub-culture and then centrifuged at l,000rpm for 5 min, (MSE
Mistral 1000) the supernatant was removed and the cells resuspended in
cryopreservation medium to give the required concentration of cells per ml of medium.
Then 1ml aliquots of cell suspension were added to freezer vials (Nunc) and these were
frozen slowly overnight at -70°C in plastic racks (Nunc). The vials were then
transferred to the liquid nitrogen freezer and stored in the gaseous phase.
2.1.5 Analysis of chromosome number
Cells for analysis were subcultured two days before they were needed and grown to
approximately 70% confluence ji^7~5cm2 tissue culture flasks. The growth medium was
removed and replaced with medium containing 1% (v/v) Colchicine (Life technologies)
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and cells were incubated for 3hrs at 37°C in a 5% CO2 incubator. Cells were
trypsinised and centrifuged at 1,000 rpm for 5 min (MSE Mistral 1000) and then
resuspended in 10ml of hypotonic solution (0.075M KC1). The cells were incubated for
15 min at 37°C to allow them to swell, then centrifuged at 800rpm for 5 min (MSE
Mistral 1000) and resuspended in 10ml freshly prepared ice-cold fixative (3:1 (v/v)
methanol, glacial acetic acid), which was added drop wise to avoid cell clumping and
allowed to fix for an hour at -20°C. The cells were then centrifuged at 1,000 rpm for 5
min (MSE Mistral 1000) and resuspended in a further 1ml of fixative. The cell
suspension was dropped on to slides that had been prepared by emersion in absolute
alcohol overnight at 4°C. The slides were allowed to dry and stained with 5% (v/v)
giemsa (Sigma). Coverslips were mounted with DPX (BDH) and the chromosome
numbers counted using the highly optimised microscope environment (HOME) (Axial)
(Brugal et al., 1992). The HOME microscope was used to ensure accuracy and
reproducibility of counting. Minimums of 25 metaphase spreads were counted for each
cell line. Spreads that had obviously been damaged in the preparation process were not
included in the counts.
2.1.6 Differentiation of ES cells with Retinoic acid
ES cells were seeded at a density of approximately 2xl05 cells in 90mm diameter petri
dishes (Geiner) and allowed to plate down in normal ES cell medium overnight. All
trans-retinoic acid (Sigma) was dissolved in DMSO (stock concentration of lOmM) and
added to the medium, which lacked LIF at final concentrations of lpM, 5pM, and
10|lM. All treatments, including control plates had DMSO added to the same final
concentration (0.05%). The control medium also lacked LIF to control for possible
differentiation effects seen in the absence of LIF and presence of DMSO that were not
attributable to retinoic acid. The cells were grown for five days and the medium
replenished each day to maintain the retinoic acid concentration.
2.1.7 Mitomycin C treatment of STO Fibroblasts
Fibroblasts were grown in non-gelatinised 125cm2 tissue culture flasks. In ES cell
medium, but lacking LIF and (3-mercaptoethanol. Mitomycin C (Sigma) was made up
to a stock solution of lmg/ml with sterile PBS. Cells were then treated with mitomycin
C at a final concentration of lOpg/ml in tissue culture medium, for 2-3 hrs at 37°C. The
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mitomycin C medium was removed and cells washed three times with IX PBS,
trypsinised and frozen away as described above for cryopreservation of ES cells. To
prepare a feeder layer 1 vial of fibroblasts was raised from liquid nitrogen storage and
9 c
added to a 25cm~ flask as previously described. The fibroblasts were allowed to attach
to the surface before the ES cells were added.
2.2 Manipulation of Plasmid DNA
2.2.1 Transformation of bacteria with plasmid vectors
Library efficiency ®DH5a ™ Competent cells (Life Technologies) were used for the
transformation. The competent cells were thawed on ice, gently mixed, and aliquots of
lOOpl were put into pre-chilled Eppendorf tubes. To the competent cells l|ll (l-10ng)
of DNA to be transformed was added. The cells were incubated for 30 minutes on ice,
heat-shocked for 45 seconds in a 42°C water bath, placed on ice for a further 2 minutes,
then 0.9ml of room temperature S.O.C medium (Life Technologies) was added. The
cells were then shaken at 225rpm for 1 hour at 37°C. The experimental reaction was
diluted as necessary and 100-200pl of this dilution was spread on L broth plates
containing 50|Ug/ml ampicillin (L Amp) (appendix I), and then incubated overnight at
37°C to allow colony growth.
2.2.2 Plasmid Miniprep
Bacterial colonies were picked from plates and used to create a culture by inoculating
10ml of L Amp broth. The bacterial cultures were grown at 37°C overnight, shaking at
180rpm. Wizard Plus minipreps (Promega) were used, as per manufacturers
instructions. In brief, 1.5ml of the bacterial culture was used for each miniprep. The
supernatant was removed following centrifugation and the Eppendorf tubes blotted to
remove excess liquid. The pellet was resuspended in 200|il of cell resuspension
solution (Promega) and cells lysed by the addition of 200p,l of cell lysis solution
(Promega). After mixing by inverting and addition of 200p1 of neutralisation solution
(Promega) the suspension was centrifuged at 10,000rpm for 5 min (MSE Microcentaur).
Syringe barrels were attached into columns and inserted into a vacuum source
(Vaccman, Promega). DNA purification resin (Promega) was added to each barrel with
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the cleared lysates and the resin and lysate were pulled into the column by vacuum
pump. Columns were washed with column wash solution and the vacuum was
continued for a further 30 seconds to dry the resin. Finally, the columns were
transferred to new Eppendorf tubes and the DNA was eluted from the columns into a
volume of 30(tl TE buffer by centrifugation for 20 seconds at 10,000rpm (MSE
Microcentaur).
2.2.3. Plasmid Maxi Preps
This procedure used the Hybaid Maxi-prep system. Starter cultures were established by
inoculating 8ml of L Amp broth with 100)il of bacterial stock containing the plasmid of
interest. The culture was grown for a minimum of 8 hrs but usually overnight at 37°C
shaking at 180rpm. The culture was then used to inoculate 500ml of L Amp broth and
grown overnight as before. The maxi-prep was performed according to manufacturers
instructions. The culture was centrifuged at 6,000rpm for 30 min at 4°C (Sorvall), and
the supernatant removed. The bacterial cell pellet was resuspended in 20ml of
resuspension solution (Hybaid) and the cells lysed with 20ml of cell lysis solution
(Hybaid). Following incubation at room temperature for 5 min the lysate was
neutralised with 10ml of neutralising solution (Hybaid) and then centrifuged at 20°C for
20 min at 6,000rpm (Sorvall). Columns were equilibrated using 30ml of equilibration
solution (Hybaid) and the cleared lysate added and allowed to flow through by gravity.
Columns were washed with 2X 30ml of wash solution (Hybaid) and the DNA eluted
with 15ml of elution solution (Hybaid), and precipitated with 10.5ml of room
temperature isopropanol. The tube was centrifuged at 4°C for 30 min at 6,000rpm
(Sorvall) to pellet the DNA, which was then washed with 70% ethanol and centrifuged
at 13,000rpm for 5 min (MSE Microcentaur). The DNA was air dried and resuspended
in of TE buffer.
2.2.4 Restriction digest of Plasmid DNA
Plasmid DNA was digested with the appropriate restriction endonuclease in the
presence of the ionic strength buffer recommended by the manufacturer (the restriction
enzymes were supplied by either Life Technologies or New England Biolabs). The
digests were carried out in lOpl reaction volumes. Restriction enzymes were used at the
volume required to give complete digestion of the target DNA, where lunit of enzyme
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is enough to digest l|ig of X DNA in 1 hour. Enzymes were used in volumes of <10%
of the final reaction volume, since an excess of glycerol (the enzyme solution is
composed of 50% glycerol) has an inhibitory effect on the reaction. The 10X stock
ionic strength buffer solution was diluted 1:10 in the reaction volume to give a final IX
buffer concentration and lpl plasmid DNA was added. Some enzymes required
addition of bovine serum albumin (BSA), which was provided by the manufacturers in
these cases as a 100X stock solution, which was diluted to give a IX concentration in
the reaction volume. Water was added to make the final volume up to lOjil. Digests
were carried out at 37°C for a minimum of 1 hour.
2.2.5 Agarose gel electrophoresis
Agarose gels were routinely used at 0.8% (w/v) for minigels, but concentrations of up to
2% (w/v) were used if small fragments needed to be separated. Agarose (Sigma) was
added to a IX Tris, boric acid, EDTA (TBE) solution (appendix I) diluted from a 10X
stock, to give the final concentration of agarose (w/v), and this was heated in a
microwave oven to dissolve the agarose. Ethidium bromide (Sigma) was added
(0.5(ig/ml) and the molten agarose poured into a mould and allowed to set. Once set the
gel was place into a gel tank (Anachem) containing running buffer (IX TBE) to a level
above the gel and the samples loaded into the wells using a TBE based loading buffer
containing bromophenol blue (Appendix I). Current was supplied by an electrophoresis
power supply (Amersham Pharmacia Biotech Inc). The fragments were visualised
using an ultraviolet transilluminator and the images were captured using the GelDoc
1000 system (Bio-rad) and molecular analyst software.
2.2.6 Isolation of DNA from agarose gels
The band corresponding to the fragment size of interest was cut out of the gel with a
clean scalpel blade, and weighed. The extraction used Glassmax spin columns (Life
Technologies). For each O.lg of agarose, 0.45ml of DNA binding solution was added
and 20|al of TBE enhancing buffer. The tubes were heated to 50°C until the agarose
melted. The solution was added to the spin column and centrifuged at 13,000rpm for 20
seconds (MSE Microcentaur). The flow through was discarded. To the spin column
0.4ml of cold wash buffer was then added and centrifuged as above and this procedure
was repeated twice more. The column was centrifuged at 13,000rpm for lmin (MSE
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Microcentaur) to ensure that all residual wash buffer was removed. The spin cartridge
was transferred to a new tube and 40|il of TE buffer (appendix I) preheated to 65°C
added. The cartridge was then centrifuged at 13,000rpm for 20 seconds (MSE
Microcentaur) to elute the DNA. The product was then run on a minigel to confirm the
size, purity and integrity of the DNA band. Products were then stored at -20°C in small
aliquots.
2.3 Genetic Manipulation of ES cells
2.3.1 Preparation of the pPTKiNKiA4A targeting vector
Approximately 150pg of the pPTKiNKiA4A targeting vector plasmid was linearised by
restriction digest with the EcoRl enzyme (see digestion of plasmid DNA 2.2.4). To
ensure that the plasmid was completely linearised, a small aliquot of digested plasmid
DNA was run on an agarose minigel against undigested plasmid DNA. The linearised
plasmid DNA was precipitated with lA volume 7.5M ammonium acetate and 2 volumes
of absolute ethanol at -70°C for 1 hour, and then centrifuged at 13,000rpm for 10 min
(MSE Microcentaur). The DNA was sterilised by washing with 750(.il of cold 80%
ethanol and centrifuged as above. The supernatant was removed under sterile
conditions, and the DNA pellet air-dried. The pellet was then resuspended in 600pl
sterile PBS.
2.3.2 Electroporation of ES cells with the pPTKiNKiA4A targeting vector
Cells for electroporation were grown to subconfluence in a 125cirr tissue culture flask
(approximately 108 cells). The cells were dissociated with ES cell trypsin, resuspended
in fresh medium, and centrifuged, the pellet washed with IX PBS. The cell pellet was
then resuspended in the 600pl DNA/PBS mixture (prepared as described 2.4.1). This
suspension was incubated for 10 min at room temperature. The cells were transferred to
a sterile cuvette and electroporated at 0.8kV and 3pF capacitance with a time constant
of 0.1 seconds (Bio-Rad Gene -Pulser). The cells were resuspended in 100ml of non-
selective tissue culture medium and added to ten 75cm gelatinised tissue culture petn
dishes. The selection with 150pg/ml geneticin (G418) (Life Technologies) started the
following day. The selection with 2pM ganciclovir (Sigma) started four days after
56
electroporation. Selection continued for approximately 14 days or until colonies
became visible. The surviving clones were then picked. The colonies to be picked were
ringed with a marker pen and detached from the surface of the petri dish using a p200
pipette tip. The colony was then taken up into the tip with a small volume of medium
and pipetted into ES cell trypsin. The colony was left to dissociate for a few minutes at
37°C. The colony was then transferred to a single well of a 24 well plate (Nunc),
containing non-selective medium. Medium was changed the following day and when
the well became confluent the cells were sub-cultured into the adjacent well to expand
the colonies. Cells from these colonies were then either prepared for cryopreservation
or used for DNA extraction when both wells became confluent.
2.3.3 Selection for transqene homozygosity in ES cells
This method was adapted from Mortensen et al., (1992). Heterozygous ES cells were
plated at 1.25xl05 cells per 75cm2 gelatinised petri dish and allowed to attach for 24
hours in normal growth medium. The medium was then replaced with medium
containing different concentrations of geneticin G418 (Life Technologies). There were
duplicate petri dishes for each concentration. The G418 was kept as a stock of 20mg/ml
in ES cell medium and diluted to a final concentration of lmg/ml, 1.5mg/ml, 2mg/ml,
2.5mg/ml and 3mg/ml in cell culture medium. The medium was changed every day
initially to maintain selective pressure. The selection was maintained for approximately
14 days; at which time the surviving clones were picked as above and transferred to 24
well plates. Cells were harvested for DNA extraction or prepared for cryopreservation.
2.3.4 Single Cell Cloning
Single cell cloning was performed using flat-bottomed 96 well plates (Corning, Costar).
Cells were trypsinised and counted. Then aliquots calculated to have on average less
than 1 cell were added to the wells, which ensured that as many of the wells as possible
had only single cell colonies. Cells were grown for approximately 14 days then the
single colonies were picked and transferred into 24 well plates for expansion as
described above (2.3.2).
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2.4 Manipulation of Genomic DNA
2.4.1 DNA Extraction
DNA extraction from either cell pellets or tissue samples was performed as follows. To
the sample 500)Ltl of DNA lysis buffer (appendix I) and 40jil of proteinase K (PK)
(20mg/ml) (ICN) was added. The pellet was incubated overnight at 37°C, shaking at
180rpm.
To the lysate 500p,l of phenol (Sigma) was added, the phases were mixed by inverting
the tube and then centrifuged 13,000rpm 5 min (MSE Microcentaur). The aqueous
phase was transferred to a fresh tube containing an additional 500|il of phenol. The
phases were again mixed by inversion, and centrifuged as above. The aqueous phase
was removed to a fresh tube containing 500|il of chloroform (Fisher). The phases were
again mixed and centrifuged as above. The upper layer was transferred into a fresh tube
to which an equal volume of isopropanol (Fisher) was added to precipitate the DNA.
The solution was mixed vigorously and centrifuged at 13,000rpm for 10 min (MSE
Microcentaur). The supernatant was removed and the pellet allowed to air dry for a few
minutes. The pellet was then resuspended in an appropriate volume of TE buffer.
2.4.2 Estimation of DNA concentration and purity
Spectrophotometric analysis and ethidium bromide fluorescent quantification were used
for analysis of genomic DNA concentration and digested plasmid DNA concentration
respectively. Concentrations were measured on a spectrophotometer (Biomate 3,
Thermo Spectronic, Fisher Scientific) initially. Optical densities (OD) of double
stranded DNA solutions diluted 1:500 were measured at X = 260nm. The ratio of
measurements made at ODs of 260nm and 280nm gave a measure of the purity of the
DNA sample.
Ethidium bromide fluorescent quantitation was performed by running a small sample of
DNA for analysis, against known quantities of X DNA ladder (Life Technologies) on an
agarose gel. The gel was visualised by ultraviolet transilluminator and the DNA
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concentration was estimated by comparing the fluorescent intensity of the sample
against the X DNA control.
2.4.3 Restriction digest of genomic DNA
A 50jcl1 reaction mix was made up using the required enzyme at 10% of the total
reaction volume. The 10X stock ionic strength buffer recommended for use with the
enzyme by the manufacturer was diluted to a IX solution in the reaction volume.
Spermidine was used at a concentration of 2mM and deionised water was added to
make up the final volume taking into account the volume of DNA to be added. The
digest was incubated at 37°C overnight. Aliquots were analysed on minigels prior to
proceeding to ensure that complete digestion had occurred.
2.4.4 Southern Analysis
Restriction digest products for Southern analysis were run on large agarose gels. The
DNA digested with Hind III to be probed with the internal probe was run on a 0.8% gel
and that for the external probe on a 1% agarose gel. This ensured that proper separation
of the DNA fragments would occur. The samples were loaded and run overnight at
4°C. A X Hind III DNA ladder (Life Technologies) was run along side the samples to
identify the size position of the DNA fragments. Once the DNA size marker showed
that the product sizes of interest had separated sufficiently the gel was photographed
and cut to size.
The DNA was then transferred to a membrane by capillary action. Firstly, the gel was
soaked in denaturing buffer (0.5M NaOH, 1.5M NaCl) for 2X 30min with constant
agitation. This made the DNA single stranded, which was important to enable the probe
to bind to its target sequence. The gel was then placed onto the blotting apparatus,
which was arranged as follows. Two pieces ofWhatman's filter paper (cut to the width
of the gel) placed on top of each other were used as a wick from the reservoir of transfer
buffer (denaturing buffer). The gel was placed upon the wick making sure that there
were no air bubbles between the wick and the gel, as this would impair transfer. The
nylon membrane (Hybond H+, Amersham) was cut to size and soaked in deionised
water for 5mins followed by transfer buffer for 5 mins and placed on top of the gel,
ensuring that there were no air bubbles. Three pieces of Whatman's filter paper cut to
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size were soaked in buffer and also placed on top of the membrane. Finally, layers of
paper towel were placed on top with a weight to encourage the capillary action. The
DNA was left to transfer overnight. Next day the membrane was removed and air-
dried.
2.4.5 Radioactive probing of Southern Blots
2.4.5.1 Radiolabelling of Probe DNA
Probe DNA was labelled using a random primer labelling kit (Stratagene), which
provided tubes containing freeze dried primers. An aliquot of DNA was added to the
probe labelling mixture to give a final concentration of between 25-50ng in a total
volume of 42pl made up with deionised water. The primer/DNA mix was incubated at
room temperature for a few minutes to ensure that the constituents were properly
resuspended. The primer/DNA mixture was then boiled for 10 min to denature the
DNA and centrifuged briefly to collect the entire volume. To the primer/DNA mixture
3|il of magenta polymerase and 5pl (50jitCi) of a32P dCTP (ICN) were then added in a
safety cabinet behind a Perspex shield, to give a final reaction volume of 50pl. The
reaction was incubated for approximately 1 hour at 37°C, to allow maximum
incorporation of the radioactive isotope in to the probe, after which time the reaction
was stopped with 2pl stop mix.
2.4.5.2 Probe purification
The probes were purified using Sephadex Nick translation columns (Amersham
Pharmacia Biotech). The columns were washed through with TE buffer prior to use.
To the tube containing the radioactively labelled probe 20pl of lOmg/ml sonicated
salmon sperm DNA was added. The probe solution was added to the column and
washed through with 2X 400pl of TE buffer. The second eluate was collected and the
level of radioactivity incorporated checked using a Geiger counter. Unincorporated
isotope remained in the column. As a rough guide, if the amount of radioactivity in the
probe eluate was greater than that remaining in the column the probe was used for the




Trichloroacetic acid (TCA) precipitation was used to measure the incorporation of
radioactive isotope into probe DNA. To 1ml of pre-chilled distilled water lOpl of
carrier DNA (either salmon sperm or herring sperm DNA) and lpl of sample DNA
were added. This was mixed and then 1ml of 10% TCA was added and the mixture was
incubated on ice for 3mins. The apparatus arranged as follows: A glass filter holder
was placed into a conical flask with a vacuum attachment. A Whatman 2.4cm
glassmicrofibre filter was placed on to the holder and a Pyrex 15ml Millipore funnel
was placed on top and the apparatus clamped together. The vacuum was applied and
the funnel was wet with a squirt of 10% TCA. The sample was added to the funnel and
the tube rinsed with 10% TCA, which was then poured on to the filter. The filter was
rinsed with 10% TCA followed by absolute alcohol. The filter was removed with
forceps, dried under a heat lamp, then placed in a scintillation vial with 5ml of
scintillation fluid (Ultima gold, Packard Biosciences), and the radioactivity was counted
by liquid scintillation counting (TRI-CARB 2100TR Liquid scintillation analyser,
Packard Biosciences). Samples of probe DNA were analysed before and after
purification, with and without TCA precipitation. This allowed analysis of the total
counts/minute (cpm) incorporated into the reaction and the cpm that were precipitated
with the purified probe DNA. This was necessary to assess the effectiveness of the
labelling reaction described above.
2.4.5.4 Pre-hybridisation of membranes
Membranes were washed in 2X SSC (appendix I) and placed into hybridisation tubes
(Hybaid). Large membranes were rolled up with gauze, to separate overlapping edges
of the membrane. The hybridisation solution (appendix I) was preheated to 65°C.
Sonicated salmon sperm DNA (lOmg/ml stock) was denatured by boiling for lOmin and
200|ig/ml was added to 25ml of hybridisation solution. This was enough for one
membrane. The hybridisation solution was then added to the tube and the membrane
was pre-hybridised for 3 hours at 65°C in a rotating oven (Hybaid).
2.4.5.5 Hybridisation of membranes
Following pre-hybridisation the radioactively labelled probes were denatured by boiling
for 10 min, and added to the hybridisation solution. The probes were hybridised to the
membranes overnight at 65°C in the rotating hybridisation oven. Next day the
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membrane was washed with preheated wash solution (0.1X SSC, 1% SDS) for 2X
30min at 65°C. Membranes were sealed in Clingfilm whilst still damp and subjected to
autoradiography. Membranes were placed in to an autoradiograph cassette with
Medical X-ray film (Super RX, Fuji). The cassette was then stored at -70°C and the
film developed 24 hours later using a hyperprocesser (Amersham). A new film was
added if it was necessary to give a longer exposure.
2.4.6 Polymerase Chain Reaction (PCR)
The PCR master-mix proportions and reagents were the same for all PCRs unless
otherwise stated. PCR primer sequences are shown in the table 2.1. PCR conditions
were as follows. In a reaction volume of 50(il, the 10X PCR buffer (Life Technologies)
was diluted to IX buffer, MgCL (Life Technologies) was added to a final concentration
of 1.5mM. dNTPs (Amersham Pharmacia Biotech Inc) were used at 200|aM each. The
primers (Genosys, Sigma) were used at l.OpM each. Taq DNA polymerase (Life
Technologies) was used at 1 unit per reaction. The remaining volume was made up
with sterile water. A master reaction mix was made up enough for all samples to
reduce pipetting errors and then aliquoted into sterile 0.5ml eppendorf tubes. To each
tube an equal volume of liquid paraffin was layered on top, to stop evaporation during
thermocycling. The template DNA was added at lul per tube through the liquid paraffin
layer. Positive and negative controls were set up for each PCR. The negative control
had water added in place of DNA template to act as a control for possible contamination
of the PCR master mix with foreign DNA. The positive control had DNA that was
known to show the expected result and therefore confirm that the PCR conditions were
optimal. The PCR reactions were carried out in a thermocycler (Hybaid). Positive
displacement pipettes (Microman, Gilson) were used to reduce the risk of cross
contamination due to aerosols. The cycle conditions and the expected product sizes for
each primer pair are shown in the table 2.1.
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Table 2.1 PCR primer sequences, primer targets, expected product sizes and the
PCR cycle conditions used.




125 bp 1 cycle of
94°C for










Neo 52 GATGCCTGCTTGCCGAATATCATGG neor 206bp 58°C for 30
Neo 22 CGATAGAAGGCGATGCGCTGCGAAT sec
2.4.7 Colony PCR
A PCR strategy was developed to increase the speed of screening for homologous
recombination, which meant that only targeted cells were harvested (as described above
2.3.2).
This method was adapted from McMahon and Bradley, (1990). Cells were targeted,
selected and picked as before, with the exception that when the colonies were picked
they were added to 400pl of medium containing 300pg/ml G418. Cell colonies were
dissociated by pipetting and then split (4 and % into corresponding wells of two 24 well
plates, and 1ml of medium containing G418 was layered on top. When the well
containing % of the colony was confluent it was harvested by scraping the cells into 1ml
of medium, which was transferred to an Eppendorf tube and centrifuged at 13,000rpm
for 5 min (Microcentaur, MSE) and the supernatant removed. The pellet was briefly
centrifuged again to remove any remaining medium (which could inhibit the PCR
reaction) and resuspended in 80|il of IX PCR/PK buffer (see appendix I). The samples
were incubated at 65°C for 2hr and then the PK was heat inactivated at 90°C for 15 min.
This crude cell lysate was then used directly in the PCR reaction. The primer sequence,
expected product size and cycle conditions are shown in table 2.2 below. The PCR
master mix was made up as above with a few minor alterations as follows; 5|il of DNA
template were used instead of l|il. MgCl2 was not added separately as it was contained
in the 10X Colony PCR buffer (Appendix I) and EDTA (lOmM) was added to the
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reaction. The volume of water was adjusted accordingly to give a final reaction volume
of 50)al as before.
Table 2.2 Table shows the PCR primer sequences, primer targets, expected
product sizes and the PCR cycle conditions used in the colony PCR


















2.5 Manipulation of the mouse embryo
2.5.1. Collection of Blastocysts for Microinjection
Mice were superovulated by injections of pregnant mares serum (PMS) on day 1 and of
human chorionic gonadotrophin (HCG) on day 3, which was followed by mating. On
day 3.5 post coitum the mice were sacrificed and the uterine horns removed. Using a
fine gauge needle blastocysts were flushed out using cell culture medium 9without LIF
or (3-mercaptoethanol) into a petri dish. The embryos were collected and placed in a
fresh petri dish in a small drop of medium under mineral oil (Sigma) and maintained at
37°C in a 5% CO2 incubator until microinjection.
2.5.2. Production of chimaeras by blastocyst injection
Dr Charles Patek, Jan Ure and Jennifer Doig performed the blastocyst injections on my
behalf. Targeted ES cells were injected into, either day 3.5pp F2 (C57BL/6 x CBA), or
day 3.5pp C57 BL/6 blastocysts. Approximately 10-12 ES cells were injected into each
blastocyst and implanted into the uteri of, either day 2.5pp Fi(C57BL/6 x CBA), or CD1
pseudopregnant recipients. Vasectomised males were used to generate pseudopregnant
females. The chimaeric offspring were identified on the basis of coat colour analysis.
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2.6 Detection of protein expression in tissue sections
Immunohistochemistry was performed using a K-Ras 4A rabbit polyclonal antibody
(Santa Cruz) and a K-Ras 4B rabbit polyclonal antibody (Santa Cruz). Antibody
dilution curves were performed to establish the correct concentration of antibody to be
used in each case.
The samples collected for analysis were treated as follows: The embryos were fixed for
approximately 8hrs in 10% formal buffered saline to prevent over fixation, and the
neonatal and adult tissue samples were fixed in 10% formal buffer saline overnight. All
samples were processed for paraffin embedding. The embryos were all mounted so that
the sectioning would be transverse.
2.6.1 Immunhistochemistry: Paraffin embedded sections
From paraffin blocks 5|im thick sections were cut and attached to polylysine coated
slides (BDH). The sections were de-waxed using Histoclear (National Diagnostics) for
2x 5min and then rehydrated by immersion in a series of graded alcohols 100% 2x
2min, 90% 2x 2min, 70% 2x 2min, finally immersing the slides in tap water. Then a
method of antigen retrieval was used. Several were tried in order to optimise the signal
strength for each antibody used
1) Citrate buffer pH6.6 antigen retrieval solution (Vector) 1% in deionised water. The
antigen retrieval solution (400ml) was pre-warmed in the microwave (950W) for 5min
on full power. Then the slides were heated in the microwave for 2x 5min on full power.
Topping up the solution as necessary to ensure that the sections remain submerged.
The slides were then immediately removed to running tap water.
2) The pepsin (Sigma)/ saponin (Sigma) method was also used. The sections were
incubated for 15min in a 5pg/ml in 0.01M HC1 buffer pH2.5 pepsin solution at room
temperature. The sections were washed twice in deionised water. The sections were
then incubated for 30min in a saponin solution (5pg/ml in deionised water) at room
temperature and washed 3x in PBS.
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3) The urea antigen retrieval method was used. A solution of 0.8M urea pH6.4 was
heated up for 5min prior to the sections being added and then 2x 5min with the sections
and the levels topped up as necessary. Sections were washed in running water.
Endogenous peroxidase was blocked using a solution of 3% hydrogen peroxide (Sigma)
in water for 15min at room temperature. The sections were washed in IX PBS. The
signal was visualised by the avidin biotin complex method using Vector Elite goat anti-
rabbit ABC kit (Vector Labs). The blocking serum (normal goat serum) was diluted to
1.5% in IX PBS and added to the sections for 20 min in a humid chamber. The excess
was serum was removed and the primary antibody added at the required dilution
(diluted in 0.01% BSA) for, either 2 hour in the humid chamber at room temperature, or
overnight at 4°C. The negative control had the primary antibody omitted and was
incubated in 0.01% BSA. The slides were then washed for 5 min in IX PBS and the
goat anti-rabbit secondary antibody (Vector Labs) added for 30 min and followed by
washing in IX PBS. The ABC reagent (Vector Labs) was added for 30 min and the
sections washed in PBS. Finally, the DAB substrate (Vector Labs) was added for 5 min
and the sections washed in running water. Sections were then counterstained with 50%
haematoxylin (BDH) for 30 seconds, dehydrated through graded alcohols and placed
into xylene. The coverslips were mounted with DPX (BDH).
The use of blocking peptides was included as an additional control to ensure that signals
produced were the result of the specific binding of the K-Ras 4A and K-Ras 4B rabbit
polyclonal primary antibodies to their epitopes. The amount of primary antibody
needed for the experiment was calculated and for neutralisation a volume of blocking
peptide was added to give 50-100 the weight (w/w) of peptide to primary antibody, and
then a small volume of PBS was added to the tube (~lOOju.1). The mixture was
incubated on a rocking platform overnight at 4°C, and then centrifuged for 15 min at
4°C to pellet any immune complexes. The primary antibody/peptide mixture was





To avoid RNase contamination all lab ware and reagents were set aside for RNA work
only. The water used was DEPC treated and autoclaved. Surfaces and equipment were
cleaned with RNase Away (Life Technologies) and gloves and a clean lab coat were
worn at all times.
RNA was extracted from cells and tissues using the Trizol (Life Technologies) method.
Lor tissues 1ml of Trizol reagent was used per 50-100mg of tissue and homogenised
using a power homogeniser (Ultra-Turrax T25, Janke-Kunkel IKA Labortechnik). ES
cells were lysed directly in the culture dish using 1ml of Trizol reagent per 10cm2 of
tissue culture area. The cells were then scraped from the surface and the lysate was
transferred to a 15ml Lalcon tube. It was possible to store the lysates at this stage at -
70°C. If the samples were to be used immediately they were incubated at room
temperature for 5 mins to permit the complete dissociation of the nucleoprotein
complexes. Lor every 1ml of Trizol reagent used 0.2ml of chloroform was added and
the samples shaken vigorously, incubated at room temperature for several minutes and
then centrifuged at 12,000xg for 15 mins at 4°C (Sorvall). The upper aqueous phase
was transferred to a fresh tube and the RNA precipitated using 0.5ml of isopropanol per
lml of Trizol reagent used for the initial homogenisation. Samples were incubated at
room temperature for 10 mins and then centrifuged at 12,000xg for 10 mins at 4°C. The
supernatant was removed and the RNA pellet washed once with 75% ethanol (made
with DEPC treated water) using at least lml of 75% ethanol per lml of Trizol. Samples
were mixed and centrifuged at 7,500xg for 5 mins at 4°C. The supernatant was
discarded and the RNA briefly air-dried before redissolving in DEPC-treated water.
Samples were incubated for lOmins between 55-60°C to help the RNA redissolve. The
A260/280 and concentration were determined by spectral analysis.
2.7.2 First-strand cDNA synthesis
First-strand cDNA synthesis was performed using the Superscript™ preamplification
system for first strand cDNA synthesis (Life Technologies) according to manufacturers
guidelines.
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RNA/primer mixtures were made up with an aliquot of RNA (l-5pig), lpl of
01igo(dT)i2-i8 (0.5jug/ptl) and DEPC-treated water to a final volume of 12pl. Duplicate
samples were prepared for plus and minus RT controls. Each sample was incubated at
70°C for 10 mins and then on ice for at least 1 minute. A master reaction mix was
prepared containing 2|il 10X PCR buffer, 2pl 25mM MgCE, lpl lOmM dNTP mix and
2p,l 0.1M DTT for each sample. This was then mixed and 7pl was added to each
RNA/primer mixture. This was mixed, collected by brief centrifugation and incubated
at 42°C for 5 min. To the plus RT samples lpl (200 units) of Superscript II RT was
added, tubes were mixed and then all samples were incubated at 42°C for 50 min.
Reactions were terminated at 70°C for 15 min and then chilled on ice. Reactions were
collected by brief centrifugation and 1 pi of RNase H was added to each tube and
reactions were incubated for 20 min at 37°C.
2.7.3 Amplification of target cDNA
The first strand cDNA obtained above was then amplified directly using PCR. Only
10% of the first strand reaction was used, since larger amounts decreased the amount of
product synthesised. The PCR reaction mixture was made up as previously described
excepted that 2pl of cDNA template were used. The primer sequences, expected
product sizes and cycle conditions are shown in the table below.
Table 2.3 PCR primers and conditions for amplification from cDNA




KRF GGAATTCCGCCTGCTGAA K-ras cDNA 30 cycles of





KRR CGGGATCCCGTGTACACC K-ras cDNA






KRF and KRR are as previously published (Pells et ai, 1997).
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2.8 In vitro analysis of ES cell proliferation, differentiation and apoptosis
2.8.1 Proliferation assay
Cells were grown in 75cm flasks to approximately 80% confluence, trypsinised and
counted using a Coulter particle count and size analyser (Beckman-Coulter), and seeded
at ~7.5x10s cells/90mm petri dish. Dishes were set up in triplicate for each time point.
Cells were harvested at 24, 36, 48, 72, 84 and 96 hours after seeding. At each time
point the cells were harvested by trypsinisation (as previously described) and cell pellets
were resuspended in 1ml of cell culture medium and diluted 1 in 20 in Isoton II
balanced electrolyte solution (Beckman-Coulter) and cell numbers were counted as
above.
2.8.2 Stem cell renewal assay
Cells were grown to subconfluence in 75cm" tissues culture flasks, trypsinised and
counted (as described above). The cells were seeded at lxlO3 cells per well of a
gelatinised 6 well plate. The cells were cultured in normal growth medium that
contained different levels of LIF either, 250U, 100U, 10U, 1U or in the absence of LIF
for 5 days. At which time they were stained for the presence of alkaline phosphatase
activity.
The alkaline phosphatase activity was detected using an alkaline phosphatase kit (Sigma
Diagnostics). The volumes of solutions required were calculated according to the
number of wells to be analysed, with 1ml of solution sufficient for one well of a 6 well
plate. Proportions were as follows: 0.2ml of sodium nitrite and 0.2ml of FRV-alkaline
solution were mixed, allowed to stand for 2 mins and added to 9ml of deionised water.
To this solution 0.2ml of Naphthol AS-BI alkaline solution was added. The growth
medium was removed and the cells were fixed for 30 sec and then rinsed with water for
45 sec. The stain solution was then added to the cells and incubated in the dark at room
temperature for 15 mins. After removal of the stain the cells rinsed with water and
allowed to air dry. ES cell colonies stained intensely pink.
69
2.8.3 Treatment of ES cells with apoptosis inducing agents
Cells were treated with etoposide (Sigma), TNF alpha (Cambridge bioscience), Fas
monoclonal antibody (Jo2) (BD PharMingen) or recombinant Fas ligand (Upstate
biotechnology).
Cells were grown to subconfluence in 75cm2 tissue culture flasks, trypsinised and
seeded at, either 2xl06 cells/90mm petri dish for etoposide treatment, or 9xl05 cells/
well of a 6 well plate for TNF alpha, Fas monoclonal antibody and Fas ligand
treatments. Cells were allowed to attach overnight in normal growth medium. Next
day the medium was replaced with medium containing the apoptosis-inducing agent.
Etoposide was dissolved to a stock concentration of lOOmM in DMSO for long-term
storage. A working stock of 20mM etoposide was prepared in DMSO, which was
further diluted to give final concentrations of between 5-40pM. All plates received
DMSO to a final concentration of 0.02%. Untreated controls and controls with DMSO
alone were used to control for the effect of DMSO and etoposide on the system. Cells
were treated with etoposide for between 6 to 48hrs and then harvested for analysis as
described below.
TNF alpha was dissolved to a stock concentration of lp.g/ml in medium containing 5%
FCS (normal growth medium). This was diluted further to treatment concentrations of
lOng/ml, 50ng/ml and lOOng/ml in growth medium. Cells were incubated in the
presence of TNF alpha for 24 and 48hr and then harvested for analysis.
Fas monoclonal antibody (Jo2) was provided at a concentration of lmg/ml and was
diluted to the required concentration in normal growth medium.
In the case of Fas ligand, the lyophilised powder was resuspended in 50|il of sterile
water to give a concentration of 100jag/ml. The stock solution was then further diluted
to the required concentrations with normal growth medium.
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2.8.3.1 Treatment of ES cells with signal transduction pathway inhibitors
ES cells were treated with the MEK inhibitor PD98059 (Promega) and the PI-3Kinase
inhibitor LY294002 (Promega). Both inhibitors were provided as lyophilised powders,
which were reconstituted with DMSO to give 20mM stock concentrations. The stock
solutions were then diluted to the required concentration with culture medium.
2.8.4 Flow-cytometry (Vindelov analysis)
The DNA content of ES cells was analysed by flow-cytometry (adapted from Vindelov
et al., 1983). Cells were trypsinised and resuspended to a concentration of 2xl06
cells/ml in cell culture medium, of which 0.5ml was transferred to a Eppendorf tube and
centrifuged for 30 sec at 4,000rpm (MSE, Microcentaur). The supernatant was
discarded and the cell pellet was resuspended in lOOpl of citrate buffer (appendix I). To
the cell/citrate buffer suspension 450pl of solution A containing a strong trypsin
(0.3mg/ml) (appendix I) was added and the sample was mixed by inversion and
incubated at room temperature for 10 min. To this 325pl of solution B containing a
trypsin inhibitor (0.5mg/ml) and ribonuclease A (O.lmg/ml) (appendix I) was added,
and the sample incubated at room temperature for 10 min following mixing by
inversion. Finally, 250pl of solution C containing 0.4mg/ml propidium iodide
(appendix I) was then added to the sample, mixed and incubated at 4°C in the dark for
10 min. The samples were run through a Coulter EPICS XL flow-cytometer, and the
DNA content of the sample was analysed by the EPICS software.
2.8.5 Detection of phosphatidyl serine by annexin V
Annexin V detects the presence of phosphatidyl serine, which is externalised to the
outer surface of the plasma membrane as an early event in apoptosis. Cells were treated
with apoptosis inducing agents, harvested and washed once with ice cold PBS and then
gently resuspended in 100pl of annexin V/propidium iodide buffer (R&D Systems)
(0.35|ig/ml annexin V and 0.25|ig/ml PI) per Ixl05-lxl06 cells for 15 min at room
temperature in the dark. Then 400|il of IX binding buffer was added and the samples
were analysed immediately on a Coulter EPICS XL flow-cytometer.
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2.8.6 Immunofluorescent staining with Hoechst 33342 and propidium iodide
Hoechst 33342 and propidium iodide immunofluorescence was used for morphological
analysis to detect nuclear changes consistent with apoptosis. The culture medium was
aspirated into a universal tube and the cell monolayer was washed with PBS, which was
then aspirated into the same universal. Trypsin was added to the monolayer, and the
cells were transferred to the same universal tube. This ensured that the whole cell
population was collected. The cell suspension was centrifuged at l,000rpm for 5 min
(MSE Mistral 1000) and the pellet was resuspended in IX PBS to ~5xl05 cells/200pl.
This was transferred to an Eppendorf to which 8pl of 200pg/ml Hoechst 33342
(Molecular Probes) was added. This cell suspension was incubated at 37°C for 10 min.
Then 2pl of lmg/ml propidium iodide (Molecular Probes) was added just prior to
analysis and the samples were incubated on ice in the dark until needed, to reduce the
fading of the stains. Slides were prepared with 30|il of cell suspension, which was
added to the slide immediately prior to analysis, a cover slip was placed on top and the
sample analysed by immunofluorescence using a UV microscope (Axioskop, Zeiss).
For each sample 250 cells were scored from at least two random fields, and classified as
either viable, apoptotic, late apoptotic or necrotic and expressed as a percentage of the
total number of cells counted (representative pictures are shown in chapter 6.3).
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Chapter 3
The Generation Of K-ras 4A Mutants By Gene Targeting
Introduction
Recent years have seen an emerging body of evidence for differential signalling
amongst Ras protein isoforms. Far from being a highly homologous functionally
redundant family of proteins, it is now becoming increasingly clear that the Ras proteins
weave a complex web of interactions with exchange factors and signal transduction
pathways, which is determined at least in part by the subcellular localisation of the
proteins. Therefore, it is of interest to investigate the relative importance of the
expression of the K-ras 4A and 4B isoforms during embryonic development and in
adult tissues, to elucidate further their contribution to the phenotype associated with the
complete deletion of both K-Ras proteins (Johnson et al., 1997; Koera et al., 1997).
The study of transgenic animals derived using ES cells heterozygous for the deletion of
K-ras exon 4A, and examination of ES cells homozygous null for this deletion provides
a model system with which to explore the role of K-ras 4A in vitro and in vivo. This
system also dissects the relationship between the K-ras 4A and 4B isoform and could
address vital questions regarding their interaction during mouse development. ES cells
with a heterozygous deletion of the K-ras 4A exon had previously been derived by this
laboratory (E14 A4A 73). Nevertheless, the aim of this work was to generate a new
independent heterozygous null cell line for the deletion of exon 4A and then generate
homozygous null cell lines from both of these. This was of importance, since it was
necessary to establish the reproducibility of any observed phenotypes between
independent clones of the same genotype.
3.1 Generation of ES cells heterozygous for the deletion of exon 4A
3.1.1 Characterisation of targeting vector pPTKiNKiA4A
The targeting vector pPTKiNKiA4A used in these experiments was designed and
constructed by Dr James Williamson. A diagrammatic representation of the vector is
shown in figure 3.1. The targeting vector comprises an upstream and a downstream arm
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of homology designated KRI4 and KRI5 respectively, which were isolated from a
pBR322 plasmid containing an EcoRl fragment of K-ras (George et al., 1985)
encompassing the region immediately upstream of exon 3 to just upstream of exon 4B.
KRI4 was excised from the plasmid by Hindlll digestion, and KRI5 was isolated by a
EcoRl/Xbal digest. Therefore, the arms of homology are segments of intronic sequence
flanking exon 4A. The vector contains a Herpes simplex virus (HSV)- thymidine kinase
(tk) cassette to enable negative selection by ganciclovir, and a neomycin resistance
(neo) cassette driven by a phosphoglycerate kinase (PGK) promoter to enable positive
selection of targeted clones in the presence of geneticin (G418). The integration site of
the targeting vector and the expected alterations to the K-ras gene are shown
schematically in figure 3.2. The targeting vector replaces exon 4A with the neo1
cassette, generating a targeted allele, which is designated K-ras+tm 4A. Prior to carrying
out the electroporation of the ES cells with the targeting vector, diagnostic cuts were
performed to confirm the identity of the plasmid. The 12.2Kb targeting vector was
linearised by digestion with the EcoRl restriction enzyme, and a triple digest with




Figure 3.1 Diagrammatic representation of pPTKiNKiA4A. The targeting vector was constructed
using the pUC19 plasmid. The vector was linearised by digestion with EcoRl. The positions of the
restriction enzyme sites for diagnostic digest are indicated (EcoRI, NotI and Xbal). KRI4 is the upstream
arm of homology and KRI5 is the downstream arms of homology corresponding to intronic sequence
adjacent to K-ras exon 4A.
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Figure 3.2 Schematic representation of the targeting strategy used to delete exon 4A. Wild-type
genomic DNA shows exons 3, 4A and 4B of the K-ras gene with the relevant restriction sites. The
targeting vector was designed to delete exon 4A by the insertion of the neomycin resistance (ned)
cassette. The probes used to screen for homologous recombination by Southern analysis are shown with






Figure 3.3 Diagnostic triple digest of pPTKiNKiA4A. The plasmid pPTKiNKiA4A was digested using
a triple digest with EcoR], Xbal and Notl to produce four bands of approximately 1.3, 1.9, 3.5 and
4.5Kb. The DNA marker is a 250bp ladder (Life Technologies).
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3.1.2 Electroporation of E14 IV embryonic stem cells
The pPTKiNKiA4A targeting vector has previously been used successfully by Dr James
Williamson to generate the E14 A4A 73 cell line. However, since only one K-ras+/""A4A
cell line was isolated it was important to generate further independent cell lines with a
heterozygous deletion of exon 4A. Therefore, E14 IV ES cells (kindly gifted by Dr
Julia Doran) were electroporated with 150pg of the targeting vector, which had been
linearised with EcoRl. Following electroporation the ES cells were plated down
overnight in normal growth medium then cultured in the presence of 150pig/ml
geneticin for four days. The concentration of geneticin had been pre-determined by a
dose response analysis of wild-type ES cells. The concentration used was the minimum
required to cause total cell death over a period of approximately one week. After four
days of positive selection by geneticin, negative selection was begun by the addition of
ganciclovir to the media. One of the petri dishes was maintained in the presence of
geneticin alone to analyse the additional selection caused by the ganciclovir treatment.
The selection was carried out for 14 days as described in section 2.4.2, at which time the
surviving colonies were picked and expanded. The negative selection with ganciclovir
caused an approximate 2-fold increase in selection, compared to geneticin alone. The
plate receiving geneticin alone had 82 colonies, whereas the plate receiving geneticin
and ganciclovir had 45 colonies.
Surviving clones were screened by Southern analysis for homologous recombination
(figure 3.4). In total 306 clones were screened with the internal probe, this identified
both homologous and non-homologous recombinants, since the probe hybridised to a
region within the targeting vector. Following digestion of genomic DNA with Hindlll,
the internal probe identified a 2Kb band in wild-type DNA, and a 2Kb to 6Kb transition
following homologous recombination, due to the loss of the Hindlll restriction site
upstream of exon 4A by the integration of the neo cassette (figure 3.2). Of the 306
clones screened with the internal probe 22 colonies were identified that showed the
correct band pattern.
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Figure 3.4 Detection of targeted clones by Southern analysis following homologous recombination
with the targeting vector pPTKiNKiA4A. A) Repeat Southern analysis with the internal probe of 11 of
the 22 clones isolated following the initial screen of all 306 clones with this probe. Homologous
recombination results in the detection of a 6Kb band as well as the wild-type 2Kb band. B) Southern
analysis using the external probe. Homologous recombination results in a 5kb to 4Kb transition. The use
of this probe showed that only 4 of the 22 clones analysed had undergone homologous recombination.
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These clones were then screened with the external probe; which identified only those
clones that had undergone homologous recombination. DNA was digested with Pvull
to identify a 5Kb band in wild-type DNA and a 5Kb to 4Kb transition following
homologous recombination. Of the 22 clones analysed only 4 clones showed the
correct band pattern with the external probe and an approximate 1:1 ratio of band
intensity (figure 3.4).
The low percentage of homologous recombination (1.3%) observed in this targeting
strategy was not unexpected, since the arms of homology used to create the targeting
vector were non-isogenic, as the ES cells were derived from the 129/Ola strain of mice
and the homology arms were from CBA mice. The heterozygous clones (K-ras+/"nA4A)
that were identified following Southern analysis were designated E14 IV 136, 142, 197
and 213. These clones were then expanded into cell lines for further analysis.
3.1.3 Analysis of ES cell chromosome number
Due to the potential for ES cells to undergo spontaneous chromosomal trisomy and
other abnormalities (Liu et al., 1997) in culture it was important to ensure that the
targeted clones had the correct chromosome number, since chromosomal abnormalities
have been shown to reduce ES cells contribution to the germline. A representative
number of metaphase spreads (-25) were counted for each of the 4 clones. Clones that
had more then 70% of the metaphase spreads containing 40 chromosomes were
considered to be normal. In all four heterozygous cell lines approximately 80% of the
metaphases counted had 40 chromosomes (Table 3.1).
Table 3.1 Percentage of chromosomally normal metaphase spreads
Cell line Passage number % chromosomally normal
E14IV (+/+) +20 81%
E14IV136 (+/tmA4A) + 10 78%
E14IV142 (+/tmA4A) +6 85%
E14IV197 (■+/tmA4A) +8 75%
E14IV213 (•+/tmA4A) +8 83%
Wild-type (+/+) parental E14 IV cell line and the four cell lines with heterozygous deletions of exon 4A
(+/tmA4A). The passage numbers at which the chromosome numbers were counted are also indicated.
For the +/tmA4A cell lines the passage number represents the number of passages since isolation of the
targeted cell line.
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3.2 Isolation of K-rastmA4A/tmA4A ES cells
3.2.1 Attempt to isolate K.rastmMA/tmA4A ES cells from clone E14 A4A 73
High G418 selection (section 2.4.3.) selects for cells that have undergone spontaneous
loss of heterozygosity (LOH) (Mortensen et al., 1992). These cells have a duplication
of the ned cassette and can be selected for by culturing of heterozygous cells in high
concentrations of geneticin. The mechanism of duplication is believed to be either,
mitotic recombination or, chromosome loss and duplication (Lefebvre et al., 2001).
The K-ras+/""A4A cell line designated E14 A4A 73 (as described above), as it was already
available was used initially to generate K-ras""MA/,"'A4A cell lines. This cell line had
been characterised previously and been shown to have the correct genotype by Southern
analysis with the internal and external probes and the correct chromosome number by
metaphase spread analysis. Several high G418 selections were performed on the E14
A4A 73 cell line, but all proved unsuccessful. Extremely high concentrations of
geneticin (Life Technologies) were used (up to 7mg/ml) and these did not cause
significant cell death, and following 14 days of growth under these conditions it was not
possible to identify individual colonies.
3.2.1,1 Investigation of the geneticin resistant nature of E14 A 4A 73
There were two possible reasons for this: firstly, that the E14 A 4A 73 cell line
contained a mixed population of targeted cells and cells that contained a second random
integration, or alternatively that a secondary event had occurred in some cells of the
original clone. Both hypotheses would lead to a subpopulation of cells containing two
neox cassettes, resulting in those cells surviving selection. If either of the above
hypotheses were correct it predicts that subcloning this population should result in the
isolation of cells that contain only the desired genotype. Therefore, to investigate this
further E14 A 4A 73 cells were used for single cell cloning.
For the subcloning of E14 A 4A 73 a dilution was calculated to give less than 1 cell per
well of a 96 well plate. Cells were grown for several days and only those wells that
were deemed to have colonies derived from a single cell were harvested. A total of 62
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clones were derived and screened by Southern analysis with a probe that detected the
neo cassette. The 2.7Kb neo probe was generated by an Xhol digest of the pUHD172-
neo plasmid (Gossen et al., 1995). A 6Kb band was expected in cells containing the
homologously recombined targeting vector following digestion of genomic DNA with
Hindlll. The detection of an additional 9Kb band in some clones confirmed the
existence of a mixed cell population (figure 3.5 A). These same clones were
subsequently screened with the internal and external probes as previously described
(section 3.1.2), which also confirmed the presence of a mixed cell population,
identifying the same abnormal clones as the neo probe (Figure 3.5 B and C).
Therefore, using this method it was possible to isolate clones that had the correct
genotype. One of these was E14 A4A 73/39. The chromosome number of this clone
was analysed following its isolation to ensure that a chromosomally abnormal clone had
not been selected (table 3.2). The chromosome number was found to be comparable to
its parental cell line. Therefore, using single cell cloning it was possible to isolate a
new cell line containing the correct genotype with the correct chromosome number.
Table 3.2. The percentage of metaphase spreads counted containing 40
chromosomes
Cell line passage number % chromosomally correct
E14A4A73 (+/tmA4A) + 12 72%
E14A 4A 73/39 (■+/tmA4A) +2 70%
Analysis of the chromosome number of the parental K-ras+/""MA cell line E14 A4A 73 and the
heterozygous cell line re-derived from it by subcloning E14 A 4A 73/39 by metaphase spread analysis.
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Figure 3.5 Southern analysis of K-ras+/"',A4A clones derived from single cell cloning. DNA extracted
from the cell lines isolated following single cell cloning was analysed by Southern analysis. A) neo
probe. B) Internal probe. C) External probe. These probes clearly show a mixed cell population. The
correct band sizes expected for each probe are indicated.
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3.2.2 Isolation of K-rasftn*M/f'n*M clones from E14A4A 73/39 ES cells
Following the isolation of the E14 A4A 73/39 cell line high G418 selections (l-3mg/ml)
were carried out on this and other cell lines containing the heterozygous deletion of
exon 4A, (E14 IV 136, 197 and 213, as described previously (3.2.1)). The cells were
grown for 14 days under these conditions changing the media regularly to maintain
selective pressure. Significant cell death was observed with the formation of discrete
colonies. The surviving colonies were picked and screened for the lose of exon 4A
using primers in exon 4A and primers in either exon 3 or 4B as a control to confirm that
DNA was present and of the appropriate quality for PCR. However, only the
heterozygous cell line E14 A4A 73/39 produced ES cells homozygous for the dJfetion
of exon 4A designated K-rastmA4A/tmA4A, these were termed E14 A4A 73/39/9 and E14
A4A 73/39/22. The PCR analysis confirmed that these clones lacked the 72bp exon 4A
product (figure 3.6), but that they were still able to produce the exon 3 PCR product.
However, when the chromosome numbers of these two clones were counted, they were
found to be abnormal. The majority of metaphase spreads counted had 42 instead of 40
chromosomes (Table 3.3). Therefore, a further high G418 selection was performed
using the E14 A4A 73/39 heterozygous cell line and two more homozygous clones (E14
A4A 73/39/137 and E14 A4A 73/39/145) were identified by PCR analysis (figure 3.6).
The relative efficiency of the high G418 selection for the various heterozygous cell lines
used is shown in table 3.4. However, these cell lines were also determined to be
chromosomally abnormal by metaphase spread analysis (Table 3.3), with the
predominant chromosome number again being 42 instead of the expected 40.
Table 3.3 Proportion of metaphase spreads counted containing 40 chromosomes
Cell line passage number % chromosomally normal
E14 A 4A 73/39 (+/tmA4A) +2 70%
E14 A 4A 73/39/9 (,tmA4A/tmA4A) +7 38%
E14 A 4A 73/39/22 (tmA4A/tmA4A) +7 5%
E14 A 4A 73/39/137 (tmA4A/tmA4A) +7 0%
E14 A 4A 73/39/145 (tmA4A/tmA4A) +7 0%
The parental K-ras+/""A4A cell line E14 A4A 73/39 and the four Y.-ras'n'MA"mA4A cell lines derived by high
G418 selection. Passage numbers indicate passages since isolation of targeted clone.
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The reasons for this are unknown, but the E14 A4A 73/39 cell line had been through
several rounds of selection and extensive cell culture, which may have led to the
selection of a chromosomally unstable subpopulation, although this was not apparent
when this cell line was isolated. The generation of such low percentages of homozygous
null ES cell clones from this procedure was unexpected. Elowever, the percentage of
homozygous null colonies derived by this procedure has been shown to vary greatly
(Mortensen et ai, 1992). The failure of the heterozygous E14 IV clones to generate any
homozygous null clones suggested that the conditions were not optimal for these cell
lines.
Table 3.4 Percentage of K-ras"nMA/"nA4A clones derived from K-ras+/tmAfA cell lines
following high G418 selection.






E14 A4A 73/39 71 2 2.8
E14 A4A 73/39 75 2 2.7
E14IV 136 146 0 0
E14 IV 197 96 0 0
E14IV213 96 0 0
The two entries for E14 A4A 73/39 refer to the two independent high G418 selections performed on this







Figure 3.6 Detection of i&_rastmA,AltmMA cen clones by PCR analysis. The figure shows the
identification of the 4 clones generated by high G418 selection. The presence of PCR
quality DNA is established by primers in exon 3, which produce a 125bp PCR product. Deletion of exon
4A was established by the absence of the 72bp exon 4A PCR product. The PCR negative controls are
designated (-). A) Identification of clones E14 A4A 73/39/9 and E14 A4A 73/39/22 showing absence of
the 72bp exon 4A product. B) Shows presence of exon 3 PCR products in E14 A4A 73/39/137 and E14
A4A 73/39/145 cell lines. C) Shows absence of exon 4A PCR product in the E14 A4A 73/39/137 and E14
A4A 73/39/145 cell lines.
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3.2.3 RT-PCR establishing correct splicing to exon 4B in K-rastmA4A/tmA4A cells
Due to the nature of the targeting event it was important to establish that the
homologous recombination of the vector did not interfere with the correct splicing to
exon 4B, as this would result in a K-ras homozygous null genotype. Therefore, once K-
rastmA4A/tmA4A es cells had been isolated the mRNA splicing of these was analysed.
RNA was extracted from wild-type and K-ras""A4A/t"lA4A ES cells and RT-PCR was
performed. The primers were positioned in exon 1 and exon 4B and PCR conditions
were as previously described (Pells et al., 1997). The use of these particular primers
meant that both the K-ras 4A and K-ras 4B transcripts were amplified in the same
reaction. The result showed that both of the K-ras"nA4A/,mA4A cell lines analysed were
capable of producing the K-ras 4B transcript, demonstrating that the targeting vector
did not compromise the splicing to exon 4B. This also showed that while wild-type ES
cells produce the K-ras 4A mRNA transcript, K-ras"nA4A/lmA4A ES cells do not, so
confirming that the cell do not expression the K-ras 4A isoform (figure 3.7 A). This
result was confirmed by the analysis of K-ras"nA4A/"nA4A mice (figure 3.7 B).
3.2.4 Microinjection of blastocysts with K-ras+/,mA4A ES cell lines
Having successfully isolated K-ras+/""A4A ES cells with the desired genotype and the
correct chromosome number and proved that the targeting strategy resulted in deletion
of K-ras 4A mRNA, but not K-ras 4B mRNA, the ES cells were used for blastocyst
injection. Initially cells were grown in the presence of LIF. However, following the
failure to generate chimaeras the cells were grown on a feeder layer of mitomycin C
treated STO fibroblasts to ensure a proper ES cells morphology, as experiments have
shown that ES cells showing non-ES cell morphology failed to contribute to embryos
(Rathjen et al., 1999). Two independent clones were injected by Dr Charles Patek
(Molecular Medicine Centre) and a further two clones were injected by Jan Ure (Centre
for Genome Research). The creation of chimaeras following blastocyst injection was
monitored by coat colour. However, the maintenance of ES cells upon the feeder layer
did not improve contribution to blastocysts. Despite extensive efforts no coat colour








Figure 3.7. Detection of K-ras isoform mRNA by RT-PCR. A) Wild-type adult stomach (St) cDNA
was used as a positive control. Wild-type ES cells (+/+) show both the K-ras 4A (687bp) and the K-ras
4B (565bp) mRNA products. The K.ras""A4A/""MA ES cell lines show the K-ras 4B product only. The
marker is a 1Kb ladder. -/- (1) E14 A 4A 73/39/9 -/- (2) E14 A 4A 73/39/22. B) Wild-type (+/+) adult
mouse large intestine showing the K-ras 4A (687bp) and the K-ras 4B (565bp) mRNA products and K-
rastmMAJ,mMA (_/_) adult mouse large intestine showing only the K-ras 4B (565bp) mRNA product,
confirming that the targeting strategy results in the deletion of the K-ras 4A (687bp) mRNA.
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# offspring # coat colour
chimaeras
E14IV 136 2 11 0
E14 A 4A 73/39 2 9 0
Of the 20 animals produced by these two injection sessions no coat colour chimaeras were identified from
either of the independent K-ras+/'mA4A cell lines used.
3.2.5 Mycoplasma testing
A possible reason for the failure to generate chimaeras was Mycoplasma infection. This
was tested using a Mycoplasma PCR test (Stratagene). The test was performed using
medium that cells had been cultured in. An internal control producing a product of
1Kb was included to confirm that the PCR conditions were optimal and the template
DNA was amplifiable. The positive control of 874bp corresponded to the expected
product size produced by Mycoplasma infection. The investigation confirmed that
Mycoplasma was not infecting the cells at levels detectable by this method (Figure 3.8).
Therefore, while Mycoplasma infection could not be completely ruled out, as it could
have been infecting cells at levels undetectable by this method, it appeared unlikely that
this was the reason that the cell lines were not contributing to chimaeras.
The failure to generate chimaeras, the negative mycoplasma status and the presence of a
good chromosome number, suggested that the ES cells may have been compromised
due to the length of time in culture. Extensive cell culture may have lead to an inability
to form chimaeras possibly due to the ES cells being overgrown by variants,
compromised in their ability to contribute to the tissues of chimaeras, that had a
selective growth advantage as a result of suboptimal culture conditions. Although
measures had been taken to try and avoid this by growing the ES cells on a feeder layer
of mitomycin C treated STO fibroblasts. Therefore, due to these difficulties and
problems encountered with the production of K-ras"nA4A/tmA4A ES cells, it was decided
that further heterozygous ES cell for the deletion of exon 4A should be generated using
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Figure 3.8. Test for Mycoplasma infection by PCR analysis. The internal control product (1Kb)
confirmed that PCR conditions were correct and the positive control (874bp) showed the expected
product size corresponding to Mycoplasma infection. There are no bands of corresponding size in the test
lanes 1) E14 (+/+), 2) HM-1 (+/+) wild-type ES cell line, 3) E14 A4A 73/39, 4) E14 IV 136, 5) STO neo
fibroblasts, 6) E14 A4A 73/39/9, 7) E14 A4A 73/39/22, 8) positive control.
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3.3 Generation of HM-1 K-ras +/tmA4A ES cells
In order to try and improve the results from the electroporation of wild-type ES cells
with the pPTKiNKiA4A targeting vector and because of the limited time span available,
several alterations were made to the targeting strategy and screening methods for
identifying homologous recombination. A new cell line was used for the
electroporation. HM-1 ES cells were kindly gifted by Professor David Melton. These
ES cells are an HPRT deficient cell line (Magin et al., 1992), which were only 14
passages from their original isolation and it was hoped that this would overcome
problem encountered with failure to generate coat colour chimaeras. HM-1 ES cells
contribute with high frequency to the germline of chimaeric animals (Selfridge et al.,
1992). In addition, in order to increase the rapidity of the screening for homologous
recombinants a PCR strategy was developed to replace the initial screen by Southern
analysis carried out previously.
3.3.1 Development of PCR strategy to detect homologous recombination
To improve the rapidity of the isolation of putative heterozygous clones a PCR screen
was to be carried out on a crude DNA extract from half the picked colony following
selection (method described in section 2.4.8), while the other half of the colonies were
expanded in 24 well plates (adapted from McMahon and Bradley, 1990). In this way
the genotype of the colonies could be confirmed before they required expanding.
The development of the PCR method was made possible by the publication of the
mouse chromosome 6 sequence in the region around the K-ras gene, as previously the
intronic sequence had not been available. This allowed the identification of the exact
start and end points of the arms of homology within the intron and therefore possible
primer positions. However, because the downstream arm of homology terminated
~300bp from the 5' end of exon 4B it was decided to position the reverse primer in exon
4B to minimise any possible problems associated with divergence in intronic sequence
between mouse species. The forward primer was designed to anneal to the 3' end of
the neo' gene, resulting in the amplification of a 2.1Kb PCR product (Figure 3.9) only in
cells that had undergone homologous recombination.
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K-ras targeted DNA
Exon 3 Exon 4B
Figure 3.9. Diagrammatic representation of the PCR strategy to identify homologous recombinants.
The figure shows a portion of the K-ras DNA following the homologous recombination event and the
position of the PCR primers used to screen for heterozygous clones. Primers are positioned at the 3' end
of the neomycin resistance cassette and at the 5' end of exon 4B and in heterozygous clones this resulted
in a PCR product of 2.1 Kb in length.
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The PCR method was validated on DNA extracted from the K-ras+/""A4A cell line E14
A4A 73/39 by phenol/ chloroform extraction. The expected 2.1Kb product was
produced. The PCR was then optimised on small quantities of crude DNA extract to
ensure that the PCR product could be generated under these conditions. Therefore, the
PCR was worked up on crude cell lysates from cell numbers ranging from 100 - 10000
to represent the likely range of cells present in half a colony. However, despite varying
annealing temperature and cycle numbers the 2.1Kb product could not be amplified
under these conditions. Therefore, ES cells were plated at a variety of seeding densities
and grown in 24 well plates to different levels of confluency, ranging from 30%-90%.
The cells were processed to make a crude lysate, which was then used for PCR analysis.
The 2.1Kb targeted band was present in all the samples under these conditions (figure
3.10), suggesting that this method could be used for the screening of homologous
recombination with this modification.
3.3.2 Electroporation of HM-1 ES cells with the pPTKiNKiA4A targeting vector
To optimise the selection for homologous recombination after electroporation two cell
densities of 1.25x10s and 2.5x10s cells per 100mm petri dish were used and the cells
were treated with, either 200pg/ml, or 300pg/ml geneticin. However, selection was
increased to 300pg/ml geneticin for all petri dishes after several days to eliminate
background colonies persisting on control plates that had not undergone electroporation
with the targeting vector. Geneticin and ganciclovir treatment gave approximately a 2-
fold increase in selection compared to geneticin alone. The plates of unelectroporated
cells had no surviving colonies, suggesting that the selection was successful.
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30% 40% 50% 60% 70% 80% 90% + -
Figure 3.10 Development of a colony PCR to detect K-ras+/"nMA targeted clones. E14 A4A 73/39 cells
were grown in 24 well plates to different levels of confluence as indicated and harvested for colony PCR
to determine the approximate destiny of cells needed to provide enough material to detect the 2.1Kb PCR
product. The positive control (+) is E14 A4A 73/39 DNA that had been extracted by phenol/chloroform
extraction; whilst a product is detectable these conditions are clearly not optimal for amplification of this
sample. The PCR water negative control is designated (-).
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Each plate was used once for picking colonies, which minimised the risk of re-picking
colonies that may have re-seeded following this procedure. Picked colonies were
resuspended in medium and !4 was placed in a well of a 24 well plate and the remaining
% was placed in the corresponding well of a separate 24 well plate. Since PCR
amplification had shown that there was enough material when the well was only 30%
confluent well, this allowed cells to be analysed by PCR several days before the
remainder of the cell population required subculturing. The use of separate plates
reduced the risk of potentially targeted clones becoming infected and therefore lost, due
to the disturbance caused by harvesting the other well for PCR. The picking was also
staggered over several days to allow time for the PCRs to be carried out.
Table 3.6. Percentage of homologously recombined clones identified under the
different selection conditions.






1.25xl06 11 156 (10) 6%
2.5xl06 10 168 (7) 4%
Following PCR screening only those clones that were shown to be targeted by the PCR
were subcultured into 25cm2 flasks. Of the 324 colonies screened 17 (-5%) were found
to have the 2.1Kb PCR product corresponding to the targeting event (table 3.6). The
percentage of homologous recombination was improved in this new electroporation,
although the number of positive colonies is fairly evenly spread between the two
selection conditions (Table 3.6).
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2.1 Kb
173 187 194 196 221 226 248 +/+ +/-
Figure 3.11. Detection of 2.1Kb targeted band by PCR. The gel shows seven targeted clones that
were isolated and grown up into cell lines following the electroporation. Wild-type (+/+) and previously
targeted heterozygous DNA (E14 IV 73/39) (+/-) was included as a control. Wild-type DNA did not
produce the PCR product as expected. The negative control (-) had water added in place of DNA and as
expected there is no PCR product.
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Fresh DNA was isolated from seven of the clones (173, 187, 194, 196, 221, 226, 248)
and the PCR repeated, which confirmed the result of the initial screen (Figure 3.11).
Southern analysis was then performed to ensure that there were no additional non¬
homologous events present within the genome (using the internal probe) and that the
targeting vector had integrated correctly within the genome by use of the external probe,
since this detected only homologous recombination. Therefore, by using the external
probe, the PCR strategy and the internal probe it was possible to show that the flanking
regions around the site of the targeting vector's integration were correct.
The results of the Southern analysis with the internal and external probes confirm the
PCR results. All seven heterozygous clones identified following the selection had the
correct band pattern of a 2Kb wild type and a 6Kb targeted band with the internal probe,
and a 5Kb wild type and 4Kb targeted band with the external probe (Figure 3.12). The
Southern analysis also showed that the bands were roughly in a 1:1 ratio.
3.4 Generation of ES cells from HM-1 K-ras+*mMA cell line
Following the successful generation of K-ras+/""A4A ES cells with using the HM-1 ES
cell line, generation of K-ras"nA4A/""A4A ES cells by high G418 selection was undertaken.
It was necessary to generate an independent K-raslmA4A/""A4A cell line with the proper
chromosome number to corroborate any in vitro data generated. One heterozygous cell
line, HM-1 R42 #248, was used for a high G418 selection.
Following 14 days selection in geneticin, 48 colonies were picked and split half and half
into two wells of separate 24 well plates and grown to expand the colony. Once
confluent one well was harvested for DNA extraction and PCR analysis. The cells
growing in the corresponding well were subcultured into 6 well plates. Analysis with
primers in exon 4A found that approximately 60% of the clones did not have the 72bp




+/+ +/- 173 187 194 196 221 226 248
Figure 3.12 Southern analysis of targeted K-ras*"mMA clones. A) Southern analysis with the internal
probe. Genomic DNA digest with Hindll produces a 2Kb band with wild-type DNA (+/+) and a 2Kb to
6Kb shift in heterozygous DNA. B) Southern analysis with the external probe. Genomic DNA digest
with PvuII results in a 5Kb band in wild-type DNA and a 5Kb to 4Kb transition in heterozygous DNA.
Wild-type (+/+) and K-ras*/tmMA DNA (+/-) from previously targeted E14 A4A 73/39 cell line were
included as controls.
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Six of these clones were expanded into 25cm2 flasks and DNA extracted. PCR analysis
was then repeated which confirmed that clones 8, 12, 16, 18 and 24 were homozygous
null for the deletion of exon 4A (figure 3.13), demonstrating that selection for LOH had
occurred successfully in these clones. Clone 4 was used as a positive control
confirming that some of the cells picked from the selection retained the 4A exon. This
finding was further confirmed by Southern analysis (figure 3.14), since only the
targeted bands were detected using the internal and external probes.
3.4.1 Analysis of HM-1 K.ras^A/tmA4A Eg ce|, chromosome number
Previously isolated K-rastm tmA4A cell lines had been found to be chromosomally
abnormal, highlighting the possibility that, either the mutation, or the selection process
may affect the genomic stability of K-rastmA4A/"nA4A cell lines. However, metaphase
spread analysis performed on the five newly isolated cell lines showed that these had
the correct chromosome number (table 3.7).
Table 3.7 Percentage of metaphase spreads analysed with 40 chromosomes.
Cell line passage number % of metaphase spreads
analysed with 40
chromosomes
HM-1 R42 #248/8 32 83%
HM-1 R42 #248/12 32 83%
HM-1 R42 #248/16 32 77%
HM-1 R42 #248/18 32 80%
HM-1 R42 #248/24 32 82%
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Figure 3.13 Isolation of K.ras""MA/""MA cen lines. The figure shows the PCR strategy to identify
those clones that had undergone LOH following high G418 selection. A) Primers in exon 3 resulting in
125bp product confirming that DNA was of PCR amplification quality. B) Primers in exon 4A resulting
in 72bp product present in wild-type (+/+) cells, HM-1 R42 #248 K-ras+/unMA (+/-) cells used for the
selection and clone 4 produced in this selection. Clones 8, 12,16,18 and 24 do not have the exon 4A
product, indicating that they have undergone LOH, and duplication of the mutant allele.





+/+ +/- 12 16 18 24
Figure 3.14. Southern analysis of putative K.ras'mMA"mMA cen lines. Analysis of five putative K-
ras'mMMmA4A ce]i ]jnes with the internal and external probes. A) Probing with the internal probe, +/+ cells
contain a 2Kb band, +/tmA4A contain a 2Kb and 6Kb band and K-ras'mA4A"mMA ceus contain only the
targeted 6Kb band. B) Probing with the external probe, +/+ DNA contains the 5Kb wild-type band,
+/tmA4A DNA contains a 5-4Kb transition and the putative Y^-ras""MMmA4A cell lines contain only the
targeted 4Kb band.
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3.5 Blastocyst injection of ES cells heterozygous for the deletion of exon
4A
All Five of the targeted clones (HM-1 R42 #173, 187, 194, 226 and 248) were used for
blastocyst injection. The ES cells were maintained in the presence of LIF and absence
of a feeder layer. Each of the K-ras+/""A4A ES cell lines were used to inject
approximately 24 blastocysts, which were returned to two recipient females, except
clones 187 and 226, which were used to inject 12 blastocysts and which were returned
to one recipient female. Jennifer Doig performed the injections on my behalf. For each
injection 8-12 ES cells were injected into C57 BL/6 blastocysts generated either by
superovulation or by natural mating and they were returned to recipient psuedo pregnant
female CD1 mice. In conjunction wild-type HM-1 ES cells were also used to inject 12
blastocysts, which were returned to one recipient mouse to act as a control to ensure that
any lack of coat colour chimaeras was not as a result of problems with the parental ES
cell line.
In total nine coat colour chimeras were generated from three of the K-ras+/""A4A ES cell
lines used for microinjection, the results are shown in table 3.8 and pictures of the
animals are shown in figure 3.15.
Table 3.8. Number of coat colour chimaeras derived from ES cell lines used for
microinjection.
Cell line injected Litter size (surviving birth) Coat colour chimaeras
HM-1 R42 #194 6 (3) 3M
HM-1 R42 #226 5 (5) 1M/3F
HM-1 R42 #248 4 (3) 2M
HM-1 9 (8) 4M/3F
The number of male (M) and female (F) coat colour chimaeras are indicated.
3.6 Transmission of the K.ras+/tmA4A mutation through the qermline
The coat colour chimaeras produced by blastocyst injection were then used to generate
K-ras+/""A4A animals. The coat colour chimaeras were mated with wild-type 129/Ola
and C57 BL/6 mice. Germline transmission of the mutation was assessed by the coat
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colour of the offspring following these crosses. Mice from ES cell-derived germ cells
were predicted to be light yellow with pink eyes, when crossed with 129/Ola mice. In
contrast, blastocyst derived germ cells would result in offspring with agouti coats and
black eyes. Animals derived from crossing to C57 BL/6 mice were predicted to have an
agouti coat colour and black eyes if ES cell-derived, and a black coat colour and black
eyes if host blastocyst-derived. Crosses with C57 BL/6 mice were performed in order
to increase the speed at which germline transmitters were identified, since 129/Ola mice
have small litter sizes. The results of breeding the heterozygous chimaeras are shown in
table 3.9. To the date of writing this thesis 4 male chimaeras and 1 female chimera
have, produced litters containing germline animals. The male chimaera designated SP 7
was found to be a total transmitter.
3.6.1 Identification of K-ras+/lmA4A animals
Germline animals identified by coat colour were genotyped by analysis of tail tip DNA
to assess whether they had the heterozygous mutation. The genotyping of these animals
was initially performed using the neor to exon 4B PCR used to identify K-ras+/""A4A ES
cells as described in section 3.3.1. However, this PCR method was found to be
inefficient at amplifying the 2.1 Kb product from the tail DNA. Therefore, a new PCR
strategy was designed using two primers within the neo cassette, and the details of the
primer sequences and PCR conditions can be found in chapter 2.4.6. Figure 3.16 shows
the result obtained from screening some of the germline offspring derived from the
founder SP-7. Both male and female K-ras+/"nA4A animals were identified on both the
inbred 129/Ola and outbred backgrounds. It was possible to determine that the correct
ratio of heterozygous animals (50%) was resulting following germline transmission
(table 3.9).
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Figure 3.15. Coat colour chimaeras generated by blastocyst injection. The coat colour chimaeras
produced by injection of C57 BL/6 blastocysts with K-ras+/lmA4A 129/Ola ES cells (A-H). Coat colour
chimaera produced by injection ofwild-type HM-1 129/Ola ES cells into C57 BL/6 blastocysts (I).
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At the time of writing the K-ras+/lmA4A animals are viable at the age of 17 weeks and
both males and females are fertile. Presently, K-ras+/""A4A animals on both the inbred
and outbred backgrounds are being mated to generate K-ras""A4A/""A4A animals in order
to assess the phenotype of these animals and therefore the effect of this mutation in vivo.
Table 3.9. Coat colour chimaeras transmitting the ES cell derived genes through
the germ line.
Founder designation Number of Number of germ line Number of
(heterozygous ES cell offspring transmissions heterozygous
line generated from) animals
SP 1 (248) male 21 0 0
SP 2 (248) male 50 1 1/1
SP 3 (226) female 22 0 0
SP 4 (226) female 2 0 0
SP 5 (226) female 27 2 0/2
SP 6 (226) male 39 24 13/24
SP 7 (194) male 47 47 13/29
SP 8 (194) male 0 0 0
SP 9 (194) male 35 7 4/7
3.7 Characterisation of K-Ras 4A expression in ES cells
It was previously reported that K-ras 4A mRNA was not expressed in ES cells and that
the transcript only became detectable following differentiation of these cells into
embryoid bodies (Pells et al., 1997). However, here using the same primers low levels
of K-ras 4A mRNA were found to be detectable in wild-type ES cells growing under
normal culture conditions (figure 3.7).
Due to the low level of expression of the K-ras 4A isoform mRNA detected in wild-
type ES cells, a pilot study was performed to determine whether expression was indeed
linked with differentiation by treatment with retinoic acid (RA). RA treatment of ES
cells has previously been reported to induce differentiation, which was accompanied by
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Figure 3.16. Identification of K-ras+""l/UA animals following transmission of the mutation through
the germline. The primers within the ned cassette amplified a 206bp product, which is only detectable
in animals harbouring the mutant allele. The samples analysed here were from a litter sired by the male
chimaera SP 7 that was a total transmitter, which demonstrate the correct ratio of heterozygous offspring
(5/9). 1) +/+, 2) 1-SP7, 3) 2-SP7, 4) 3-SP7, 5) 4-SP7, 6) 5-SP7, 7) 6-SP7, 8) 7-SP7, 9) 8-SP7 10) negative
control, 11) HM-1 R42 #248 heterozygous DNA which was included as a positive control.
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Figure 3.17. RA differentiation of ES cells. ES cells were differentiated in the presence of the
indicated concentrations of all trans-retinioic acid for 5 days. RT-PCR was performed with primers in
exon 1 and exon 4B to show the relative K-ras 4A/4B ratio after this treatment. Amplification of the K-
ras 4A mRNA produces a 687bp product, and the K-ras mRNA a 565bp product. RNA from adult
mouse large intestine (LI) is included as a positive control. All cultures were maintained in the absence
of LIF.
107
the up-regulation of expression from some genes (Scharnhorst et al., 1997). Cultures
were treated with ljaM, 5pM or lOpM RA and in the absence of LIF for 5 days.
Controls cultures, either containing DMSO and no LIF, or no LIF without DMSO were
set up.
Following five days of treatment the cultures were deemed to be differentiated by
morphological analysis. RNA was extracted and RT-PCR was performed using primers
that amplified both the K-ras isoforms, as described previously. This analysis of K-ras
isoform mRNA expression showed that under all treatment conditions the ratio
observed between the K-ras 4A and K-ras 4B mRNA was similar to that observed in
the control cultures, demonstrating that the presence of RA does not cause an up-
regulation of the K-ras 4A mRNA (Figure 3.17). Thus, absence of K-ras 4A mRNA in
the K-ras'mA4A/""MA cell lines shown in figure 3.7 results from the deletion of this exon
rather than absence of differentiation in this culture, since culturing wild-type ES cells
in the absence of LIF does not up-regulate the expression.
3.8 Discussion
The study reports the successful isolation of cells heterozygous for the deletion of the
K-ras 4A exon. These cells were generated following electroporation of ES cells with
the targeting vector pPTKiNKiA4A. Heterozygous cell lines were derived from two
different parental ES cell lines (E14 and HM-1). Homologous recombination of the
targeting vector into the mouse genome was confirmed using PCR and Southern
analysis. These methods clearly demonstrated that the flanking regions surrounding the
site of integration were correct and that non-homologous integrations had not occurred
elsewhere within the genome of these cells.
The primary aim of the experiments detailed in this chapter was the generation of
chimaeras heterozygous for the deletion of K-ras exon 4A. Three independent HM-1
K-ras+/,mMA ES cell lines were successfully used to generate 9 coat colour chimaeras.
This observation was important for two reasons; firstly it demonstrated that altering the
genome of the ES cells in this way did not hamper their ability to contribute to
developing blastocysts. Secondly, ES cells could be isolated by this selection procedure
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and maintain the ability to differentiate into many cell lineages. Since, abnormal
chromosome numbers and Mycoplasma infection were not implicated in the failure of
the four E14 derived heterozygous ES cells lines to contribute to developing embryos
these observations indicate that this may have resulted from the outgrowth of a variant
sub population of cells with a growth advantage that were compromised in their ability
to contribute to the tissues of chimaeras, possibly due to sub-optimal culture conditions.
The chimaeras were used subsequently for breeding studies, which identified 5
chimaeras that transmitted the mutation through the germline. Of the germline
offspring produced, wild-type and K-ras+/tmA4A animals were present in a 1:1 ratio,
which indicated that no embryonic lethality was associated with this mutation. The K-
ras+/"nA4A animals were outwardly healthy at 5 months of age. Importantly, both male
and female K-ras+/"nA4A animals were found to be fertile and currently breeding studies
are underway to generate K-ras""A4A/tmA4A animals. These mice will prove a powerful
tool to investigate the role of the K-ras 4A isoform in development and tissue function.
Further experiments led to the successful isolation of ES cells with the K-ras""A4A/"nA4A
genotype. These cell lines were generated for two main purposes: firstly, to screen for
the loss of the K-ras 4A mRNA and to ensure that this mutation did not interfere with
splicing to exon 4B, and secondly, to use this cell line for analysing the effect of
deleting of this protein isoform in culture. The K-ras""A4A/tmA4A cell lines were derived
by high G418 selection. This method selects cells that have undergone spontaneous
loss of heterozygosity (LOH) (Mortensen et al., 1992). The loss of the wild-type allele
and duplication of the mutant allele meant that cells could be selected for by resistance
to geneticin. The mechanism of duplication is believed to involve, either chromosome
loss and duplication, or mitotic recombination (Lefebvre et al., 2001). Since, this
results in extensive LOH in regions surrounding the area of targeting this has
implications if for example these areas contain imprinted gene. However, this may not
apply to the present work, since previous studies by this laboratory have shown that
transfection of a minigene expressing wild-type K-ras can rescue the phenotype in
culture of K-ras4' ES cells that were generated by high G418 selection (Brooks et al.,
2001). Therefore, phenotypes resulted from the specific mutation and not
altered/inappropriate expression of genes within the chromosomal region affected by the
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duplication of the transgene. Therefore, this should also apply for the targeting
experiments described here, as the same gene and chromosomal region are involved.
The K_ras'mA4A/tmA4A cell lines were generated from two independent K-ras+/tmMA cell
lines. Approximately 60% of the clones isolated following the high G418 selection
using a HM-1 K-ras+/""A4A cell line were positive for the duplication of the transgene.
Five of these clones were expanded into cell lines. When analysed by metaphase spread
analysis these cell lines all had the correct chromosome number. Therefore, this
selection produced roughly the expected proportion of clones having undergone LOH,
although proportions are known to vary (Mortensen et al., 1992). However, only 4
K_ras""A4A/""MA clones (-2%) were derived following high G418 selection using the E14
A4A 73/39 cell line and these were all determined to be chromosomally abnormal by
metaphase spread analysis. In addition, no K-ras'm tmA4A clones were derived from
the three E14 IV heterozygous cell lines used. The problems generating the E14
K~ras"nA4A/lmA4A cell lines were most likely due to unknown intrinsic problems with the
parental cell K-ras+/tmA4A lines. These problems may also relate to their failure to
contribute to developing embryos. Thus, neither the K-ras"nA4A/""A4A mutation, nor the
selection process appears to have an adverse affect on the genomic stability of ES cells
as seen grossly by metaphase spread analysis. Furthermore, the isolation of several
chromosomally normal K-ras""A4A/""A4A cell lines, demonstrates that K-ras 4A is not
essential for the viability of ES cells in culture.
Importantly, analysis of the K-ras mRNA expressed in the K-ras'mA4A/""A4A cell lines
demonstrated that the targeting strategy had been successful. These cells were no
longer able to generate the K-ras 4A mRNA. Therefore, the use of the pPTKiNKiA4A
targeting vector allowed the specific deletion of the K-ras 4A splice form. Furthermore,
from the construction of the targeting vector and the known positions of the canonical
splice acceptor sequences, which occur at the 3' boundary of exon 3 and the 5'
boundaries of exon 4A and 4B (McGrath et al., 1983) it was predicted that the
pPTKiNKiA4A targeting vector would not have an adverse affect upon splicing to exon
4B. Importantly, analysis of the K-rastmA4A/tmA4A cell lines by RT-PCR confirmed that
the size and production of the alternative K-ras 4B splice form was indeed not affected
by the introduction of the targeting vector. This was an extremely important result, as
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adverse effects upon the K-ras 4B splice isoform following homologous recombination
of the targeting vector would have generated a K-ras homozygous null genotype.
Whilst it was previously reported that the K-ras 4A transcript was not present in ES
cells (Pells et al., 1997) it was detected in the present study albeit at low levels. This
discrepancy could be due to the fact that Pells et al., (1997) used radioactive isotopes to
visualise the RT-PCR products, and therefore it is possible that the strong signal of the
K-ras 4B transcript masked the much weaker signal of the K-ras 4A transcript.
However, this discrepancy is unlikely to reflect the presence of differentiated cells
within the cultures examined, since differentiation induced by, either LIF withdrawal, or
RA treatment failed to up-regulate the expression of the K-ras 4A transcript in relation
to the K-ras 4B transcript. In addition, the presence of a generally more differentiated
culture would have an adverse effect upon the ability of the ES cells to contribute to the
developing inner cell mass of a blastocyst. The data presented here indicates that this is
not the case, since both wild-type and K-ras+/tmA4A ES cells contribute to developing
embryos, confirming their pluripotent nature. In addition, Pells and co-workers did not
detect the K-ras 4A transcript until the second differentiation stage, indicating that the
level of differentiation reported to be needed to induce K-ras 4A expression is unlikely
to be seen in a ES cell culture.
In conclusion, the aims and of objectives of this part of the research project were
successfully completed with the generation of K-ras+/,mA4A coat colour chimaeras, which
were capable of transmitting the mutation through the germline, and the generation of
K-ras tmA4A/"nA4A £$ cells. These model systems can now be used for the analysis of K-




Expression of K-Ras during mouse embryonic development
Introduction
Transgenic studies have shown that the K-ras gene products are essential for embryonic
development (Johnson et al., 1997; Koera et al., 1997). However, due to the failure of
these two studies to identify consistent abnormalities, the critical sites of K-ras gene
expression during embryonic development remain unclear.
Analysis of the expression of the Ras proteins during embryonic development has until
now relied almost exclusively upon analysis of the relative level of transcription.
Therefore, while several studies have shown differential regulation of Ras transcription
during mouse development (Muller et al., 1983; Leon et al., 1987; Pells et al., 1997) the
regulation of protein expression and the sites of expression within embryonic and
neonatal tissues are unknown. Therefore, the aim of this study was to examine the
expression pattern of the K-Ras isoforms during mouse development using wax
embedded sections.
4.1. Development of Immunohistochemical analysis using the K-Ras
isoform specific polyclonal antibodies on wax sections.
Balb/c mice were examined, since this strain has been used previously to assess mRNA
levels and for limited analysis of K-Ras 4A and 4B protein expression in adult tissues
(Pells et al., 1997).
Balb/c mice were mated and checked for plugs. Embryonic mice were harvested at
embryonic day 12.5 (E12.5), E14.5, E16.5, E18.5 post cotium using ethically approved
methods. Tissues from neonatal mice were harvested at day 8 pp and those from adult
mice at 10-12 weeks of age. The embryos were analysed from E12.5 onwards, since the
embryonic lethal phenotype of K-ras'1' mice occurred between E12.5 and E14.5
(Johnson et al., 1997).
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The K-Ras 4A and 4B protein isoforms have been detected previously in adult mouse
tissues using cryostat sections with rabbit polyclonal antibodies (Santa Cruz) (Pells et
al., 1997). However, since poor histology is a problem with cryostat sections, the aim
was to use these same two antibodies to investigate the observed temporal and spatial
differences in expression pattern detected at the RNA level during mouse development,
using wax embedded sections (Pells et al., 1997).
To develop this technique various antigen retrieval methods were tested, including
citrate buffer, enzymatic retrieval (i.e pepsin digestion) and urea treatment. The citrate
buffer antigen retrieval method gave the strongest signal with the least tissue
degradation. Antibody dilution curves were performed to assess the appropriate
concentration of antibody, to give the strongest signal possible without incurring non¬
specific staining. Problems were encountered with background staining on negative
control sections from embryonic samples (incubated in the presence of the antibody
diluent 0.01% BSA). However, this was overcome by using a biotin-blocking reagent.
While this procedure was found to work well for the K-Ras 4B polyclonal antibody, no
signal was evident with the K-Ras 4A antibody.
The failure of the K-Ras 4A antibody to detect expression in mouse tissues may have
been due to a low level of expression, which was below the sensitivity of this detection
method. However, this seems unlikely, as Pells and co-workers found that in certain
embryonic and adult tissues the expression of K-ras 4A mRNA equalled that of K-ras
4B mRNA (Pells et ah, 1997). In addition, the K-Ras 4A protein was expressed at
sufficient levels to be detectable in adult human colon (see chapter 5). The K-Ras 4A
antibody was raised against human K-Ras 4A using a peptide mapping to the carboxy
terminus. However, the single amino acid difference between the human and mouse
protein sequence is unlikely to explain the lower affinity of this antibody for the mouse





Therefore, there is no apparent explanation for this result other than the possibility of
differences occuring in the posttranslational modifications of this protein in mouse and
humans.
Thus, only expression of the K-Ras 4B protein was investigated. The K-Ras 4B
primary antibody was used at 1/6400 dilution and the sections were incubated in the
presence of the primary antibody overnight at 4°C. Negative controls were included
for all samples analysed where the primary antibody was omitted and the sections were
instead incubated in the presence of the primary antibody diluent (0.01% BSA). No
staining was detected on any of the negative control sections analysed in this chapter
(data not shown).
To confirm that the staining pattern produced was due to the specific interaction of the
primary antibody with its epitope, a blocking peptide was used (figure 4.1). Following
pre-treatment of the primary antibody with the blocking peptide no signal was detected,
confirming that the immunoreactivity detected resulted from the association of the
primary antibody with its specific epitope.
To enable direct comparison of the staining intensity the same tissue from different
stages of development were analysed together, to minimise the possibility that any
differences in the intensity of staining observed were attributable to experimental
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Figure 4.1 Neutralisation of K-Ras 4B polyclonal antibody with a blocking peptide. The figure
shows transverse sections through an El6.5 embryo stained with the K-Ras 4B polyclonal antibody. A)
Section stained with K-Ras 4B, showing immunoreactivity of the surface epithelium of the developing
intestine (solid arrow) and the hepatocytes of the developing liver (broken arrow) B) Section stained with
K-Ras 4B polyclonal antibody pre-incubated overnight with blocking peptide. The intestine (solid arrow)
and liver (broken arrow) are indicated and show no staining. Bar represents 50pm.
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4.2 Analysis of K-Ras 4B protein expression in mouse tissues
4,2.1. Examination of K-Ras 4B expression in the developing liver
In liver, K-Ras 4B is expressed strongly in the hepatocytes from El2.5 (figure 4.2 A).
A general decrease in the intensity of expression was observed from E12.5 to E18.5
(figure 4.2 A-D). The level of protein expression in the 8 day old animal appears to be
greater than that of the adult liver and the stain was cytoplasmic in nature, compared to
the more obviously membrane associated stain of the adult tissue.
4.2.2 Expression of K-Ras 4B in the developing intestine
In colon, the epithelium of the large intestine showed strong immunoreactivity for the
K-Ras 4B antibody at all stages examined and expression increased throughout
embryonic development to the adult stage (figure 4.3 A-D). No gradient of expression
was detected in colonic crypts as all cells stained equally strongly. K-Ras 4B protein
expression was not detected within, either the smooth muscle of the intestine, or the
lamina propria. Therefore, within the developing large intestine the expression of K-
Ras 4B was restricted to the epithelium, a pattern that was maintained in the neonatal
and adult tissues.
In small intestine, the expression of K-Ras 4B showed a more regulated pattern.
Expression of K-Ras 4B in the epithelium was high in the E16.5 intestine, but was
greatly reduced by the El8.5 stage, suggesting that the K-Ras 4B protein was important
for earlier stages of development (figure 4.4 A-B). The expression in the neonatal small
intestine was increased compared to the El8.5 section (Figure 4.4 B-C) and showed a
gradient of expression, with stronger signal detected in the crypts, compared with the
villi. The expression in the adult small intestine was intense. The gradient of expression
detected in the neonatal small intestine was no longer evident, which led to the overall
impression of increased expression (figure 4.4 C-D). The smooth muscle layers and
lamina propria showed no immunoreactivity. The data suggest that, in contrast to
colon, there are two peaks of K-Ras 4B expression the in mouse small intestine, one















Figure 4.2 Expression of K-Ras 4B in embryonic, neonatal and adult mouse liver. K-Ras 4B
immunoreactivity is present in hepatocytes of all stages examined. A) E12.5 foetal liver showing strong
stain. B) E14.5 hepatocytes. C) E16.5 hepatocytes. D) E18.5 hepatocytes. E) Day 8pp hepatocytes
showing moderate cytoplasmic stain. F) Adult hepatocytes showing weak membrane-associated stain.
The bar represents 50pm.
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Figure 4.3 Expression of the K-Ras 4B protein during embryonic development and in neonatal and
adult sections of large intestine. The surface epithelium of all stages examined show intense
immunoreactivity. A) E16.5 large intestine. B) Large intestine of an E18.5 foetus. C) Day 8 pp large
intestine showing specific staining of the surface epithelium. D) Adult colon. The smooth muscle (solid
arrow) and lamina propria (broken arrow) show no staining. Bar represents 50pm.
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Figure 4.4 Expression of K-Ras 4B isoform in embryonic, neonatal and adult small intestine. The
expression pattern appears to vary markedly depending upon the stage examined. A) E16.5 intestine
showing strong stain of surface epithelium B) El 8.5 small intestine, which shows weak staining. C) Day
8pp, showing strong stain in the crypts but weak stain in the villus. D) Adult mouse small intestine.
Intense staining is uniformly detected in the cells of the crypt and villus. Bar represents 50pm.
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4.2.3 Analysis of K-Ras 4B expression in the mouse pancreas
The expression of the K-Ras 4B protein was examined at the following stages El6.5,
E18.5, day 8 pp and in 10-12 week old adults. In the pancreas, the acinar cells of the
exocrine portion show immunoreactivity at all stages analysed (figure 4.5 A-D). The
expression of the K-Ras 4B protein in the embryonic and neonatal pancreas was very
similar, but was higher in the adult pancreas, suggesting an up-regulation of expression
later in neonatal development. Interestingly, K-Ras 4B expression was not detected in
the pancreatic ducts or islets examined. This is an important observation since
pancreatic tumours are derived from duct and islet cells, suggesting that K-Ras 4B
expression may not be important in the development of this tumour type at least in the
mouse. Analysis of K-Ras 4A expression in this tissue could lend further insight into
this finding.
4.2.4 Analysis of K-Ras 4B expression in the adult stomach
Immunohistochemistry was performed on adult mouse stomach showing K-Ras 4B
protein was expressed in the basal part of the gastric gland and the level of expression
was intense (figure 4.6 A-B). The expression appeared to be specific to the chief
(zymogenic) cells of this region, whereas the parietal cells were not immunoreactive,
identified by PAS staining of a corresponding section (figure 4.6 C). Staining was also
evident in the surface columnar epithelium, but the muscularis mucosae and lamina
propria were negative.
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Figure 4.5 Expression of the K-Ras 4B protein in sections of E16.5, E18.5,8 day old and 10-12 week
old mouse pancreas. Strong expression of the K-Ras 4B protein is detected in acinar cells at all stages
examined. A) E16.5 pancreas. B) E18.5 pancreas. C) Day 8pp pancreas. D) Adult pancreas showing
intense staining of the acinar cells. Bar represents 50pm.
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4.6 Expression of the K-Ras 4B isoform in the adult stomach. The expression of the K-Ras 4B protein
was detected in the chief (zymogenic) cells in the base of the gastric gland. A) Adult stomach. B) Area
of adult stomach indicated in A at higher magnification. Parietal cells (solid arrows) are negative. C)
PAS staining of adult stomach. Zymogenic cells (solid arrows) and parietal cells (broken arrow) are
indicated. Bar represents 50pm
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4.2.5 Examination of K-Ras 4B expression in the mouse lung
The expression of the K-Ras 4B protein was examined in E14.5, E16.5, E18.5, neonatal
and adult mouse lungs. The expression pattern was well defined and restricted to the
respiratory epithelium lining the airways, (figure 4.7 A-D). No difference in the level of
K-Ras 4B expression was detected in the embryonic sections analysed. In the bronchi
and bronchioles of neonatal and adult lungs there was an up-regulation of K-Ras 4B
expression, compared to embryonic sections. However, the level of expression was of a
similar intensity for neonatal and adult mouse lung. The expression appeared to be
specific to the epithelium of the bronchi and bronchioles, as neither the alveoli, nor the
linings of the blood vessels showed immunoreactivity. In addition, the smooth muscle
surrounding the bronchioles did not show immunoreactivity (figure 4.7 D). The results
indicate an up-regulation of the K-Ras 4B protein levels in the epithelial lining of the
airways following embryonic development in neonatal and adult stages.
4.2.6 Examination of K-Ras 4B expression in the kidney
K-Ras 4B protein expression was analysed in the developing kidney. Strong expression
was detected in the developing glomerulus as early as E16.5 (Figure 4.8 A). There was
a down-regulation of protein expression detected in the developing kidney at the E18.5
stage, compared to the intensity of expression observed at the El6.5 stage. The
strongest expression was detected in the neonatal kidney, suggesting that there is
postnatal up-regulation of this protein in the kidney (Figure 4.8 C). The expression
appears to be associated with the tubules, but also cells of the glomerulus, which may be
podocytes based upon their position within the glomerulus, the expression of K-Ras 4B
remains high within the adult glomerulus and tubules (Figure 4.8 D). The medulla of
the neonatal and adult kidney showed no immunoreactivity (data not shown).
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Figure 4.7. Immunohistochemical detection of K-Ras 4B protein in embryonic, neonatal and adult
lung. The expression of the K-Ras 4B protein increases through development. The highest levels appear
to be achieved by the neonatal stage and these levels are maintained in the adult lung. A) El6.5 lung. B)
El8.5 lung. C) Neonatal lung showing immunoreactivity of the respiratory epithelium lining the
bronchiole. D) Adult lung showing immunoreactivity of the respiratory epithelium lining (solid arrow)
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Figure 4.8 Immunohistochemical detection of the K-Ras 4B protein in embryonic, neonatal and
adult kidney. The K-Ras 4B protein is strongly expressed in the neonatal and adult tissues, and
particularly in the glomerulus. A) El6.5 kidney. Arrows indicate areas of strong stain present in the
developing glomerulus. B) E18.5 foetal kidney. C) Neonatal kidney. Intense immunoreactivity is detected
in tubular and glomerular structures. Arrows indicate cells within the glomerulus that are showing
particularly strong staining. D) Adult kidney showing the staining pattern observed in the glomerulus.
The arrow indicates a cell within the glomerulus that is strongly immunoreactive, which may be a
podocyte. Bar represents 50pm.
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4.2.7 Examination of K-Ras 4B expression in the heart
K-Ras 4B was found to be expressed in the mouse heart from El2.5 (figure 4.9 A). The
expression appeared to peak about E18.5 (figure 4.9 B) and then declined following
postnatal development to barely detectable levels in the adult myocardium (figure 4.9
D). This staining was specific to the myocardium, since the endothelium and smooth
muscle lining of the veins and arteries showed no immunoreactivity.
4.2.8 Examination of K-Ras 4B expression in the nervous system
The analysis of the developing embryos showed that K-Ras 4B was expressed strongly
in the ganglia and peripheral nerves from E14.5 onwards with no apparent alteration in
intensity or location of expression during this period (figure 4.10 A-B). There was no
evidence of expression at any embryonic stage in cells within the spinal cord (figure
4.10 C). The expression was not analysed in adult mice therefore it is unknown whether
this pattern persists in the adult mouse. K-ras'1' embryos were reported to have
increased apoptosis of motoneurones in the medulla and cervical spinal cord from
El 1.5, suggesting that K-ras has a role in the development of the nervous system
(Koera et al., 1997). Therefore the lack of K-Ras 4B expression implies that the defect
observed in the spinal cord may result from a lack of K-Ras 4A expression in the
K-ras''' embryos. This is an important observation that points to the potential for the
development of neurological defects in K-rastmA4A/tmA4A mice.
Whilst examining the embryonic sections cytoplamic K-Ras 4B expression was also
observed within the chondrocytes of the cartilage and the osteocytes of the bone at all
stages analysed (figure 4.10 D-E). The intensity and localisation of expression did not
alter during the embryonic stages analysed. However, whether this pattern persists in
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Figure 4.9. Analysis of the expression of the K-Ras 4B protein in the developing mouse heart.
Immunohistochemistry was performed on hearts from E12.5, E14.5, E16.5, E18.5, and neonatal and adult
mice. Immunoreactivity was detected at all stages examined, but declined during postnatal development
to very low levels in the adult stage. A) E12.5. B) E18.5. C) Day 8 pp. D) Adult cardiomyocytes showing
weak stain only. Bar represents 50pm.
127
E
Figure 4.10. Analysis of the expression of the K-Ras 4B protein in the peripheral nervous system,
spinal cord and in cartilage and bone. The expression of the K-Ras 4B protein was detected in the
ganglia and peripheral nerves at all stages examined from E14.5 onwards with no alteration in intensity or
location of expression. Therefore the pictures are representative. A) E14.5 ganglia. B) E14.5 peripheral
nerve. C) Section showing the E16.5 spinal cord with no immunoreactivity. D) E14.5 chondrocytes




Previous studies using Northern analysis have reported changes in K-ras mRNA
expression during embryonic and postnatal development (Muller et al., 1983: Leon et
al., 1987). However, these studies give no information regarding which cell types
express K-ras. In view of reports the K-ras homozygous null mice die between E12.5
and term due to liver, heart and motoneuron abnormalities (Johnson et al., 1997; Koera
et al., 1997), and that K-ras activating mutations are linked with particular types of
cancer (Bos et al., 1989) the analysis of K-Ras 4B protein expression, which is the
major K-ras isoform expressed (Pells et al.., 1997), can shed valuable insight in
identifying which cell types express K-Ras, and therefore where K-ras null and
activating mutations might act.
In the liver, the K-Ras 4B protein was detected in the hepatocytes with the strongest
expression observed at E12.5. This time point coincided with the occurrence of liver
abnormalities in K-ras'' mice (Johnson et al., 1997). These observations indicate the
importance of K-Ras 4B expression for the early development of the mouse liver. The
overall decline in K-Ras 4B protein expression from El6.5 to low levels in adult liver is
in agreement with reported changes in K-ras transcription as determined by Northern
analysis (Muller et al., 1983; Leon et al., 1987). Hence, K-ras 4B expression may be
important for the development of embryonic and neonatal mouse liver, with a reduced
requirement for K-Ras 4B protein expression in adult mouse liver.
In the heart, K-Ras 4B expression was detected in the cardiomyocytes from El2.5, and
this early expression, combined with higher expression in embryonic than adult heart,
suggests that expression of the K-Ras 4B protein plays an important role during the
early stages of heart development. Expression of K-Ras 4B in the developing heart
agrees with the finding the K-ras" embryos display heart defects; including decreased
heart size and thin ventricular walls, compared to wild-type littermates (Koera et al.,
1997). Therefore, the expression of the K-Ras 4B protein appears to be important for
the development of the mouse heart. However, reduced expression in the adult heart
indicates that there may be decreased requirement for this protein following neonatal
development. The detection of only low levels of K-Ras 4B protein in adult mouse
heart is supported by previous observations using this antibody on cryostat sections
(Pells etal, 1997)
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K-ras mutations have recently been shown to be associated with the progression of lung
tumours in mouse models of oncogenic K-ras action (Fisher et al., 2001; Jackson et al.,
2001; Johnson et al., 2001). Furthermore, the study of chimaeric mice composed of
wild-type and K-ras1' cells found that the latter colonised the lung poorly (Johnson et
al., 1997). The result suggests that K-ras has an important role in both lung
development and function. The present work found that the K-ras 4B isoform was
detected in the lung from E12.5 and that the expression was confined to the respiratory
epithelium. However, postnatal development was marked by an increase in expression,
culminating with highest levels in the adult lung. Importantly, transcriptional analyses
also indicate that K-ras is expressed at high levels in adult lung (Leon et al., 1987; Pells
et al., 1997).
Previous findings, which detected high levels of K-ras gene transcription in the kidneys
of 8-day-old-mice (Muller et al., 1983), support the observations made here that the
strongest expression of the K-Ras 4B protein was detected in the neonatal kidney. The
down-regulation of K-Ras 4B expression detected in the kidney late in embryonic
development may reflect the general decrease in K-ras transcription observed at this
stage (Muller et al., 1983; Leon et al., 1987).
K-Ras 4B protein was detected in the epithelium of both the large and small intestine.
The highest level of expression was detected in the adult tissues. These observations
are supported by the analysis of K-ras transcription showing an increase from day 5 to
day 30 of postnatal development and high levels in the adult mouse gut (Leon et al.,
1987: Pells et al., 1997). The K-Ras 4B protein was also detected most strongly in the
acinar cells of the adult pancreas following an up-regulation of protein expression
during embryonic and neonatal development in this tissue. The strong up-regulation of
K-Ras 4B expression during development of the gut, lung and pancreas, suggests that
this isoform may play an important role in the homeostasis in these tissues, which give
rise to tumours that contain a high proportion of K-ras mutations (Bos et al., 1989).
The stomach has previously been identified as a specific site of strong K-Ras 4B
expression (Pells et al., 1997) here it was found that K-Ras 4B protein was strongly
expressed in the chief (zymogenic) cells of the gastric glands. This site of expression
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could reflect functional involvement of the K-Ras 4B protein in the production of the
precursors of the enzymes pepsin, rennin and lipase. Similarly, the strong expression of
K-Ras 4B in the acinar cells of the adult mouse pancreas may also suggest a functional
role in the production and/or secretion of digestive enzymes, since the acinar cells
contain zymogenic granules and secrete digestive enzymes.
In conclusion, the general trends observed in the patterns of immunoreactivity are as
follows: The expression of K-Ras 4B decreases following embryonic development in
the liver and heart. The expression increases during the development of the lung, small
intestine, large intestine, pancreas and kidney. Finally, the expression is strong and
remains so in the ganglia, peripheral nerves, chondrocytes and osteocytes during
embryonic development. Thus, the expression of the K-Ras 4B protein is differentially
regulated during mouse development.
131
Chapter 5
The expression of the K-Ras isoforms in human colorectal and
cervical neoplasia
Introduction
K-ras mutations are associated with 40-50% of sporadically occurring human colon
cancers (Bos et al., 1989). The most common mutations are point mutations found in
codon 12, 13 and 61, which lead to constitutive activation of the Ras proteins (reviewed
Lowy and Willumsen, 1993). However, K-ras mutations are rarely associated with the
progression of some other types of epithelial derived cancers, such as cervical tumours
(Stenzel et al., 2001). Activating mutations affect both K-ras isoforms, since they share
their first three coding exons. Therefore, the possibility arises that both isoforms may
be activated in colon cancer, which could in part explain the prevalence of K-ras
activating mutations in some human cancers, compared to H-ras and N-ras mutations.
The aim of this study was to investigate whether both K-ras isoforms are indeed
expressed at elevated levels in colon cancer. For comparison, the expression patterns of
the K-Ras protein isoforms were examined in cervical intraepithelial neoplasia, which
are not normally associated with K-ras mutations.
5.1 Analysis of expression of K-Ras protein isoforms in human colon
Analysis of the expression of Ras proteins in normal and neoplastic tissues by
immunohistochemistry has been studied previously using a variety of pan-Ras
antibodies that detect all four Ras proteins (Garin Chesa et al., 1987; Jansson et al.,
1990; Visca et al., 1999). These studies found a progressive increase of Ras protein
expression in all phases of the sequence of colorectal carcinogenesis (Visca et al.,
1999). Whilst this has provided a useful insight into the expression of Ras proteins in
these tissues interpretation of these results is limited by the general reactivity to all Ras
proteins of the antibodies used in these studies. Therefore, it was of interest to clarify
these observations by using antibodies that specifically detect the K-Ras 4A and K-Ras
4B proteins.
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Specimens were anonymised archival samples that had previously been screened and
known to have K-ras mutations, either by direct sequencing, or by RFLP analysis
(details were published as part of a larger study (Andreyev et al., 1998)). Twenty-two
tumour blocks containing adenocarcinomas were selected for analysis that had normal
colon adjacent to the area of tumour. The normal tissue acted as an internal control,
which allowed direct comparison between the intensity of staining in the tumour,
compared to normal colon. The tumours were stained using the K-Ras isoform specific
rabbit polyclonal antibodies described in the previous chapter (chapter 4). Dr Maureen
O'Sullivan performed the analysis of the histopathological features of the samples.
Since the antibodies had only previously been used on cryostat sections (Pells et al.,
1997), it was necessary to optimise the technique for use on wax embedded sections.
Antibody dilution curves were performed to determine the correct concentration of
primary antibody required to give specific signal. Various antigen retrieval methods
were tested to find the conditions that gave maximal specific staining. The conditions
that were selected for the immunohistochemical analysis with the rabbit polyclonal
antibodies were the citrate antigen retrieval method and a 1/2000 dilution of the primary
antibody, with the sections incubated overnight at 4°C in the presence of the primary
antibody (chapter 2.6.1). These conditions were used for all analyses described in this
chapter. Negative controls were performed for each sample. The negative controls had
the primary antibody omitted and were incubated in the presence of the antibody diluent
(0.01% BSA) alone. In all cases no background staining was observed (data not
shown).
The staining intensity for the K-Ras 4A and 4B isoforms was scored independently. All
staining was compared to the normal colonic mucosa within the same section. The
intensity of expression of the protein within the tumour was scored on an arbitrary scale
of (+1) for minimal increase in staining intensity to (+4) for strong increase in intensity
of staining. No increase in staining intensity was indicated by (0) and a reduction in
staining intensity by (-1) to (-4). The scoring for these sections is shown in the table
5.1. Representative images are shown for K-Ras 4A (figure 5.1) and K-Ras 4B (figure
5.2).
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Table 5.1 Scoring of colorectal tumours for expression of the K-Ras isoforms





13216 Moderately differentiated adenocarcinoma Duke's stage B Codon 12 +3 0
8872 Moderately differentiated adenocarcinoma Duke's stage B Codon 12 + 1 0
22335 Moderately differentiated adenocarcinoma Duke's stage B Codon 12 +3 + 1
15144 Poorly differentiated adenocarcinoma Duke's stage D Codon 12 +2 -1
9379 Moderately to poorly differentiated adenocarcinoma.
Duke's stage B
Codon 12 +3 + 1
21314 Rectal carcinoma. No data Codon 12 +4 + 1
12462 Moderately differentiated adenocarcinoma. Duke's stage B Codon 12 + 1 0
3180 Poorly differentiated adenocarcinoma. Duke's stage B Codon 12 +3 0
2877 Moderately differentiated adenocarcinoma. Duke's stage B Val 12 + 1 0
2461 Moderately differentiated adenocarcinoma. Duke's stage B Codon 12 + 1 +1
3676 Moderately differentiated adenocarcinoma. Duke's stage C Codon 12 + 1 +2
4382 Early invasive adenocarcinoma. Duke's stage A Codon 12 +3 0
6999 Moderately differentiated adenocarcinoma. Duke's stage B Asp 13 +3 +1
4465 Moderately differentiated adenocarcinoma. Duke's stage B Codon 12 +2 +2
20910 Moderately differentiated adenocarcinoma. Duke's stage B Val 12 + 1 0
4692 Moderately differentiated adenocarcinoma. Duke's stage B Codon 12 +2 + 1
9865 Poorly differentiated adenocarcinoma. Locally advanced
Duke's stage B
Codon 12 +3 +3
1493 Moderately differentiated adenocarcinoma. Duke's stage C Codon 12 0 -2
82-
4345
Moderately differentiated adenocarcinoma. Duke's stage B Val 12 0 +2
5203 Moderately differentiated adenocarcinoma. Duke's stage B Conservative
codon 13
+ 1 0
1352 Moderately differentiated adenocarcinoma. Duke's stage B Ala 12 +2 +2
24571 Moderately differentiated adenocarcinoma. Duke's stage B Codon 12 +2 0
2028 Moderately differentiated adenocarcinoma. None 0 0
21352 Moderately differentiated adenocarcinoma. None + 1 0
23749 Moderately differentiated adenocarcinoma. None 0 0
1551 Moderately differentiated adenocarcinoma. None 0 0
25643 Moderately differentiated adenocarcinoma. None +2 0
4634 Moderately differentiated adenocarcinoma. None + 1 0
5391 Moderately differentiated adenocarcinoma. None 0 0
Mutations in codon 12 and 13 were screened for using either, RFLP analysis or, direct sequencing.
Unless the specific mutation is stated the codon that the mutation occurs at is indicated. The intensity of
the staining was scored against the intensity of staining seen in the normal colonic mucosa within the
same section as either, +1-+4 or, -1- -4. No change in the intensity of staining is indicated by 0. Duke's
stage A, tumours that have not breached the muscularis propria. Duke's stage B, tumours that have
breached the muscularis propria. Duke's stage C, Lymph node involvement and Dukes stage D are
tumours with distal metastases.
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The staining pattern with the K-Ras 4A antibody was as follows: in the normal colonic
mucosa the cells of the crypt had a diffuse light cytoplasmic stain, which appeared to be
evenly distributed throughout the crypt showing no evidence of a gradient of expression
(figure 5.1 A and B). The muscle layer and the lamina propria showed no
immunoreactivity, demonstrating that the immunoreactivity was specific to the
epithelial cells of the crypt.
Whilst the staining seen in adenocarcinomas shows the same specificity of
immunoreactivity, the staining intensity compared to the normal colonic mucosa
described above was in general more intense (figure 5.1 C and D). The figure shows
images of sections that are representative for most cases examined. The section from
sample 9379 shows normal and abnormal crypts adjacent to each other. Here direct
comparison shows that the staining in the abnormal crypts is more intense then the
staining in the normal crypt (Figure 5.1 E and F).
The staining pattern in the normal colonic mucosa visualised with the K-Ras 4B
antibody was similar to that observed with the K-Ras 4A antibody. The epithelium of
the colonic crypts shows moderate staining, which was evenly distributed from the base
of the crypt to the luminal surface (block 13216) showing that the stem cell
compartment did not preferentially stain with K-Ras 4B. As in the case of K-Ras 4A
the immunoreactivity was specific for epithelial cells of the crypt, with the muscle
layers and lymph and blood vessels negative (Figure 5.2 A and B).
The abnormal crypts of adenocarcinomas from the same section, while showing the
same expression pattern, do not however show the expected increase in staining
observed with K-Ras 4A. The staining is still localised to the epithelial derived cells,
but the staining intensity remains moderate (block 13216), although there is possibly a
minor increase, but this is less marked than for K-Ras 4A (Figure 5.2 C and D). This
observation is confirmed by the images from another case (block 9379) showing
adjacent normal and abnormal colonic crypts where the intensity of staining is very
















Figure 5.1 Expression of the K-Ras 4A protein in normal human colon and adenocarcinomas.
Shows representative pictures of immunohistochemical staining with an antibody to detect the K-Ras 4A
protein. A) Normal colonic crypts indicated by an arrow (sample 13216). B) Magnified view of normal
colonic crypt as indicated in A. C) Adenocarcinoma of the colon (sample 13216). D) Magnified view of
area indicated in C. E) Adjacent areas of normal colon and adenocarcinoma (sample 9379). F) Magnified
view of area indicated in E, a solid arrow indicates the neoplastic crypt; the adjacent normal colonic crypt
is indicated with a broken arrow. The bar represents 50pm.
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An additional control was used in these experiments to confirm that the staining pattern
observed with the K-Ras 4A and K-Ras 4B antibodies was the result of interaction with
their specific epitopes. The primary antibodies were pre-incubated with blocking
peptides and then used for the immunohistochemistry as described previously. The
absence of stain (figure 5.3) indicated that the staining observed resulted from the
binding of the primary antibodies to their specific epitopes, since the sections stained
with the antibodies that had been pre-incubated in the presence of the blocking peptides
did not show stain.
The scoring of the tumour sections showed that in general there appeared to be a greater
increase in the expression of the K-Ras 4A protein isoform in moderately differentiated
adenocarcinomas, when compared to the normal colon crypts, than for the K-Ras 4B
isoform. Of the 22 tumours analysed 20 showed an increase in K-Ras 4A intensity,
whereas only 11 of the tumours showed an increased intensity in K-Ras 4B staining,
compared to the normal colon. Of those tumours that had increased staining with K-Ras
4A, 13 out of the 20 showed a difference of +2 or more compared to normal colon. In
the case of K-Ras 4B the intensity of only five of the sections increased by +2 or more
compared to normal colon. Two of the sections analysed with K-Ras 4A and 9 of the
sections analysed with K-Ras 4B showed no change. None of the sections analysed
with K-Ras 4A had decreased staining in the tumour compared to the normal colon.
However, in 2 of the sections the K-Ras 4B staining was reduced in the tumour
compared to the normal colon. The comparison between normal colon and areas of
moderately differentiated adenocarcinomas was used as a way of controlling the
observations and therefore the results only show the overall increase or decrease in
staining observed in the tumour, rather than the level of staining originally seen in the
normal crypt.
Additional samples were analysed that had been screened for K-ras mutations at codons
12 and 13 and had been found to have none. However, some (3/7) of these cases were
also shown to have up-regulated K-Ras 4A expression (Table 5.1) resulting possibly
from undetected K-ras mutations, or overexpression or amplification of the K-ras gene.
Alternatively, the upregulation may have occurred as a result of mutations in other
genes within the tumours that affect K-ras expression.
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Figure 5.2 Expression of the K-Ras 4B protein in normal human colon and in moderately
differentiated adenocarcinomas. Representative pictures of immunohistochemical staining with an
antibody to detect the K-Ras 4B protein. A) Normal colonic crypts (block 13216). B) Magnified view of
area indicated in A. C) Moderately differentiated adenocarcinoma (block 13216). D) Magnified view of
area indicated in C. E) Adjacent areas of normal conic crypts and moderately differentiated
adenocarcinoma (block 9379). F) Magnified view of area indicated in E. The solid arrow indicates an
area of tumour; the broken arrow indicates the adjacent normal colonic crypt. Bar represents 50pm.
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Figure 5.3 Neutralisation of the activity of K-Ras 4A and K-Ras 4B rabbit polyclonal antibodies
with a specific blocking peptide. This was performed as a control to confirm the staining patterns
observed were due to the specific interaction of the primary antibody with its epitope. A) K-Ras 4A
primary antibody (block 4465). The solid arrow indicates an area of intensely staining tumour. The
broken arrow indicates normal lightly staining crypt. B) K-Ras 4A primary antibody neutralised
following incubation with specific blocking peptide (block 4465). C) K-Ras 4B primary antibody (block
4465). The solid arrow indicates an area of strongly staining tumour. The broken arrow indicates an
adjacent normal crypt strongly staining. D) K-Ras 4B primary antibody neutralised following incubation
with specific blocking peptide (block 4465).
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5.2 Analysis of the expression of K-Ras proteins in cervical intraepithelial
neoplasia
Due to the difficulty of interpreting the observations in colon adenocarcinomas with no
detected K-ras mutations, another tumour type was sought that was known to be rarely
associated with K-ras mutations. It was hoped that such a tumour type would act as a
control to confirm that the up-regulation of expression detected in the adenocarcinomas
of the colon resulted from the specific up-regulation of K-ras expression associated
with the activating mutation, rather than a general consequence of the dysplastic
changes occurring within the tissue.
Normal cervix has a stratified squamous epithelium. The epithelium is composed of
three layers of cells, which differ in their differentiation status. The basal cells are the
most undifferentiated type, which mature through parabasal cells and are the
proliferative compartment. As cells progress further up the epithelium they become
more differentiated, until they are terminally differentiated and eventually sloughed off.
Cervical intraepithelial neoplasia (CIN) is believed to be the precursor lesion to
squamous cell carcinoma of the cervix and is rarely associated with K-ras mutations
(Parker et al., 1997; Ferguson et al., 1999). Immunohistochemistry was performed as
described above using the K-Ras isoform specific polyclonal antibodies.
The five anonymised archival cervical samples analysed were obtained from women
who had undergone resection following detection of CIN abnormalities. Only samples
that had normal cervical epithelium and CIN within the same section were used for this
analysis. The K-ras mutational status of these samples is not known. Dr Maureen
O'Sullivan again performed the histopathological analysis of these sections.
The staining pattern observed using the K-Ras 4A antibody is as follows: there is very
minimal staining in the basal area of the normal cervical epithelium. Staining is
observed approximately three quarters of the way up the epithelium in the terminally
differentiated cells (Figure 5.4 A). The areas of CIN compared to the areas of normal
cervix from three separate blocks clearly show that the K-Ras 4A protein is not
expressed in CIN (Figure 5.4 B-D).
140
The K-Ras 4B antibody showed a different pattern of expression, compared with the K-
Ras 4A antibody. In the normal epithelium of the cervix the expression of the K-Ras
4B is most intense in the basal cells of the epithelium. The staining is intense and
cytoplasmic. The K-Ras 4B staining shows a clear gradient of expression, with the
intensity of expression decreasing as the cells become more differentiated (figure 5.5 A
and B). The expression of the K-Ras 4B isoform is specific to the epithelium of the
cervix, as the muscle layers do not show any immunoreactivity. The expression of the
K-Ras isoforms therefore appears to be compartmentalised in this tissue.
Examination of the areas of CIN within the same sections show that there is a dramatic
reduction in the amount and intensity of staining (Figure 5.5 C, D and E). The areas of
CIN examined in general showed either no immunoreactivity, or minimal residual
staining in the basal area of the epithelium.
In conclusion, the results indicate that K-ras expression is not associated with CIN.
This observation shows that up-regulation of K-ras 4A expression is not a general
consequence of dysplastic change and coupled with the use of blocking peptides, shows
that the up-regulation of the K-Ras 4A isoform expression in colon adenocarcinomas is
likely to reflect a genuine increase in protein expression resulting from specific
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Figure 5.4 Detection of the K-Ras 4A protein in normal cervical epithelium and cervical
intraepithelial neoplasia. Immunohistochemistry with the K-Ras 4A rabbit polyclonal antibody. A)
Normal cervical stratified squamous epithelium (block 12832). Arrow indicates area of K-Ras 4A
immunoreactivity in the upper differentiated layer of the epithelium. B) Arrow indicates area of cervical
epithelium showing characteristic features of CIN (block 12829), which shows no immunoreactivity. C)
Arrow indicates area of CIN that shows no staining (block 12834). D) Arrow indicates area of CIN that
shows no staining (block 12832). Bar represents 50pm.
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Figure 5.5 Detection of the K-Ras 4B protein in the normal cervix and in cervical intraepithelial
neoplasia. A) Normal cervical stratified squamous epithelium (block 12831). The stratified epithelium
shows a gradient of expression, with the highest level of expression detected in the basal cells. B)
Normal cervical epithelium magnified area indicated in A. Shows more clearly the strong cytoplasmic
staining of the basal cells. C) Area ofCIN with weak staining in the basal region (block 12829). D) Area
of CIN (block 12832). Arrow indicates area of weak residual K-Ras 4B immunoreactivity present in the
basal cells of the epithelium. E) Area ofCIN showing no staining (block 12834). Bar represents 50pm.
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5.3 Discussion
The data presented here for the first time examines the expression of the K-Ras protein
isoforms in normal and neoplastic tissues. Previous examination of the expression
pattern of the Ras proteins within normal colonic mucosa identified immunoreactivity
of the surface epithelium absorptive and goblet cells (Garin Chesa et al., 1987; Visca et
al., 1999). The adenocarcinomas were associated with enhanced immunoreactivity
(Visca et al., 1999). The staining detected was diffuse and cytoplasmic (Hayashi et al.,
1994; Visca et al., 1999). Therefore, the staining pattern produced with the K-Ras 4A
and K-Ras 4B primary antibodies reproduced the previous observations described
above, which were detected using pan-Ras antibodies. The results presented in this
chapter indicate that in general the pattern of expression of the K-Ras 4A and K-Ras 4B
protein isoforms is very similar in the human colon. However, the level of expression
appears to be different, there is a general up regulation of the K-Ras 4A protein
expression in human colonic adenocarcinomas with known K-ras mutations compared
with normal colonic mucosa. The level of the K-Ras 4B protein does not appear to
undergo this up-regulation to the same extent.
Caution was exercised in the interpretation of these results. Due to the malignant
process the tissue architecture is altered, the normal colonic crypts contain little
cytoplasm, as there are many globules of mucin present. However, the malignant tissue
has lost this differentiated feature, which could lead to over interpretation of the results,
since the cells are much more densely concentrated. Nevertheless, a general trend was
observed in the sections examined, with a transition from a cytoplasmic blush stain in
normal colon to a more intense cytoplasmic stain in the adenocarcinoma with the K-Ras
4A antibody.
K-Ras 4A was strongly up-regulated (+2 and above) in 13 of the 22 samples examined
and showed a minor increase in a further 7 of the samples (+1). This is an important
finding, since the K-Ras 4A protein has been considered to be a minor protein isoform.
This is important, as the mutation present in the tumour will generate activated forms of
both isoforms, since the most common mutations (codons 12, 13 and 61) occur within
the first three coding exons that these two protein isoforms share. Clearly the
mechanisms underlying this selective up-regulation of the 4A isoform need further
investigation. The K-ras 4A transcript has been detected in a variety of human cancer
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cell lines but at a lower level than the K-ras 4B transcript, the relative abundance of the
two RNA species was found to be maintained in the different cell lines examined
(Capon et al., 1983). The authors suggest that their results indicate that the splicing
pathway is not significantly altered in cell lines with activated K-ras transforming
genes. However, it is unlikely that the K-Ras 4A protein is up-regulated as a by-product
of the K-ras gene mutation, since its up-regulation in human adenocarcinomas is not
associated with an accompanying up-regulation of the K-Ras 4B protein. While, the
relevance of the selective K-Ras 4A up-regulation in colon tumorigenesis is unclear,
mutant K-Ras 4A protein can induce transformed foci and growth in soft agar more
efficiently than the K-Ras 4B mutant protein in a variety of cell lines; including rat
intestinal epithelial cells (Voice et al., 1999). Thus, suggesting possible functional
relevance of the increased expression of K-Ras 4A observed in this study.
The K-Ras 4B protein was not strongly up-regulated in these tumours, which may
reflect that up-regulation of K-Ras 4B protein expression, is not necessary for its
tumorigenic potential. There has been relatively little investigation into the level of K-
Ras protein expression, as most research has concentrated upon the presence or absence
of activating mutations. In addition, those studies that have shown up-regulation of
Ras proteins in colon tumours, compared to normal colon have used pan-Ras antibodies,
which could have reflected the up-regulation of the K-Ras 4A protein. Therefore, the
data suggests that K-Ras 4A may have a key role in the development of human colon
cancer.
Analysis of expression of Ras proteins within the cervix using pan-Ras antibodies has
shown discrepancies in the staining patterns observed. Furth and co-workers report that
the staining was most intense in one to two layers above the basal cells (Furth et al.,
1987), whilst Garin Chesa and co-workers report that Ras proteins were detected in all
cellular layers of the stratified epithelium (Garin Chesa et al., 1987). Nevertheless, both
groups agree that the patterns of expression were consistent for all stratified epithelium
examined suggesting that Ras proteins have a role in the proliferation and
differentiation of stratified epithelium of other tissues including the epidermis and
oesophagus. This relationship has been identified recently: activation of Ras protein
signalling drives proliferation of the basal cells and importantly the absence of Ras
protein signalling drives differentiation (Dajee et al., 2002). Disparity also exists in the
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literature about the relationship between the expression of Ras proteins in CIN using
pan-Ras antibodies. Sagae and co-workers showed an increase in Ras positivity
associated with increasing CIN stage (Sagae et al., 1990), whilst Ngan and colleagues
showed no Ras immunoreactivity in normal or dysplastic cervical cells (Ngan et al.,
1999). Slagle and co-workers detected a similar staining pattern from normal through
CIN III histology (Slagle et al., 1998). However, it should be noted that Ngan and co¬
workers and Slagel and colleagues used the same primary antibody and yet obtained
different results, suggesting that the differences may result from failure to optimise
procedures or differences in experimental techniques.
Therefore, analysis of the expression of the K-Ras proteins in the cervix acts as a useful
control for the observations in colon adenocarcinomas, and the isoform specific
antibodies could also be used to clarify previous observations regarding the expression
of Ras proteins within this tissue. The staining pattern observed in the cervix revealed a
different pattern of expression, with the K-Ras 4A protein detected in the upper part of
the stratified squamous epithelium and either, only staining lightly or, not at all in the
basal layers, whereas the K-Ras 4B protein is detected strongly in the basal proliferative
layers of the epithelium and not the upper more differentiated layers. This
compartmentalisation of the protein isoforms could indicate different roles for these
proteins in proliferation and differentiation of stratified squamous epithelium.
The expression of both isoforms was dramatically reduced in the regions of CIN. K-
Ras 4A staining was not detected in any areas of CIN examined, and only minimal K-
Ras 4B protein expression was detected in the basal areas of CIN examined. Although,
only five cervical blocks were examined it is possible that the absence of K-Ras protein
expression may be important for the development of CIN. Thus, the use of isoform-
specific antibodies shows that compartmentalisation of Ras protein expression occurs
within stratified epithelium and highlights the possibility that Ras proteins may be
differentially regulated in the progression from normal cervical epithelium to CIN.
In conclusion, these observations have important implications for the development of
anti-ras therapies and for the future direction in which investigation into the role of K-
ras in tumorigenesis should progress.
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Chapter 6
In vitro analysis of K-Ras protein function
Introduction
The role of K-ras in cellular proliferation, differentiation and apoptosis has been
investigated extensively in vitro. However, despite this concerted effort there has been
relatively little investigation into the role of the individual K-ras isoforms. However,
recent evidence suggests that the individual K-ra.v isoforms may have unique functions
(Pells et ah, 1997; Voice et al., 1999), possibly mediated by association with a different
subset of guanine nucleotide exchange factors (Mizuno et al., 1991; Orita et al., 1993;
Nakanishi et al., 1994). Therefore, the generation of the K-ras'mA4A/""A4A ES cells
provides an ideal model system to assess the functional role of the K-ras 4A and 4B
isoforms in proliferation, differentiation and apoptosis in vitro. Importantly,
information gained from such studies may contribute to understanding the phenotype
arising from this mutation in vivo.
6.1 Cell Proliferation
Ras is essential for cell cycle progression (Mulcahy et al., 1985; Feig and Cooper, 1988;
Cai et al., 1990). Studies with neutralising antibodies showed that Ras is required at
multiple points throughout the G1 phase of the cell cycle in order for growth factors to
stimulate quiescent cells to enter DNA synthesis, until shortly before entry into S phase
(Dobrowolski et al., 1994; Aktas et al., 1997). Following growth factor stimulation of
quiescent cells Ras signalling via the Raf/MAPK pathway, PI-3Kinase-PKB/Akt
pathway and to a lesser extent the Rac GTPase pathway leads to up-regulation of the
cyclin D1 gene product (Gille and Downward, 1999). However, deletion of the K-ras
gene product has not been investigated in the context of cell cycle regulation.
Therefore, the availability of targeted ES cells described in chapter 3 and those
generated previously by this laboratory (Brooks et al., 2001) permits investigation as to
the effects of the K-ras isoforms on proliferation.
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Since, the K-ras targeted deletions were generated in different ES cell lines i.e. E14 and
HM-1, a growth curve was performed comparing E14 ES cells and HM-1 ES cells, to
ensure further experiments could be interpreted correctly and any differences observed
could not be attributable to intrinsic differences between the parental cell lines.
Analysis of proliferation clearly showed that the parental ES cell lines had very similar
growth characteristics over time (figure 6.1). The estimated doubling times, calculated
from the exponential line fitted to the graph, were 22.4hrs and 22.9hrs for E14 IV and
HM-1 respectively. The similarities observed made it possible to directly compare the
targeted ES cells with the knowledge that any observed growth differences were
attributable to the K-ras mutations.
Having performed the initial experiment, the growth characteristic of wild-type, K-
ras""A4A/""A4A and K-ras homozygous null ES cells were analysed. The results showed
that the proliferation of these three genotypes was very similar, wild-type, K-
ras""A4A/tmA4A ancj -ras1' cell lines had estimated doubling times of 17.3hrs, 16.2hrs and
16.1 hrs respectively (figure 6.2). The results from the 96hr time point are not included
in either the graph or the calculations, as the growth of all the cell lines analysed had




Figure 6.1 Analysis of wild-type ES cell proliferation. Cell numbers were counted at the indicated time
points following seeding. The graph represents the mean of duplicate samples ± s.e.m. The trend lines
were fitted to the data points using the Microsoft Excel package. The exponential equations for the lines
were y = 0.7936e°'0309x for E14 IV and y = 0.7423e°'°303x for HM-1, which resulted in estimated doubling
times of 22.4hrs and 22.9hrs for E14 IV and HM-1 cells respectively.
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Figure 6.2 Analysis of the proliferation characteristics of targeted ES cells. Cell numbers were
counted at the indicated time points following seeding. The mean number of cells for duplicate
measurements ± s.e.m. are shown. The exponential trend lines were fitted to the data points using the
Microsoft Excel package. The equations for the lines were y = 0.7865e°'()401x, y = 0.664 le0 0427x and y =
0.6837ea043x for wild-type, Y^-ras"',A4A/""MA and K-ra.v"'" cell lines respectively. The estimated doubling
times calculated from these were 17.3hrs, 16.2hrs and 16.1 hrs for wild-type, K_ras""MA/""MA ancj K-rax"'"
cell lines respectively. The observed doubling times of the wild-type ES cells varied between experiments
and this probably reflected differences in growth medium.
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Activated K-ras causes cellular senescence in primary cell cultures, which can be
overcome by the presence of other mutations in genes such as p53 and pl6INK4d that are
often present in immortalised cell lines (Serrano et al., 1997). The cooperation of these
mutations results in deregulated cell growth and a shortening of the G1 phase of the cell
cycle (Lui et al., 1995; Maher et al., 1995; Winston et al., 1996). Therefore, having
established that K-ras was dispensable for normal proliferation in ES cells, it was of
interest to investigate the effect of a K-ras activating mutation in this experimental
system. Hence an additional growth curve was performed in triplicate using a K-ras
homozygous null ES cell line that expressed an activated K-ras G12V minigene
(Brooks et al., 2001).
The estimated doubling times were -19.5, 18.7, 19.5 and 19.5hrs for wild-type, K-
ras"nA4MmA4A, K-raTA and K-ras G12V cell lines respectively (figure 6.3). The growth
curve is a representative result of the three growth curves performed. Thus, the K-ras
G12V activating mutation does not affect the growth rate of ES cells.
However, K-ras G12V can alter cell-cycle kinetics while population doubling times
remain unaffected (Orecchia et al., 2001). Therefore, to address this possibility and to
confirm the proliferation results using an independent method, the DNA profiles of
wild-type, K-ras""A4A/""A4A, K-ras1' and K-ras G12V cell lines were compared by flow
cytometry. Differences in the relative proportion of ES cells in each of the cell cycle
phases from the genotypes analysed could indicate alteration of the cell cycle kinetics.
The samples for analysis were taken at time points during the cell growth analysis
above, so the DNA profiles could be directly compared. The DNA profiles show no
appreciable difference between the genotypes analysed (figure 6.4.) confirming the
results of the proliferation assay. In conclusion, K-ras is dispensable for the
proliferation of ES cells, which is confirmed by the observation that the K-ras G12V
activating mutation does not affect the growth characteristics of ES cells.
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Figure 6.3 Analysis of the proliferation of wild-type, K-ras'mMA/lmA4A, K-ras'1' and K-ras G12V ES
cell. The cell numbers for the four genotypes were measured at the indicated time points after seeding.
The mean number of cells counted for three replicate dishes are shown + s.e.m. The trend lines were
fitted to the data points using the Microsoft Excel package. The equations for the lines are as follows:
wild-type y = 0.767eao355\Ky = 0.836 lea0371x, K-ras'- y = 0.8439ea0356x and K-ras G12V y
= 0.7088e(l0355x. From these the estimated doubling times were calculated as 19.5hrs, 18.7hrs, 19.5hrs
and 19.5hrs respectively.
Wild-type trendline K-ras"'" trendline
K-rasmMAAmMA trendline K-ras G12V trendline
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Pre GO G1 S G2/M
Cell cycle phase
■ wild type □ K-ras tm4/Vtm4A □ K-ras-/- □ K-rasG12V
Figure 6.4 The DNA profile of ES cells growing for 24 hours following seeding. The figure shows the
proportion of cells of each genotype examined in the pre GO, Gl, S and G2/M phases of the cell-cycle, as
measured by flow cytometry. The measurements were made 24 hours after the cells had been seeded.
The samples were taken during the cell proliferation analysis, so to be directly comparable. The mean of
three replicate measurements ± s.e.m. is shown.
153
6.2 In vitro differentiation of ES cells and analysis of alkaline phosphatase
activity
Analysis of cell cycle parameters such as, population doubling times and DNA profile,
suggested that these were not dependent upon K-ras. Therefore, it was of interest to
investigate other cellular processes that Ras proteins may regulate using this
experimental system. Ras proteins have been implicated as important regulators of
differentiation in several different cell types (Szeberenyl et al., 1990; Verheijen et al.,
1999; Dajee et al., 2002). Furthermore, the Ras/MAPK pathway has a potential role in
the renewal of stem cell populations by the LIF cytokine in vitro, as it has been linked
to signalling from the gpl30 receptor following LIF stimulation (Ernst et al., 1996).
To investigate whether ES cell self-renewal and differentiation are dependent upon the
K-ras gene product, wild-type, K-ras'mA4A/tmA4A, K-ras'1', K-ras G12 and K-ras G12V ES
cells were grown in 6 well plates in the presence of various concentrations of LIF for 5
days. Alkaline phosphatase activity has been shown to be a marker of a stem cell
population (Bernstine et al., 1973). Therefore, at the end of this time the cells were
stained for endogenous alkaline phosphatase activity to identify those colonies that
maintained a stem cell population.
The alkaline phosphatase staining identified three types of colony representative
pictures of which are shown in figure 6.5. Firstly, an ES cell colony is an intensely pink
staining colony of tightly grouped cells showing minimal differentiation at the colony
edge (figure 6.5 A). Secondly, there was the mixed type, that still showed alkaline
phosphatase activity, but the cells were less tightly grouped and the colony had a much
larger proportion of differentiated cells growing out from the colony (figure 6.5 B).
Finally, the third type was the differentiated colony, which showed no alkaline
phosphatase activity (figure 6.5 C). For the purposes of this experiment the first two
types were grouped together under the term alkaline phosphatase positive colony.
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Figure 6.5 Alkaline phosphatase staining of ES cell colonies. ES cells were grown for 5 days in
various concentrations of LIF then stained for the presence of alkaline phosphatase. A) Alkaline
phosphatase positive ES cell colony comprised of undifferentiated cells B) Mixed ES cell colony showing
some alkaline phosphatase positive undifferentiated cells but also with some differentiation ES cells C)
Alkaline phosphatase negative colony comprised of differentiated ES cells.
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Figure 6.6 Alkaline phosphatase staining of ES cell colonies. The graph shows the percentage of
alkaline phosphatase negative colonies present in each genotype after 5 days of growth in the indicated
concentrations of LIF. Each data point is representative of three separate samples ± s.e.m. Under normal
growth conditions there are no statistically significant differences between genotypes. In the absence of
LIF K-ra.v G12 and K-ra.stmA4AAmA4A cells are not statistically different from wild-type. However, there are
significantly fewer alkaline phosphatase negative colonies for the K-ras" (P=0.022 r-test) and K-
rai'G12V (P=0.008 r-test) genotypes compared to wild-type cells. The graph is representative of two
experiments, which reproduce the level of sensitivity of the different genotypes examined to complete
LIF withdrawal. However, the response to the intermediate concentrations of LIF showed some degree of
variability, although overall trends were maintained.
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All colonies were counted and scored as described and the number of alkaline
phosphatase negative colonies was expressed as a percentage of the total number of
colonies for each concentration of LIF used.
In the presence of 100U of LIF the majority of the colonies in all genotypes appeared to
be ES cell like, as expected for optimal growth conditions. However, in the absence of
LIF K-ras was found to be important in ES cell differentiation (Figure 6.6), since under
these conditions wild-type, K-rastmA4A/lmA4A and K-rasG12 ES cells display similar
levels of differentiation, while K-ras''' ES cell colonies maintain a much greater level of
alkaline phosphatase activity, indicative of less differentiation. As K-ras'mA4A/""A4A ES
cells respond like wild-type ES cells the result indicates that the presence of the K-ras
4B isoform is sufficient to maintain a wild-type like response to LIF withdrawal. Thus,
ES cell differentiation in the absence of LIF is controlled at least in part, by K-ras 4B.
However, the relationship appears to be more complex, since K-ras homozygous null
ES cells expressing a K-rax G12V minigene display a pattern that is similar to K-ras
homozygous null ES cells.
6.3 Response to apoptotic stimuli
Previous work by this laboratory has found that ES cells lacking K-ras are more
resistant to apoptosis induced by etoposide, compared to wild-type cells (Brooks et a\.,
2001). Another investigation reported that K-ras'1' fibroblasts are more resistant to TNF
alpha induced apoptosis (Wolfman and Wolfman, 2000). These results suggest that K-
ras requirement for apoptosis is not a cell type specific phenomenon. In addition, K-ras
clearly plays an integral role in the induction of apoptosis, since the apoptotic stimuli
used to initiate the apoptotic pathway act by different mechanisms (Perkins et al., 2000;
Schmitz et al., 2000). However, the role of the individual K-ras isoforms in this
response is not known. Therefore, in the present study etoposide was used to examine
the role of the individual K-ras isoforms in apoptosis.
Etoposide inhibits Topoisomerase II and causes major double strand DNA breaks,
which lead to apoptosis by the release of cytochrome c from the mitochondria and
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activation of Apaf-1 and cleavage of pro-caspase 9 (Perkins et al., 2000). Since, the K-
ras mutant ES cells under analysis were derived from two different ES cell lines (El4
and HM-1) a preliminary dose response was performed using the two wild-type ES cell
lines to ensure that they responded in a similar manner to etoposide treatment. Cells
were either untreated, treated with vehicle alone (DMSO), or 5pM or 15pM of
etoposide for 24hrs before harvesting. The samples were analysed by flow cytometry
for the percentage of events in the population having hypodiploid DNA content, using
Vindelov analysis (Vindelov et al., 1983). This dose response showed that the two
wild-type parental cell lines E14 and HM-1 underwent similar levels of apoptosis
following treatment with etoposide (figure 6.7).
The study was repeated using wild-type, K_ras'mA4A/tmA4A (clone 9) and K-ras
homozygous null ES cells to investigate the role of the individual K-ras isoforms in
response to etoposide (figure 6.8). K.-ras'mA4A/""A4A ES cells underwent less apoptosis in
response to etoposide than wild-type and K-ras~'~ ES cells, as measured by hypodiploid
DNA content. This dose response was repeated using another K-ras""A4A/""A4A clone
(clone 22) derived from the same electroporation which confirmed this result, as did a
clone from a separate targeting experiment (clone HM-1 R42 #248/24). In conclusion,
the expression of K-ras 4A was found to have an important role in the response of ES
cell to etoposide treatment. Importantly, the comparison between the responsse of K-
rastmA4A/tmA4A es cells and that of the K-ras~'~ ES cells suggests that this reduced
sensitivity to etoposide treatment results from an alteration of the balance between the
expression of the K-Ras 4A and 4B isoforms.
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Figure 6.7 Induction of apoptosis in wild-type ES cells in response to etoposide treatment. The cells
were either untreated, cultured in the presence of vehicle control (DMSO 0.02%) or with etoposide at the
indicated concentrations for 24 hours before harvesting for analysis by flow cytometry using Vindelov
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Figure 6.8 Induction of apoptosis in wild-type, K-ras""and K-ras'1' ES cells in response to
etoposide treatment. The ES cells were cultured in the presence of etoposide at the indicated
concentrations for 24 hours before harvesting for analysis by flow cytometry. The mean percentage of
hypodiploid cells for three replicate measurements ± s.e.m. is shown. There were significantly fewer
hypodiploid events detected in K-ras""MMmMA (P=0.007 and 0.035 t-test) and K-ras'' cells (P=0.003 and
0.049 /-test) treated with 5pm and 10pm of etoposide respectively compared to wild-type cells. The
results are representative of three experiments performed using three different )^_ras'n'A4A/""A4A clones E14
A4A 73/39/9, E14 A4A 73/39/22 and HM-1 R42 #248/24.
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Following these observations time course studies were performed to examine in more
detail the role of the K-ras isoforms in apoptosis. To analyse whether alteration of the
expression of the K-ras isoforms was important for the initiation of apoptosis wild-type,
K-ras""A4A/"nA4A and K-ras'1' cells were treated with 5pM etoposide for 51 hours and
analysed at different time points (figure 6.9). Increased apoptosis in wild-type and K-
ras ' ES cells (above background levels) was first detectable by hypodiploid analysis
following 12-18 hours of treatment with 5pM etoposide. However, in K-ras""A4A/,mA4A
cells the apoptotic response to etoposide treatment was delayed. An increase in
apoptosis above control levels was not detected until after 24 hours of treatment. This
was a delay rather than an inhibition of the response, as the percentage of apoptotic
events detected did increase over time. Therefore, this result indicates that the balance
of expression of the K-Ras 4A and 4B proteins is critical for the proper initiation of
apoptosis in response to etoposide treatment.
To determine whether K-ras 4A mediated effects were etoposide dose dependent a
separate study was performed. A higher concentration of etoposide (20p.M) was tested
to investigate whether this could overcome the delayed apoptotic response observed in
K-ras""A4A/""A4A cells. In the second time course experiment cells were treated with
20p.M etoposide for 48 hours. The same genotypes as described above were also
analysed in this experiment. Under these treatment conditions K-ras''' ES cells were
found to undergo apoptosis more readily than wild-type ES cells. It was also found that
the K-ms""A4A/"nA4A cells showed an increased level of apoptosis at the higher
concentration of etoposide (figure 6.10).
In this experiment the phenotype of the K_ras""A4A/""A4A ES cells was partially overcome
by the increased etoposide concentration, suggesting that the absence of K-Ras 4A and
the change in the balance of expression of the K-ras isoforms had a reduced effect
under these circumstances. Thus, higher concentrations of etoposide may induce
apoptosis by a different mechanism that is not dependent upon K-Ras expression.
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Figure 6.9 Induction of apoptosis in response to etoposide over time. ES cells were cultured in the
presence of 5 pM etoposide for the indicated times before harvesting for flow cytometry by Vindelov
analysis. The mean percentage of hypodiploid cells for duplicate measurements ± s.e.m. is shown. E14
A4A 73/39/9 (K-ras"nA4Ay""MA) ES cells were used for this analysis. Following 24 and 51hrs of treatement
there were significantly fewer hypodiploid events in K-ras'mMA/""MA cells (P=0.008 and 0.033 /-test)
compared to wild-type cells.
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Figure 6.10 Induction of apoptosis in response to etoposide treatment over time. The ES cells were
cultured in the presence of 20pM etoposide for the indicated times before harvesting for flow cytometry.
The mean percentage of hypodiploid cells for duplicate measurements ± s.e.m. is shown. No significant
differences were detected between genotypes analysed. E14 A4A 73/39/9 (K-ras""MA/"'lA4A) ES cells were
used for this analysis.
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To enabled direct comparison between the different etoposide treatments and to confirm
the results of the time course experiments discussed above, a further experiment was
performed repeating them in concert. All three genotypes were repeated, but in addition
a K-ras" ES cell line expressing an activated K-ras G12V was also included in this
study to confirm previous data (Brooks et al., 2001) and to place the YL-rastmA4A/""A4A ES
cells in relation to this data.
The data reproduced by this analysis confirmed the results of the two earlier studies
(figure 6.11). Therefore, under conditions of 5p,M etoposide treatment the order of
sensitivity to etoposide from the most sensitive is K-ras G12V then, wild-type, K-ras"
and K.ras"nA4A/"nMA ES cells showing the least sensitivity. Following 20pM etoposide
treatment K-ras"nA4A/""A4A cells showed a reduced level of apoptosis at 24hrs, but not
following 48hrs of treatment, as found previously. Following 48hrs of treatment all the
genotypes showed similar levels of apoptosis, except K-ras G12V ES cells which were
slightly more sensitive.
Whilst the measurement of hypodiploidy is an established technique (Brooks et al.,
2001) for identifying apoptosis, it was important to confirm the above results by an
independent method. The use of annexin V to detect phosphatidyl serine (PS) is a
recognised technique for detecting apoptosis (Koopman et al., 1994). The exposure of
PS on the surface of apoptotic cells is a widespread and early event during apoptosis
regardless of the initiating stimulus and is important for triggering specific recognition
and removal by macrophages (Fadok et al., 1992; Martin et al., 1995).
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Figure 6.11 Dose responses of wild-type, K-ras""MA/"nMA, K-ras'1' and K-ras G12V ES cells to 5pM
and 20pM etoposide treatment over time. A) 5pM etoposide for 24 and 48 hours. Following 24 and
48hrs of treatment respectively, K-ras'
tmMA/tmMA cells (P=0.001 and 0.006 r-test) and K-rasG12V cells
(P=0.001 and 0.002 t-test) were significantly different to wild-type cells. K-ras"" cells were only
significantly different from wild-type following 48hrs (P=0.035 r-test). B) 20pM etoposide for 24 and
48hrs. Following 24hrs, K.ras"nA4MmA4A and K-rasG12V were significantly different to wild-type
(P=0.006 and 0.012 respectively r-test). Following 48hrs only K-rasG12V cells were significantly
different from wild-type (P=0.020 ?-test). Samples were harvested for analysis by flow cytometry. The
mean percentage of hypodiploid cells for triplicate measurements ± s.e.m. is shown. HM-1 R42 #248/24
(\\-ras""MMmMA) ES cells were used for this analysis.
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The annexin V assay was used in combination with propidium iodide (PI) exclusion.
The inclusion of PI staining, which is a marker for necrosis, is necessary since the
detection of PS alone does not confirm apoptosis, as in necrotic cells annexin V can
detect PS on the inner surface of the plasma membrane, since the cells have lost
membrane integrity. The system was initially optimised on wild-type HM-1 ES cells
(figure 6.12).
The annexin V and PI exclusion method classifies cells into four categories determined
by the staining pattern. 1) Viable cells, which are not positive for either annexin V or
PI. 2) Early apoptotic cells, which are positive for annexin V but are still able to
exclude PI, as the plasma membrane has not been compromised. 3) Late apoptotic
cells, which are positive for annexin V and PI, i.e. membrane integrity has been
compromised (this is probably an artefact of the culture system, as under in vivo
circumstances these cells would be cleared by macrophages before reaching this stage).
4) Necrotic cells, which are those that are only positive for PI, having lost membrane
integrity but not undergone the nuclear changes associated with apoptosis. .
This result clearly showed that annexin V positive cells were detectable at 5pM and
20pM etoposide following 24 and 48 hours of treatment. The percentage of annexin V
positive cells increased with dose and time, as did the percentage of annexin V/ PI
positive cells. Thus, in wild-type ES cells apoptosis is detectable by this method. In
this analysis -60% of the cell population was classified as apoptotic, compared to
between 10-20% by hypodiploid DNA analysis. This reflects that the two methods are
measuring parameters associated with different stages of apoptosis, since PS exposure is
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Figure 6.12 Detection of phosphatidyl serine by Annexin V staining. Cells were cultured in the
presence of either 5pM or 20pM of etoposide for the indicated times and then harvested for annexin
V/propidium iodide staining and detection by flow cytometry. Classification was as follows: viable, no
staining; early apoptotic, annexin V staining; late apoptotic, annexin V and propidium iodide staining;
and necrotic, propidium iodide staining alone.
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This experiment was repeated in triplicate with wild-type, K-ras'mA4Ay'mA4A, K-ras" and
K-ras G12V ES cells and a representative result shown in figure 6.13. Apoptosis is
detectable by the presence of annexin V positive cells following treatment with
etoposide. However, the detection of PS by annexin V does not reproduce the order of
sensitivity to etoposide seen by hypodiploid DNA analysis of these genotypes. A study
of the number of viable cells following treatment with 5jiM etoposide, suggests that K-
ras~'~ ES cells are the most sensitive to etoposide, followed by K-ras G12V and wild-
type ES which show very similar levels of viable cells, and finally the K-rastmA4A/,mA4A
ES cells are least sensitive. In one experiment samples were also taken for hypodiploid
DNA analysis, to determine whether the data could be reproduced if the experiments
were performed on the same cell populations. The hypodiploid data confirmed the
results of previous experiments (data not shown), but the annexin V data gave the same
pattern as shown in figure 6.13. It should be noted that the annexin V/PI populations
more closely represent the hypodiploid data, suggesting that those parameters are more
closely associated. In conclusion, the detection of PS by annexin V does not reproduce
the hypodiploid DNA data, but analysis of annexin V/PI positive data does more closely
reproduce this data.
The reasons for this discrepancy are unclear, but a possible hypothesis is as follows: PS
exposure is an early event in the apoptotic process and precedes the loss of
mitochondrial transmembrane potential and release of cytochrome c, both of which
occur before late apoptotic events (Denecker et al., 2000). Therefore, if K-ras is
important for the initiation of mitochondrial events, or the events immediately
downstream of this, early apoptotic events, such as PS externalisation may be able to
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Figure 6.13 Detection of phosphatidyl serine by Annexin V in wild-type, K-ras""AJA/""/UA, K-ras'1' and
K-ras G12V ES cells. The ES cells were treated with either A) 5pM or B) 20pM of etoposide for 18
hours and then harvested for analysis by flow cytometry. Cells were stained with annexin V and
propidium iodide. The mean percentages for three replicate samples of viable, annexin V positive,
annexin V positive/Pi positive and PI positive cells are shown. The graph is representative of three
independent experiments.
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Due to the discrepancy between the annexin V and hypodiploid data a third method of
detecting apoptosis was sought. Analysis of morphological changes is the most direct
way of assessing the occurrence of classical apoptosis, since the process is defined by
the identification of these changes (Kerr et al., 1972). This method was also attractive
since these are also end stage changes and would allow easier comparison with the
hypodiploid data. This would confirm that the hypodiploid DNA content was a direct
consequence of the formation of apoptotic bodies rather than nuclear abnormalities such
as, chromosome loss or the occurrence of a non-apoptotic type of cell death.
Immunofluorescent analysis of morphological changes consistent with apoptosis was
performed using Hoechst 33342 and PI staining. This technique was optimised using
wild-type ES cells that had been treated with 5(iM and 20pM etoposide for 24 and
48hrs. The cells were classified as follows; 1) viable cells had morphologically normal
Hoechst 33342 positive nuclei; 2) apoptotic cells had chromatin condensation and
nuclear fragmentation; 3) late apoptotic cells had nuclear changes, but were also
positive for PI and finally 4) necrotic cells had no nuclear abnormalities but were
positive for PI. The data (not shown) indicated that the level of apoptosis detected
measured by morphological changes such as chromatin condensation, and membrane
blebbing increased with dose and time.
Having established the technique, wild-type, K-ras""A4MmA4A, K-ras'1' and K-ras G12V
ES cells were treated with 5|iM and 20|iM etoposide for 18hrs and analysed as above,
(figure 6.14) and a representative immunofluorescent image of the nuclear morphology
observed is shown (figure 6.15). The data supported the overall trends detected by
hypodiploid DNA analysis. K-ras"nA4A/""A4A ES cells were scored as mainly viable
under both treatment conditions. K-ras G12V cells had the greatest percentage of
apoptotic nuclei followed by wild-type, K-ras'1' and finally K-ras""A4A/""A4A ES cells
when treated with 5pM etoposide for 18 hours. When treated with 20pM etoposide for
18 hours the level of viability is still greatest in K-ras"nA4A/"nA4A ES cells, followed by
wild-type, K-ras'1' and finally K-ras G12V ES cells. Importantly, this study


















Figure 6.14 Immunofluorescent detection of apoptosis. Morphological analysis by immunofluorescent
detection with Hoechst 33342 and propidium iodide. A) 5pM etoposide for 18hrs. There were
significantly fewer apoptotic nuclei observed in K-rastmA4A/tmA4A (P=0.022 r-test) than in wild-type cells.
B) 20pM etoposide for 18hrs. The data represents the mean of three samples. The experiment was
performed on three separate occasions using three different K-ras""MA/""MA clones E14 A4A 73/39/9, E14
A4A 73/39/22 and HM-1 R42 #248/24.
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Figure 6.15. Representative image of immunofluorescent morphological analysis of ES cells
following treatment with etoposide. ES cells were counted and classified according to their nuclear
morphology and the presence or absence of Hoechst 33342 (blue nuclear stain) and PI
immunofluorescence (red cytoplasmic stain), examples are indicated Red arrow = viable, white arrow =
apoptotic, green arrow = secondary apoptotic and yellow arrow = necrotic.
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6.3.1 Analysis of receptor mediated apoptosis in ES cells
Published data has implicated K-ras as an important mediator of TNF alpha-induced
apoptosis (Wolfman and Wolfman, 2000). Therefore, since K-ras 4A expression was
found to be critical for ES cells to undergo appropriate etoposide-induced apoptosis, it
was of interest to assess its role in receptor mediated apoptosis induced by TNF alpha
and Fas ligand (CD95L). Tumour necrosis factor receptor (TNFR) and CD95 (APO-
1/Fas) are members of the TNF/NGF-receptor superfamily. These death receptors are
activated by their ligands namely TNF alpha and CD95L (FasL) and are thought to lead
to initiation of receptor mediated apoptosis by the formation of the death inducing
signalling complex and cleavage of pro-caspase 8 (reviewed Schmitz et al., 2000),
thereby initiating apoptosis through a different mechanism from etoposide.
Since ES cells express TNFR (Wuu et al., 1998) wild-type ES cells were treated with
TNF alpha to assess dose response and time course of effect. However, TNF alpha
treatment failed to induced apoptosis as measured by hypodiploid DNA content (figure
6.16). A further experiment was performed using TNF alpha in the presence of
cycloheximide, since this had been shown to cause increased apoptosis in fibroblasts
(Wolfman and Wolfman, 2000). However, co-treatment with TNF alpha and
cycloheximide did not cause an increase in apoptosis detected by hypodiploid DNA
content in wild-type ES cells above control levels (data not shown).
Therefore, Fas monoclonal antibody (MAb) and FasL treatment were also investigated
as potential initiators of receptor mediated apoptosis in ES cells. The Fas MAb (Jo2)
has been reported to induce apoptosis in ES cells (Zou et al., 2000) at a concentration of
lpg/ml. However, following 24hrs of treatment with 1 jig/ml, 2p,g/ml or 4p,g/ml Fas
MAb (Jo2) apoptosis was not detectable above control levels using hypodiploid DNA
content as a marker (Figure 6.17). Likewise, treatment with recombinant FasL did not
cause an increase in apoptosis above control levels when used at concentrations of
50ng/ml, lOOng/ml and 150ng/ml (data not shown). The reasons for this failure are
unclear, but may reflect the use of different ES cell lines and/or culture conditions.
173
Untreated 10ng/rr( 50ngtrrl lOOnghl 150ng/rt1
TNF alpha concentration
■ 24 hours □ 48 hours
Figure 6.16 Effect of TNF alpha treatment on wild-type ES cells. Represents the response of wild-
type ES cells to treatment with TNFa at the indicated concentrations for 24hrs and 48hrs. Following
treatment the cells were harvested for analysis by flow cytometry using Vindelov analysis. The data
represents the mean of three samples ± s.e.m.
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Figure 6.17 Response of wild-type ES cells to Fas MAb treatment. Represents the response of wild-
type ES cells following treatment for 18hrs and 24hrs with the concentrations of FasMAb (Jo2) indicated.
Following treatment the ES cells were harvested for analysis by flow cytometry using Vindelov analysis.
The mean of three samples ± s.e.m. is shown.
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6.3.2 Analysis of K-ras4A mRNA levels in response to apoptotic stimuli
While the level of K-ras 4A mRNA expression is very low in ES cells compared with
the K-ras 4B isoform (chapter 3). The ratio of K-Ras 4A and 4B protein isoforms has
been shown to be critical for the response of ES cells to etoposide-induced apoptosis.
Therefore, it was important to examine the possible mechanisms by which these
proteins may be mediating their affects. One avenue of investigation focused on the
level of K-ras 4A mRNA expression during apoptosis to examine the possibility that K-
ras 4A mRNA may be up-regulated during early apoptosis.
To test this hypothesis RNA was extracted from wild-type ES cells treated with
etoposide for 1, 2, 3, 4, and 8hrs and analysed by RT-PCR using primers in exon 1 and
exon 4B (described previously, chapter 3) which amplifying both the K-ras 4A and 4B
transcripts in the same reaction enabling examination of the isoform ratio. However,
the ratio between the K-ras 4A and K-ras 4B isoforms was clearly not affected by the
etoposide treatment (figure 6.18). Therefore, further quantitation of the level of
expression of the isoform transcripts was not performed.
The results indicate that K-ras 4A mRNA expression is not up-regulation during the
early stage of etoposide-induced apoptosis in ES cells, and that it plays an important
role in the apoptotic process even though it is expressed at low levels, compared to K-
ras 4B. However, this result does not exclude the possibility of regulation at the protein
level.
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Figure 6.18 Detection of K-ras 4A and 4B isoform ratio following treatment with etoposide. ES cells
were treated for the times indicated with 5p.M etoposide and harvested for RNA extraction. The figure
shows the (+) RT PCR product and the (-) RT control showing that DNA contamination is not present
and adult wild-type stomach (St) was included as a positive control. All samples contain the 687bp K-ras
4A and 565bp K-ras 4B products.
177
6.3.3 Analysis of potential effector pathways mediating K-Ras 4A involvement in
apoptosis
Ras proteins have been implicated as key regulators of several signal transduction
pathways including the Raf/MAPK, PI-3Kinase and RalGDS pathways (reviewed in
Downward, 1998). The Raf/MAPK and PI-3Kinase-PKB/Akt pathways have been
particularly intensively studied and have been implicated as regulation of pro- and anti-
apoptotic signals (reviewed Downward, 1998). The PI-3Kinase pathway has been
shown to mediate survival signals via PKB/Akt through the phosphorylation and
inactivation of Bad and other pro-apoptotic mediators and Raf/MAPK pathway has been
shown to mediate both pro- and anti-apoptotic signals.
Therefore, in order to investigate the mechanisms by which K-Ras 4A mediates such a
critical role in apoptosis its role in signal transduction via the PI-3Kinase-PKB/Akt and
Raf/MAPK pathways were investigated by the use of specific inhibitors of PI-3Kinase
(Vlahos et al., 1994) and MEK-1 (Dudley et al., 1995).
K_ras""A4A/"nA4A ES cells when treated with etoposide in the presence of the PI-3Kinase
inhibitor LY294002 at 20|iM and 50p,M had a greater percentage of hypodiploid events
than K-ras,mA4A/tmA4A cells treated with etoposide alone (figure 6.19). The percentage of
hypodiploid events seen with 50p,M LY294002 is at least as great as wild-type ES cells
treated with etoposide alone. Wild-type ES cells also showed an increase in apoptosis
when co-treated with etoposide and 50pM LY294002; this could reflect a general
sensitivity of ES cells to inhibition of the PI-3Kinase pathway, which has been reported
recently (Jirmanova et al., 2002). Since, the increased apoptosis detected in wild-type
ES cells does not account for the total increase observed in K-rastmA4A/'mA4A ES cells the
result indicates that expression of K-ras 4A may be important for counteracting cell
survival signals generated by the PI-3Kinase pathway in ES cells.
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Figure 6.19 Effect of the PI-3Kinase inhibitor on ES cell response to etoposide. Response of wild-
type and Y.-ras'mMA/""A4A ES cells to 5pM etoposide treatment for 18hrs either alone or in the presence of
the PI-3Kinase inhibitor LY294002, which was added to cells at the concentrations indicated. The data
points represent the mean hypodiploid events of three data sets. There was significantly more apoptosis
detected in K_ras""MA/""A4A gg cens (p=0.003 t-test) following treatment with 50pm LY294002 compared
to cells treated with etoposide alone. However, this was also true for wild-type ES cells (P=0.011 t-test).
The graph shown here is representative of two experiments using two different I<^_ras""A4A/lmA4A clones E14
A4A 73/39/9 and HM-1 R42 #248/24.
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Figure 6.20 Effect of the MEK inhibitor on ES cell response to etoposide. Response of wild-type and
K-ras'"' "" A ES cells to 5pM etoposide treatment either alone or in the presence of increasing
concentrations of the MEK inhibitor PD98059 as indicated for 18hrs. The data points represent the mean
of three data sets ± s.e.m. The graph shown here is representative of two experiments using two different
K.ras'mMA/,mMA clones, E14 A4A 73/39/9 and HM-1 R42-248/24. While the response of wild-type ES
cells was significantly different to ]^.ras"nA4A/""A4A es cells under all conditions (P=0.003, 0.016 and 0.004
respectively, r-test). Treatment with both 40pm and 50pm PD98059 resulted in a significant decrease in
the amount of apoptosis detected in wild-type ES cells (P=0.018 and 0.040 respectively, r-test), but not in
K-ras""A4A/"nA4A ES cells (P=0.771 and 0.551 respectively, r-test).
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In contrast, co-treatment with etoposide and the MEK inhibitor PD98059 resulted in a
different response to that seen with the PI-3Kinase inhibitor (figure 6.20). In wild-type
ES cells co-treatment with PD98059 and etoposide resulted in less apoptosis than
treatment with etoposide alone. However, the observed reduction did not decrease the
level of apoptosis to that seen in K-ras'mA4A/""A4A ES cells. The level of apoptosis
observed in K-ras'mA4A/'mA4A cells was not affected by co-treatment with PD98059 and
etoposide, compared to etoposide alone. These findings indicate that K-ras 4A may
mediate some of its effect through the MAPK pathway, although clearly other pathways
are involved, since inhibition ofMEK in wild-type ES cells did not cause the same level
of resistance to etoposide observed in K-ras'mA4A/tmA4A ES cells. In conclusion, the data
suggest that the altered balance of expression of the K-Ras 4A and 4B proteins may
result in reduced pro-apoptotic and increased anti-apoptotic signal transduction in these
cells following etoposide treatment resulting in an inappropriate response to apoptotic
stimuli.
6.4 Discussion
Gene targeting studies and mutational analyses indicate that K-ras plays an important
role in development and tumorigenesis. To gain insight as to how K-ras may affect
these processes, effects on cell proliferation, differentiation and apoptosis were
investigated using ES cells harbouring different K-ras mutations, including the
K-ras""A4A/tmA4A mutation generated in the present study, and ES cells with a
homozygous K-ras null mutation or K-ras null ES cells transfected with minigenes that
express, either wild-type K-ras, or an activating (G12V) K-ras mutation (Brooks et al.,
2001). Importantly, K-ras mutant ES cells generated by homologous recombination
offer a unique and valuable system to analyse the role of K-ras and its individual
isoforms, since interpretation of the results is not complicated by, either chromosomal
abnormalities, or mutations in other genes.
Ras activity is required at multiple points throughout G0/G1 progression until just
before entry into S phase for mitogen stimulated quiescent cells to undergo DNA
synthesis (Mulcahy et al., 1985; Feig and Cooper, 1988; Cai et al., 1990; Dobrowolski
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et al., 1994; Aktas et al., 1997). K-ras in particular modulates both positive and
negative regulators of the cell cycle; including up-regulation of cyclins A, D3 and E and
the E2F transcription factors and down-regulation of p27kipl (Fan and Bertino, 1997). In
addition, the fact that K-ras homozygous null embryos displayed growth retardation,
reduced cell numbers in foetal livers and had smaller hearts (Johnson et al., 1997; Koera
et al., 1997) implies that K-ras may have a key role in cell proliferation in vivo.
Therefore, using the ES cell model system it was possible to investigate whether these
defects were mirrored by a decreased rate of proliferation in vitro. However,
comparison between wild-type, K-ras""A4A/,mA4A and K-ras homozygous null ES cells
demonstrated that K-ras is dispensable for cell cycle progression under normal growth
conditions. Although this appears to contradict the in vivo observations there are
several possible explanations for this discrepancy. ES cells, unlike somatic cells, do not
exit from the cell cycle following serum withdrawal, but instead continue to proliferate
(Schratt et al., 2001). The activation of the immediate early gene (IEG) response by
serum response factor (SRF) following signal transduction through the MAPK pathway
is dispensable for ES cell growth. Thus, K-ras may be dispensable for the growth of ES
cells, because they lack normal cell cycle controls and do not require signal transduction
via the MAPK pathway to proliferate. However, K-ras may affect more committed cell
types in which these controls exist, since signal transduction via MEK is important for
ES cell proliferation following differentiation with retinoic acid (Jirmanova et al., 2002)
and embryonic abnormalities in K-ras" mice are not observed until the onset of
organogenesis (Johnson et al., 1997; Koera et al., 1997). Therefore, it would be of
interest to investigate proliferation in other cell types with these genotypes.
Alternatively, the failure of K-ras to influence the growth of ES cells may be because
they are cultured under optimal growth conditions. Finally, it is also possible that the
reduced cell numbers in foetal liver and thin ventricular walls in K-ras homozygous null
embryos are due to effects of the K-ras mutation upon differentiation or apoptosis rather
than proliferation.
In immortalised cell lines, such as the NIH3T3 fibroblasts expression of activated H-,
N- and K-ras genes causes transformation and deregulated growth (Maher et al., 1995),
which is accompanied by shortening of the G1 phase of the cell cycle (Lui et al., 1995;
Winston et al., 1996). In contrast, expression of oncogenic ras in primary cells resulted
in premature G1 cell cycle arrest that resembled senescence. This effect was mediated
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via an induction of p21tipl and subsequent inhibition of CDK (Lloyd et al, 1997;
Sewing et al., 1997; Woods et al., 1997), accumulation of p53 and plb11^411 (Serrano et
al., 1997), alteration in the activity of the members of the RB family (Peeper et al.,
2001) and ubiquitin dependent degradation of cyclin D1 (Shoa et al., 2000).
ES cells have the characteristics of an immortal cell line. As such ES cells cycle rapidly
and have a short G1 phase with an absence of hypophosphorylated retinoblastoma (Rb)
protein, and an apparent reduction in the overall level of this protein following the exit
from mitosis (Savatier et al., 1994). In addition, ES cells express very low levels of
cyclin E/CDK2 complexes, p21c,pl and p27kipl CDK inhibitors (Savatier et al., 1996).
Furthermore, over expression of pl61NK4a, which is associated with activated ras
induced cell cycle arrest (Serrano et al., 1997) did not cause growth arrest in ES cells
(Savatier et al., 1996). Therefore, the effect of the K-ras activating mutation was
investigated in this cell line to assess the response of a stem cell population.
However, here it was found that expression of the activating K-ras G12V mutation did
not alter the cell cycle kinetics of ES cells. Thus, the immortalised nature of ES cells
was not sufficient to cooperate with the K-ras G12V mutation in deregulating the cell
cycle and the lack of the normal G1 cell cycle controls in ES cells, which are present in
more differentiated cell types, may account for the absence of cellular senescence in K-
ras homozygous null ES cells over expressing K-ras G12V.
Differentiation has been identified as a Ras regulated process in several studies. The
differentiation of F9 embryonal carcinoma cells into primitive endoderm (PrE) and then
to parietal endoderm (PE), was demonstrated to be a ras dependent process (Verheijen
et al., 1999), since differentiation to PrE requires Ras up-regulation and the further
differentiation to PE requires down-regulation of Ras. The expression of activated Ras
was capable of blocking PrE to PE differentiation (Verheijen et al., 1999). In addition,
activated ras caused sustained proliferation and failure to differentiate when expressed
by a keratin 14 promoter in the basal dermal layers (Dajee et al., 2002), whereas
expression of dominant negative ras resulted in decreased proliferation and a thin layer
of terminally differentiated cells. Activation of the MAPK pathway following cytokine
stimulation of the gpl30 receptor (Boulton et al., 1994; Ernst et al., 1996; Sheng et al.,
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1997; Yin and Yang, 1994), suggests that ras might be important in the maintenance of
ES cell renewal.
The analysis of ES cell differentiation following LIF withdrawal highlighted the
importance of K-ras for ES cell renewal as assessed by alkaline phosphatase activity
(Bernstine et al., 1973). K-ras" ES cells were found to have a reduced requirement for
LIF, and importantly the reduced level of differentiation was rescued by the
introduction of a minigene expressing wild-type K-ras. This demonstrated that the
phenotype was due to the deletion of K-ras rather than, either the selection of a
differentiation insensitive clone, or a detrimental effect of the targeting strategy.
Importantly, the finding that K-ras"nA4A/"nA4A ES cells respond as wild-type cells
indicates that the K-ras 4B isoform plays a critical role in ES cell differentiation and,
therefore, in maintaining stem cell renewal. However, some redundancy is evident in
the pathway responsible for exit from the stem cell population, since the K-ras'1'
genotype causes only partial insensitivity to LIF. Indeed, this redundancy may explain
why K-ras'1' ES cells contribute to tissues in mouse chimaeras (Johnson et al., 1997).
Importantly, the failure of these cells to colonise efficiently some lineages; including
lung and haematopoietic tissues, support the current in vitro findings that K-ras has a
role in differentiation.
However, the finding that K-ras'1' ES cells are insensitive to LIF withdrawal is difficult
to reconcile with the finding that this also applies to ES cells expressing K-ras G12V.
Importantly, ES cells that express v-H-ras also show a reduced requirement for LIF
(Ernst et al., 1996). Furthermore, Verheijen and co-workers demonstrated that in ES
cells oncogenic Ras induced a PrE-like morphology (Verheijen et al., 1999). Therefore,
expression of the activated K-ras G12V minigene may be inducing differentiation to a
PrE-like morphology, but preventing further differentiation to PE-like cells. Therefore,
reduced requirement for LIF in the K-ras'1' ES cells may reflect the need for Ras
signalling for differentiation to PrE and in K-ras G12V ES cell lines differentiation to
PrE, but failure to differentiate further into PE. However, further experiments would be
required to identify if the specific markers for these differentiation stages were present.
Previous work by this laboratory reported that ES cells with activating K-ras mutations
were more susceptible to apoptosis induced by etoposide, whereas cells lacking K-ras
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were less susceptible (Brooks et al., 2001). Furthermore, K-ras homozygous null
fibroblasts were also less susceptible to receptor mediated cell death than wild-type
fibroblasts (Wolfman and Wolfman, 2000). This suggests that K-ras may be an integral
component of the apoptotic pathway, as both these types of cell death signal are
dependent upon its presence. Research has also indicated that different ras genes may
have different roles in apoptosis, while K-ras appears to promote apoptosis, N-ras
appears to be important for preventing apoptosis (Wolfman and Wolfman, 2000;
Wolfman et al., 2002). Therefore, the role of the individual K-ras isoforms was
investigated. In the present study apoptosis was measured using flow cytometry and
Hoechst 33342 staining, and it was found that the deletion of K-Ras 4A results in an ES
cell population with a reduced sensitivity to apoptosis induced by etoposide, compared
to wild-type ES cells. At low doses of etoposide apoptosis was not detected in K-
rastmA4AJtmA4A es cells until after 24 hours of treatment, compared to the detection of
apoptosis at 18 hours in wild-type ES cells. Indicating that this resistance occurs in the
form of a delay in the initiation of this process. Clearly expression of the K-ras 4B
isoform in these cells is not sufficient for normal apoptotic responses to occur.
Furthermore, K-ras"nA4A/"nA4A ES cells are less sensitive to etoposide than K-ras
homozygous null ES cells. Importantly, this observation suggests the possibility that
the greater sensitivity of K-ras'1' ES cells to etoposide than K-ras"nA4A/""A4A ES cells may
result from a skewing of the ratio of K-Ras 4A and 4B protein expression in the K-
ras"nA4A/"nA4A ES cells, indicating that the control of this balance of expression may
determine the apoptotic response.
The DNA damaging agent etoposide acts by inhibiting topoisomerase II, which results
in double-strand breaks that are lethal to the cell. Induction of apoptosis by this agent
has been shown to result in cytochrome c release from the mitochondria by two distinct
mechanisms, which are determined by the concentration of etoposide used (Robertson
et al., 2000). Since, caspase inhibitors can prevent cytochrome c release caused by low,
but not high doses of etoposide this could in part explain the finding that the delay in the
initiation of apoptosis shown by K-ras""A4A/tmA4A cells was evident only when treated
with the lower dose of etoposide. Therefore, K-ras 4A may play a role in the caspase-
dependent release of cytochrome c from the mitochondria or steps immediately
downstream of this in response to etoposide treatment.
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Therefore, the presence of the K-ras gene products are essential for proper apoptotic
responses when cells are exposed to DNA damaging agents such as etoposide. This
data indicates that K-ras functions as a protective mechanism by which to clear cells
with DNA damage. Over-expression of an activated K-ras G12V minigene in K-ras_/~
cells confirmed this, since elevated levels of apoptosis were detected when these cells
were challenged with etoposide, compared to wild-type ES cells. This result confirms
the previously published data (Brooks et al., 2001). However, it was important to note
that there was no increase in apoptosis under normal growth conditions, as published
data has shown that the introduction of an activated ras gene can promote cell death
without other stimuli in certain cell types (Shao et al., 2000).
The data indicates that K-ras 4A/4B ratio plays a crucial role in the initiation of
apoptosis. Therefore, in order to investigate the underlying mechanisms K-ras 4A
mRNA levels were examined to assess whether the induction of apoptosis was preceded
by an up-regulation. However, no alteration in the level of K-ras 4A mRNA was
apparent up to 8 hours after etoposide treatment. However, since this does not address
the question of possible increased protein stability or other such mechanisms of up-
regulation these cannot be excluded. Nevertheless, there is no evidence to suggest that
K-Ras 4A is up-regulated in relation to K-Ras 4B by a transcriptional method.
To examine further the role of the K-Ras 4A and 4B proteins in apoptosis, signal
transduction via the PI-3K and MAPK pathways was analysed using specific inhibitors.
These pathways have been implicated in Ras mediated signal transduction effects upon
apoptosis (reviewed Downward et al., 1998). The PI-3Kinase pathway mediates anti-
apoptotic signals (Kauffmann-Zeh et al., 1997; Xue et al., 2000), whereas the
Raf/MAPK pathway can mediate, either pro- or anti-apoptotic effects depending upon
the cell type and apoptotic stimulus (Kauffmann-Zeh et al., 1997; Xue et al., 2000).
The results presented indicated that there are two apparently paradoxical mechanisms
involved. However, this effect is not entirely without precedent, as in fibroblasts and rat
thyroid cell activated Ras caused both survival signals from PI-3Kinase and pro-
apoptotic signals via the Raf/MAPK pathway (Kauffmann-Zeh et al., 1997; Cheng and
Meinkoth, 2001) clearly demonstrating that the outcome of apoptotic signals is
dependent on the synergistic effect of these signal transduction pathways determining
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the cell fate. In this context, it appears that expression K-ras 4A may be needed to
signal via the MAPK pathway to promote apoptosis, since the MEK inhibitor caused a
reduction in apoptosis in wild-type ES cells, but not in K.ms"nA4A/""A4A ES cells when
co-treated with etoposide. However, it is clear that this is only partly responsible for the
effects mediated by K-Ras 4A, as the MEK inhibitor does not inhibit apoptosis to the
same extent as the absence of the K-ras 4A gene. Conversely, co-treatment with
etoposide and the PI-3Kinase inhibitor LY294002 caused an increase in apoptosis in K-
ras"nA4A/tmA4A es cells, suggesting that K-ras 4A may be needed to act as an antagonist
to this pathway. However, this observation was complicated by the increased apoptosis
detected in wild-type ES cells with this co-treatment, which although not as great,
suggested that these observations may reflect a general sensitivity of ES cells to
inhibition of the PI-3Kinase pathway, which has been reported recently (Jirmanova et
al., 2002). Therefore, further analysis is required to determine the involvement of K-
Ras 4A in PI-3Kinase signal transduction. However, this preliminary analysis of these
signal transduction pathways suggests a possible mechanism by which perturbation of
the K-Ras 4A/4B ratio may result in inappropriate apoptotic responses.
In conclusion, the work presented in this chapter provides a preliminary insight into the
differential regulation of cellular functions by the K-Ras protein isoforms, identifying




General Conclusions And Future Directions
The data presented in this thesis represents an investigation into the role of the K-ras
isoforms in development and neoplasia. This took the form of identifying differential
roles for the K-ras isoforms, which may in part explain the high incidence in tumours of
mutations in K-ras relative to mutations in other members of the ras family.
The aim was achieved by examination of K-ras expression in human tumours and
mouse embryos using isoform specific antibodies, and by analysing targeted ES cells
harbouring K-ras gene mutations. The K-ras+/tmA4A ES cells were generated during the
course of the present work by homologous recombination, following electroporation of
the pPTKiNKiA4A targeting vector. ES cells homozgous for the mutation, K-
ras"nMA/""MA> were derived from heterozygous cells by high G418 selection.
Importantly, K-rastmMA/tmMA ES cells continued to express the K-ras 4B isoform.
Comparative analyses between wild-type and K-ras mutant ES cells enabled detailed
investigation of the role of the K-ras isoforms in cell proliferation, differentiation and
apoptosis. It was found that K-ras was dispensible for cell proliferation, and that K-Ras
4B was implicated in stem cell renewal and differentiation, and K-Ras 4A in apoptosis.
Importantly, the different roles assigned to each isoform were confirmed by analysing
K-ras mutant clones derived from independent parental ES cell lines. While many past
studies have used transformed cell lines to examine the function of K-Ras, the gene
targeted ES cells used here have the advantage in that they harbour only defined K-ras
mutations, and therefore interpretation of the data is not complicated by mutations in
other genes.
Expression of the K-ras 4B isoform was implicated in ES cell renewal, since while K-
ras~'~ ES cells showed reduced requirement for LIF K-rastmA4A/tmA4A and wild-type ES
cells showed comparable levels. However, these analyses indicated that K-ras might
exert opposing functions within the processes determining, either stem cell renewal, or
differentiation, since expression of activated K-ras G12V within K-ras'1' ES cells also
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results in a reduced requirement for LIF. Therefore, signal transduction via K-ras may
be important for the maintenance of a stem cell population, but also for signalling stem
cells to differentiate following withdrawal of renewal signals. Further analysis of the
mechanisms underlying this apparently contradictory regulation could be of value.
Since, these findings appear to agree with the observations that the differentiation into
primitive endoderm (PrE) requires up-regulation of Ras signal transduction and
differentiation of PrE to parietal endoderm (PE) requires down-regulation of this
(Verheijen et ah, 1999), it would be of interest to analyse whether markers for these
differentiation stages are present following withdrawal of LIF. Importantly, since signal
transduction via MEK has been implicated in regulating stem cell renewal (Burdon et
al., 1999), it would be interesting to determine if this involves signal transduction via K-
ras.
ES cell proliferation and cell cycle kinetics were similar regardless of whether they
expressed K-ras. The introduction of an activated K-ras G12V minigene into K-ras'1'
ES cells confirmed these observations, as constitutive activation of this gene did not
deregulate proliferation. Thus, K-ras is dispnesible for the proliferation of ES cells.
Clearly, the regulation of the cell cycle in ES cells differs from somatic cells; therefore
this result does not preclude the involvement of the K-ras gene products as critical
regulators of the somatic cell cycle, but serves to highlight the importance of
investigation of the ES cell cycle. Further investigation is warranted in the light of a
recent publication (Jirmanova et al., 2002), which demonstrated that following
differentiation of ES cells with retinoic acid (RA) the proliferation of these cells was
dependent upon MEK activity. Since, this raises the possibility that proliferation of
differentiated cells is dependent upon Ras it would be interesting to determine whether
K-ras is involved by comparing the proliferation of wild-type and K-ras mutant ES
cells following treatment with RA.
Previously, it has been reported that K-ras expression is important for pro-apoptotic
signals in ES cells and fibroblasts (Brooks et al., 2001; Wolfman and Wolfman, 2000).
The present study demonstrated that K-ras 4A is a key regulator of ES cell apoptosis in
response to DNA damage, since K-ras""A4A/tmA4A cells were more resistant to apoptosis
induced by etoposide. The absence of both K-ras isoforms results in a slight decrease
in sensitivity, but this is not as marked. Therefore, the expression of the K-ras 4B
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isoform alone is not sufficient for the cells to respond like wild-type ES cells. Indeed,
the lack of K-ras 4A expression results in a more dramatic phenotype than the deletion
of both K-ras isoforms, indicating a possible skewing of the balance between the
expression of the isoforms during this process. Therefore, the possibility arises that the
pro-apoptotic effects of K-Ras 4A and the possible anti-apoptotic effects of K-Ras 4B
may ultimately decide the cellular fate.
Investigation of the mechanisms involved indicated that K-ras 4A mRNA was not up-
regulated in response to apoptotic stimuli. However, analysis of the signal transduction
pathways involved in known Ras pro- or anti-apoptotic responses showed different
sensitivity to inhibitors of these pathways in K-rastmA4A/""A4A versus wild-type ES cells.
The increased apoptosis elicited by the PI-3Kinase inhibitor in K-rastmA4A/""A4A cells,
suggested that this pathway may be over stimulated in these cells, explaining at least
part of the reduced sensitivity of these cells to DNA damage. The decreased apoptosis
elicited by the MEK inhibitor in wild-type, but not K-ras""A4A/tmA4A ES cells, indicated
that K-ras 4A might be important for signal transduction via the MAPK pathway in
response to DNA damage. These observations while appearing contradictory are
supported by data from effector mutant studies, which show that the Ras proteins can
activate both the PI-3Kinase and MAPK pathway in response to apoptotic stimuli and
that the balance of this activation determines the cellular response (Kauffman-Zeh et al.,
1997; Cheng and Meinkoth, 2001). In the light of these observations it would be of
interest to investigate further the pathways involved in K-Ras 4A mediated apoptosis.
These analyses could address several further questions; including whether the level of
activity of the downstream effectors of the Raf/MAPK and PI-3Kinase are altered in
response to etoposide treatment. This investigation would clarify whether the effects
observed with the pathway inhibitors reflected a genuine alteration in the level of
activity associated with these signal transduction pathways in the K-ras"nA4A/tmA4A cells
in response to etoposide treatment, compared to wild-type cell. Furthermore, since K-
Ras 4A appears to be important for the initiation of apoptosis in response to low, but not
high doses of etoposide, analysis of caspase activation in these cells could provide
useful insight into the underlying mechanisms involved in K-Ras 4A control of
apoptosis. Since, the apoptotic response to low, but not high doses of etoposide have
previously been demonstrated to be caspase dependent (Robertson et al., 2000).
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Finally, it may be of interest to examine the level of expression of anti-apoptotic factors,
such as Bcl-2 to investigate whether these are inappropriately up-regulated in K-
rastmMA/tmMA cells, compared to wild-type cells.
K-ras activating mutations occur in approximately 40-50% of colon cancers (Bos et al.,
1989). Since, these mutations primarily affect codons 12 or 13 the mutation can affect
both isoforms, and therefore both K-Ras 4A and 4B have the potential to contribute to
tumours. Analysis of the role of K-ras isoforms in cancer was performed by
immunohistochemical analysis of the expression patterns of both isoforms in colon
tumours, which had been screened previously (published as part of a larger study
(Andreyev et al., 1998)) and been shown to contain a mutation in the K-ras gene. The
results clearly demonstrated that both protein isoforms were expressed in the normal
and neoplastic colon. K-Ras 4A inparticular was strongly up-regulated in the neoplastic
colon. Therefore, K-ras 4A has the potential to be involved in colon tumorigenesis.
Importantly, up-regulation was not detected in pre-malignant cervical intraepithelial
neoplasia, which is not normally associated with K-ras mutations. The fact that both
isoforms are expressed in colorectal cancer and therefore have the potential for
combined or synergistic interactions may, at least in part, account for the higher
incidence of activating K-ras mutations, compared to either N- or W-ras. This is
supported by the present data, which shows that the K-ras isoforms are capable of
differential regulation of apoptosis and differentiation, but also by previously published
data, which demonstrated that the K-ras isoforms had different transforming abilities
and could activate the downstream signalling molecule Raf with varying efficiencies
(Voice et al., 1999).
While studies with cultured ES cells suggest that the different K-ras isoforms have
distinct roles in differentiation and apoptosis, information about their function in
cellular processes in vivo is crucial to understanding their contribution to development
and tumorigenesis.
In the first step to achieve this goal K-ras+/""A4A mice were developed as part of this
thesis. The mice are viable and show no overt abnormalities at 5 months of age on,
either inbred, or outbred backgrounds. Furthermore, analysis of K-rastmMA/tmA4A
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offspring derived from the mating of the K-ras+/""A4A animals will provide a unique
opportunity to investigate the contribution of each of the isoforms to the developmental
phenotype seen in K-ras homozygous null animals (Koera et al., 1997: Johnson et al.,
1997). Immunohistochemical analysis of developing mouse embryos has shown that
K-ras 4B is expressed in many cell lineages and is present even at early stages of
development, as has RNA analysis (Pells et al., 1997). However, importantly the
results detailed in this thesis show that differential regulation of K-Ras 4B protein levels
occurs during embryonic and neonatal development. Expression of this protein is
closely associated with those tissues that are thought to contribute to the lethality
associated with the complete deletion of both K-ras gene products, which may have
important implication for the developmental phenotype of K-ras "nA4A/lmA4A miCe.
In addition, future analyses of the K-ras+/tmA4A mice will investigate whether the
heterozygous deletion of exon 4A results in an altered ratio of expression between the
two K-ras isoforms. This analysis will be of importance to investigate whether
regulatory processes exist in vivo to ensure the correct level of K-ras 4A mRNA
transcription occurs. An absence of regulation and an absence of a phenotype in the
K-ras+/""A4A animals may reflect that a skewing of the balance of expression of these
two isoforms is unimportant in vivo.
Importantly, while TNF alpha and FasL failed to induce apoptosis in ES cells these
agents could be tested on K-ras"nA4A/"»A4A embryonic fibrobalsts to estalish whether K-
Ras 4A has a role in receptor mediated apoptosis.
Should K-rastmA4A/""A4A mice prove to be viable and survive to adulthood it will be
possible to examine the importance of this mutaion on cell growth using tissues that
normally express high levels of K-ras 4A, including intestinal epithelial cells. A crucial
role for K-Ras 4A initiating apoptosis could be confirmed in gut epithelial cells
following whole body y-irradiation, where a reduction in apoptosis might be expected.
These animals could also be used to analyse the importance of the contribution of K-ras
4A to the development of tumours in such tissues, as the lung and colon by carcinogen
studies. Since K-ras 4A is expressed highly in these tissues (Pells et al., 1997) it is
tempting to speculate that under such conditions the incidence of tumour development
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may be decreased, compared to wild-type controls if the hypothesised requirement for
combined or synergistic activation of both isoforms for tumorigenesis is correct.
Importantly, these data have demonstrated that functional redundancy between the K-
Ras protein isoforms does not occur in at least two cellular processes, which has
important implications for development and tumorigenesis. Therefore, in conclusion
the data presented as part of this thesis has added to the current understanding of the
differential regulation of cellular functions by the K-Ras isoforms.
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In de-ionised H20, autoclaved
Supplemented with 50pg/ml ampicillin where stated
Supplemented with 1.2% w/v Bactoagar for plates
Solutions for DNA analysis
IPX TBE Buffer
TRIZMA base (Sigma) 108g
Boric Acid (Sigma) 55g
0.5M EDTA pH 8.0 (Fisher) 40ml







IM Tris pH 7.5 (Fisher) 5ml
0.5M EDTA (Fisher) 10ml
5M NaCl (Fisher) 2ml
Spermidine phosphate (Sigma) 29mg
Dithiotheitol (DTT) (Sigma) 75mg
10% SDS (Fisher) 10ml
pH 8.0 and make up to 100ml with double distilled water










In 2L of distilled water pH 7.2
Hybridisation solution
For each 50ml aliquot of hybridisation solution
Dextran sulphate (Amersham Pharmica),








Store frozen, 25ml is sufficient for 1 membrane.
IPX Colony PCR Buffer
3M KC1 (Fisher) 8.3ml
1M MgCl (Fisher) 0.75ml
1% Gelatin (Sigma) 5ml
1M Tris (fFisher) pH8.3 5ml
100% Triton XI00 (Fisher) 2.25ml
100% Tween 20 (Fisher) 2.25ml
Distilled water 26.45ml
PK/PCR Buffer for Colony PCR
Proteinase K (ICN) 0.002g/100|al distilled water
Add lOjul to 2ml of IX Colony PCR Buffer
Solutions for flow cytometry (Vindelov Analysis)
Citrate Buffer
Sucrose (Fisher) 85.5g
Tri-sodium citrate (Fisher) 11,76g
Double distilled water 800ml
DMSO (Sigma) 50ml
pH to 7.6 with 5M HC1
Stock solution
Tri-sodium citrate (Sigma) 2g
TRIZMA base (Sigma) 121mg






Adjust pH to 7.6 with 5M HC1
Solution A
Trypsin (Sigma) 15mg
In 500ml of the stock solution, store frozen
Solution B
Trypsin inhibitor (Sigma) 250mg
Ribonuclease A (Sigma) 50mg
In 500ml of the stock solution, store frozen
Solution C
Propidium iodide 208mg
Spermidine tetrachloride (Sigma) 500mg
In 500ml of the stock solution, store frozen and protect from light




In IX PBS pH 7.6
Trypsin
EDTA
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